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CHAPTER 1
General introduction and  
outline of the thesis
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This thesis concerns the fiscal sustainability of healthcare. Although the continuing 
proliferation of our health system has brought tremendous benefit to our society, this has 
come at high costs, and the general consensus is that the forecasted growth in healthcare 
expenditures is unsustainable. There is thus ever more need for solutions to the cost problem 
of healthcare. The studies in this thesis explore two approaches for reducing unnecessary 
and harmful care while simultaneously improving outcomes of care. The first approach 
aims to track down unnecessary care and to identify the determinants of unnecessary care 
provision in Dutch healthcare settings; in order to effectively reduce unnecessary spending. 
The second approach encompasses an exploration of the characteristics and utilization of 
high-cost patients; the sickest patients who are in heaviest need for care, but who are most 
likely to receive suboptimal treatment and receive unnecessary care. Knowledge of this 
population is prerequisite for designing effective responses for increasing quality of care and 
reducing costs.
 This introduction starts with a background in the problem of fiscal sustainability in the 
Netherlands, and a discussion of the Dutch approach to cost-containment. After this, the 
topic unnecessary care is introduced, including the two mentioned approaches for reducing 
unnecessary care. Subsequently, the goal and research questions, and a short overview of 
the contents of the thesis are presented. 
Fiscal sustainability of healthcare
One of the most important achievements of modern Western countries has been the 
building of its comprehensive health systems. Patients receive high quality care for relatively 
low out-of-pocket costs at the point of care. As a result, people live longer and healthier lives 
than ever before. In the Netherlands, for example, life expectancy at birth has risen from 
71.4 years in 1950 to 81.5 in 2016 [1]. In addition, life expectancy without physical limitations 
has risen from 65 years in 1983 to 72 years in 2012 for males, and from 64 years to 70 years for 
females [2]. Medicine has thus brought tremendous benefit to our society. 
 This has, however, come at high costs, and the growth of our health system has become 
a major fiscal burden. For as long as we know, it seems that healthcare costs can only grow, 
and grow, and grow. In the Netherlands, collectively paid healthcare costs have risen from 
0.8% of gross domestic product (GDP) in 1950 to 9.3% of GDP in 2018 (figure 1). From the 
figure it can be inferred that from 2014 and onwards the increase in healthcare spending was 
outpaced by the growth in GDP. 
 According to a different indicator – used by Statistics Netherlands – total healthcare costs 
represented 13.8% of GDP in 2016 [3]. This means that at present, for families with modest 
incomes, healthcare costs account for about a quarter of their incomes. It has been projected 
that – with unchanged policy – in 2040 the same families with modest incomes may spend 
up to 40% of their incomes on healthcare [4]. In such scenario’s, total healthcare costs grow 
up to €174 billion euro’s in 2040 (€9.600 per capita spending, compared to €5.100 in 2015). The 
general consensus is that such an increase is unsustainable. 
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FIGURE 1   Collectively financed healthcare in the Netherlands as a percentage of GDP. Source: CPB, 
edited by Joost Wammes. 
The financial crisis and healthcare spending
During the last decade, the global financial crisis has aggravated the problems of the 
fiscal sustainability of healthcare. In addition, due to the crisis the opportunity costs (the 
value of the choice of a best alternative cost while making a decision, in this case other 
public expenses; euro’s can be spent only once) of increased spending on healthcare have 
increasingly become visible, putting ever more pressure on the health system. 
 Figure 2 shows the Dutch reaction to the global financial crisis. Dutch spending on 
healthcare and social security steadily rose as a proportion of GDP until 2013. The figure also 
shows that total public expenses as a share of GDP have continually dropped from 2010 and 
onwards; and much of this decrease in spending has been accounted for by budget cuts in 
public administration, defense and infrastructure. Honorary professor of Economics of the 
public sector Flip de Kam has referred to this when he called Dutch healthcare the ‘cuckoo 
in the nest’ (“koekoeksjong”) of public spending [5]: budget cuts in other public sectors were 
needed to accommodate the growth of healthcare costs. 
  
 
 
FIGURE 2   Public expenditures as a share of GDP (2009 proportion = 100). Source: CPB, edited by 
Joost Wammes.
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Recent cost-containment measures in Dutch healthcare
In the Dutch curative health system, the main approach to controlling costs relies on market 
forces while regulating competition and improving efficiency of care (see chapter 2: Dutch 
healthcare system. NB: this thesis was limited to the curative health system, the long term 
care system was neglected). In addition, provider payment reforms, including a shift from a 
budget-oriented reimbursement system to a performance- and outcome-driven approach, 
have been implemented. In light of the global financial crisis, many additional activities 
have been taken to contain costs. In the following paragraphs the main ingredients of the 
Dutch approach are summarized. These efforts have effectively limited spending growth; 
Edith Schippers (2010-2017) was the first Minister of Health who finished a year without 
exceeding the predetermined budget. 
 Covenants are at the heart of Dutch cost-containment. In 2011, a first agreement 
(“bestuurlijk hoofdlijnenakkoord”) was signed by a collaborate of the ministry of health, 
hospitals, and insurers. This agreement set a (voluntary) ceiling for the annual growth 
of spending on hospital care between 2012 and 2015. When overall costs exceed that 
limit, the government has the ability to control spending via generic budget cuts (via the 
Macro Management Tool “macrobeheersingsinstrument”). In the following years, similar 
agreements were signed for the mental health and primary care sector. These agreements 
included an extra 1 percent spending growth allowance for primary care practices in 2014 and 
1.5 percent in 2015–2017, provided they demonstrate that their services are a substitute for 
hospital care. The current Ministry of Health has been negotiating with the parties to extend 
the covenants. The current agreements will expire at the end of 2022. The agreement for 
hospital care dictates a maximum volume growth of 0.8% in 2019, 0.6% in 2020, 0.3% in 
2021, and 0.0% in 2022 (table 1). 
TABLE 1  Permitted volume growth in covenants. 
  
One heavily debated cost-containment measure has been the increase in cost-sharing. 
The annual deductible, which accounts for the majority of patient cost-sharing, more than 
doubled between 2008 and 2018, from €170 to €385. There are some worries that this increase 
has led to greater numbers of people abstaining from or postponing needed medical care [6].
 The 2012 coalition agreement noted that the benefit package would be ‘stringently’ 
managed (outdated treatments that do not (longer) meet the benefit package criteria would 
be excluded from public coverage. In addition, new treatments would be assessed more 
unambiguously, coherently and consistently on basis of the criteria), and that (relative) 
cost-effectiveness would get a legal status to inform coverage decisions [7]. This legal status 
has not been enforced until today, and the general consensus is that the management of 
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
Hospital care 2.5% 2.5% 1.5% 1% 1% 1% 1.4% 0.8% 0.6% 0.3% 0.0%
Mental health - 2.5% 1.5% 1% 1% 1% - 1.3% 1.1% 0.9% 0.7%
Primary care - 3.0% 2.5% 2.5% 2.5% 2.5% 2.5% 2.5% 2.5% 3% 3%
12 Chapter 1
the benefit package has not, and will not yield in substantial cost savings. For example, 
van der Wees et al. found that countries worldwide show little variation in the scope of 
benefits covered, and that it is difficult for policy makers to completely remove services 
from the essential benefit package. Nevertheless, health technology assessment is gaining 
in importance and is used mainly for decisions concerning the benefit package and the 
appropriate use of medical devices. 
 The pharmaceutical sector has contributed significantly to the decrease in growth 
of spending. Average prices for prescription drugs have declined, with – as a result of stiff 
procurement – reimbursement caps for the lowest-price generic contributing to the decrease 
in average price. During the last few years however, many new and expensive drugs have 
entered the Dutch market, which further aggravated the cost pressure on the Dutch health 
system. The former Dutch health minister has formulated an ambitious policy proposal 
aiming in part to limit the pharmaceutical industry’s power over drug pricing. During the 
Dutch European Union presidency, the topic was successfully put on the European Union 
agenda. In addition, many activities have been initiated to strengthen Dutch purchasing 
power to decrease the prize of expensive drugs. The management of the basic benefit package 
also contributes to this strategy. For example, in two technology appraisals in 2016, the Health 
Care Institute advised that Pertuzumab (Perjeta®) and Pembrolizumab (Keytruda®) (two 
expensive oncolytics) should not qualify for reimbursement, unless the cost-effectiveness 
would be improved and budget impact would be lowered through lower negotiated prices [8,9]. 
Based on this advice, the Minister negotiated lower prices with the manufacturers and 
decided that the drugs would qualify for reimbursement to the end of 2019. The effectiveness 
of these policies however, remains to be seen. 
 To conclude, many activities have been taken to reduce the growth of healthcare spending 
in the Netherlands. Based on the outcomes of these measures (the actual spending), it 
is fair to say the measures have been successful. Many questions remain however, about 
the sustainability of the measures. For example, further limitation of the basic benefit 
package or increase of the deductible are politically unattractive. In addition, new covenants 
will dictate a further reduction in the growth of services, putting again more pressure to 
the system. There is thus ever more need for alternative solutions to the cost problem of 
healthcare. Below, the topic unnecessary care is introduced, including the two mentioned 
approaches for reducing unnecessary care.
Stewardship
In 2012, the International Health Policy (IHP) survey of the Commonwealth Fund started to 
assess the overuse of health services. More than half (57%) of the Dutch general practitioners 
(GPs) believed – almost as much as their German colleagues – that Dutch patients receive 
(much) too much medical care (not just from them as a general practitioner, but from all 
care providers, including medical specialists). In 2015, that percentage fell to 46%, and the 
Netherlands was in the third place with only German (61%) and Swiss (51%) colleagues who 
scored higher. These were remarkable observations, as GPs are best positioned to overview 
and assess the value of care throughout the system, giving credibility to their assessments. 
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Besides, the gatekeeper system is designed to prevent unnecessary care. This begs for the 
questions: is the gatekeeping function still working as intended? And what did the general 
practitioners mean when they stated that Dutch patients receive ‘too much’ care? What 
is meant with the phrase ‘unnecessary care’ or ‘low-value services’? And in what type of 
providers does this unnecessary care typically prevail? And among what patients? 
What is meant with ‘unnecessary care’ or low-value services?
There is no lack of typologies to discern lower value from high values practices. For 
example, (cost-) ineffective care, inappropriately timed care, duplicate testing, medical 
errors, overtreatment, ‘avoidable’ hospitalizations and emergency department visits, or 
care that is not in line with the patients’ preferences could be categorized as unnecessary 
care. Verkerk et al. recently published a typology of low-value care, in order to guide de-
implementation. According to Verkerk, low-value services could be categorized to proven 
ineffective care, inefficient care, and unwanted care. Ineffective care is of low-value from a 
medical perspective, including proven (cost-)ineffective care for a particular subgroup or 
condition, or services which benefits do not weigh up to the harms according to scientific 
standards. Inefficient care is of low-value from a societal perspective. This care is in essence 
effective for the targeted condition, but becomes of low-value through inefficient provision 
or inappropriate high intensity or duration. Unwanted care is of low-value from a patients’ 
perspective. This is in its essence effective care, but becomes low-value because it doesn’t 
solve the individual patients’ problem or does not fit the individual patients’ preferences [10]. 
 Traditionally, lower value or lower quality of care has been classified into misuse, overuse 
or underuse of health care services [11]. Underuse is the failure to provide a healthcare 
service when it would have produced a favourable outcome for the patient. Although fixing 
underuse is generally related to increased costs, in circumstances it may result in lower costs, 
for example in case of underuse of preventive drugs (one pervasive problem has been the 
underuse of beta-blockers after myocardial infarction: it is well-known that beta-blockers 
reduce mortality and morbidity, both important drivers of costs). Misuse occurs when an 
appropriate service has been selected but a preventable complication occurs – for example 
avoidable complications after surgery – and the patient does not receive the full potential 
benefit of the service. 
 Intuitively, the term overuse is closest to the term unnecessary care. Overuse occurs when 
a healthcare service is provided under circumstances in which its potential for harm exceeds 
the possible benefit. Antibiotic treatment for treating colds are a well-known example of 
overuse. One problem with overuse is that it is very hard to measure, as it requires a strict 
definition for the appropriateness of a service, based on evidence that considers the balance 
between benefits and harms for a population or individuals [12]. Nevertheless, many scholars 
have estimated the prevalence of overuse in healthcare may represent up to 10% and 30% of 
provided services [13-15]. 
 But how to find these? What services are overused? 
 In practice, it has been proven very hard to identify services that could always be considered 
overuse or of lower value. One prominent problem in overuse is that interventions which are 
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high-value for a given subpopulation may be inappropriately applied to other populations [16]. 
As said, overuse requires a strict definition for the appropriateness of a service, based on 
evidence that considers the balance between benefits and harms for a population or 
individuals. Such clinical information is rarely identifiable from electronic health records or 
claim databases, let alone patient preferences. In addition, for the treatment of individual 
patients, the recommendations in clinical practice guidelines may not provide the clear cut 
answers as their wordings suggest they would give. This problem also persists in Verkerk’s 
typology as it does not cover services of unknown effectiveness. The prevalence of such care 
may be enormous, NHS evidence once estimated that for 50% of services the effectiveness 
is unknown [17]. 
 In summary, uncertainty exists about the exact prevalence of low-value services in the 
Netherlands. In daily practice it is difficult to discern low-value services from higher-value 
services. Being successful in this is prerequisite for developing effective policy solutions for 
reducing low-value care. Such insight might inform future policy concerning the benefit 
package, or to rationalize local delivery systems or care programs. 
 Nevertheless, the first approach geared towards services that are known to be of low-
value only partly addresses the problem of unnecessary spending. Below we introduce 
an alternative approach, which encompasses an exploration of the characteristics and 
utilization of high-cost patients; the sickest patients who are in heaviest need for care. We 
will demonstrate that high-cost patients are at high risk to receive suboptimal treatment 
and receive unnecessary care, and that such a patient-centric approach may offer alternative 
opportunities for intervention. 
High-cost patients
If unnecessary care or low-value care is not easily identifiable from electronic health records 
or claim databases, how else to find these? In what patients would we expect unnecessary 
care to be most persistent?
 We hypothesized that most low-value spending may be concentrated among so-called 
high-cost patients. For long it is known that healthcare costs are heavily concentrated: the 
top 1% high-cost patients in the Netherlands account for about a quarter of healthcare costs, 
the top 5% of high-cost patients for about halve of total costs (in these calculations, costs 
were limited to the Health Insurance Act).  
 Our hypothesis was inspired by the theoretical work of Avedis Donabedian and 
colleagues [18]. Figure 3 (left panel) presents the hypothetical relationship between resource 
expenditures and expected health improvement, in case of an “ideal physician”. The curve 
clearly shows that the marginal improvements in health sharply decline when resource 
expenditures are higher.  
 Figure 3 (right panel) shows the same curve, but now including a curve for the relationship 
between resource expenditures and expected health improvement, but for the “nonideal 
physician”. Obviously, the total expected health improvement for the nonideal physician is 
lower than for the ideal physician, at any given resource input. Besides, and most importantly, 
the ideal physician will not use any resources anymore when the maximum health benefit is 
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reached. On the contrary, the nonideal physician continues to use resources, and from RIU 
and onwards the curve actually takes a downward turn, implying health loss at increasing 
costs. According to Donabedian and his colleagues
We provide for the occurrence of harmful care at all levels of resource input, 
though we postulate that both the magnitude and the probability of harm are 
larger when resource inputs are excessive. 
Lower value services are thus most likely to persist in situations of high resource input. 
This work was developed to describe the relationship between the performance of ‘all the 
physicians in the community as they care for all patients of a particular kind’. The paper thus 
primarily takes physicians as unit of analysis. It does not rule out however, that the described 
relationships could be interpreted within patients as well.   
 
 
FIGURE 3   Left panel: Hypothetical relationship between resource expenditure and expected 
health improvement for strategies of care selected by the ideal physician. Right 
panel: Hypothetical relationships between resource expenditure and expected health 
improvement for strategies of care selected by the ideal physician and by the non-ideal 
physician. Source: Donabedian 1982. 
There are other reasons why we would expect low-value services to concentrate among high-
cost patients. By definition, high-cost patients receive most services and are thus most likely 
to experience problems with quality and safety in their care. Inherent to receiving many 
services are problems of coordination of care, or a general lack of integrated care delivery. In 
addition, medical care may be most complicated, and least supported with good evidence, 
among the sickest patients. It is widely known, for example, that clinical practice guidelines 
are written for ‘artificial’ patients with one single disease, while the majority of hospitalized 
patients suffer from several diseases. End of life periods are widely known for high costs, and 
Gilbert Welch, American medical doctor and author of the book ‘Less medicine. More Health’ 
once wrote [19].
How medical excess can be harmful is probably most familiar at the end of life. 
Here it is easy to see how aggressive intervention in the dying is not only futile, 
but inhumane. .... Medical excess is equally prevalent, however, at the other 
extreme of health: care for the well.
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In the US, high-cost patients have been increasingly studied, and many activities have 
been taken to improve care and reduce costs among high-cost patients. For example, Joynt 
et al. found that 10% of high-cost patients costs were deemed ‘preventable’ [20]. Policy and 
interventions aimed at high-cost patients, including for example care coordination and 
disease management, have had favourable results in quality of care and health outcomes, 
and mixed results in their ability to reduce hospital use and costs. Research has shown that 
the effectiveness and efficiency of the programs increase when interventions are targeted 
to the patients that most likely benefit. One such example is the ‘hot spotting approach’, 
named as such by Atul Gawande [21] 
to look for the most expensive patients in the system and then direct resources 
and brainpower toward helping them
In the Netherlands, high-cost patients have hardly been studied. In 2003, Polder estimated 
that the 1% costliest beneficiaries were responsible for 30% of spending in primary care, 
hospital care, pharmaceutical help and home and care. The costliest 5% and 10% were 
responsible for 55% and 70% of spending respectively. The costs in long term care were 
distributed even more unevenly [22]. A recent analysis by the CBS showed similar results: 
20% of beneficiaries were responsible for 80% of health care spending [23]. Much uncertainty 
remains however, about the clinical characteristics and healthcare utilization patterns 
of high-cost patients in the Netherlands, but also in any other high-income countries. For 
example, although it is known that healthcare costs rise with increasing age, the proportion 
of non-elderly among high-cost populations is not studied. Besides, a major limitation of 
current literature is that little is known about patterns in care use and characteristics among 
different age groups, and this might offer clear resolution for policy making. In addition, to 
our knowledge, until today no studies have reported the role of expensive treatments (e.g. 
expensive drugs, transplant surgery, intensive care units, dialysis) as drivers of high costs. 
As shown above, the costs for expensive drugs have risen dramatically during the last few 
years. However, little is known about the relative contribution of expensive drugs towards 
the costs of high-cost patients. Much uncertainty persists also concerning the percentage of 
high-cost patients that are in their last year of life, and concerning the percentage of high-
cost patients that persistently incur high costs (are patients incurring high costs in two or 
more consecutive years, or episodically). There is a lack of integral overview of drivers of 
high cost utilization and the relative importance of each driver among and across high-cost 
populations. Such information is prerequisite for developing tailored interventions aimed at 
high-cost patients, and to reconfigure the health system to best help the patients in heaviest 
need for high-quality care. 
Rationale and goal of this thesis
Given the projections of future healthcare spending and that the opportunity costs of 
healthcare spending are increasingly visible, there is ever more need for alternative solutions 
to the cost problem of healthcare. Above we have shown that many types of low-value 
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services exist, that many scholars believe that the prevalence of lower value care may be 
high, so that reduction of such care may improve patient outcomes and reduce costs. The 
exact identification of such services however, has proven difficult, and we have shown that it 
is likely that most low-value care prevails among high-cost patients. 
The research questions of this thesis are:
1  What are opportunities for cost-reduction through reduction of low-value services in the 
Netherlands? 
2  What are the characteristics and healthcare utilization of high-cost patients and what 
strategies do likely improve high-cost patients care and reduce costs?
The goal of this thesis is to explore two approaches to cost containment. The first approach 
concerns the identification of agreed upon low-value services, or services that can be easily 
observed as having low value, and the context in which such care prevails. We conducted 
an exploratory survey among Dutch GPs to understand where the perceived unnecessary 
care prevails; and to identify factors that are associated with too much care at the entry 
point of Dutch healthcare. In addition, we developed an objective approach to identify 
and prioritize lower value services for practical de-adoption, and developed a list of lower 
value services identified from 193 Dutch clinical practice guidelines, published between 
2010 and 2015. Furthermore, we interviewed 84 professionals to explore how Dutch health 
organizations have dealt with the cost pressure of cost-increasing and cost-ineffective 
health technologies, in order to inform future policy making concerning the introduction of 
new health technologies in the Dutch health system.
 The second approach is very much related to the first. Here, we view the cost problem 
through a lens of high-cost patients, and study the characteristics and healthcare utilization 
of high-cost patients. Such knowledge is a first prerequisite for developing effective 
interventions and inform policy aimed at high-need, high-cost populations. We performed 
a systematic literature to synthesize the literature on high-cost patients’ characteristics 
and healthcare utilization; determined the medical needs, demographic characteristics and 
healthcare utilization patterns of high-cost beneficiaries in the Netherlands; and studied the 
longitudinal healthcare utilization and characteristics of patients with heart failure and high 
costs.
Outline of this thesis
In this thesis we present six studies along our two specified approaches to cost reduction 
and healthcare improvement. Chapter 2 gives an overview of the Dutch health system. 
Approach one – that aims to track down and reduce agreed-upon unnecessary care – 
includes chapter three until chapter five. Chapter 3 presents an exploratory survey among 
Dutch GPs aiming to 1) understand where this perceived unnecessary care prevails; 2) 
identify factors that are associated with too much care at the formal entry point of Dutch 
healthcare. In doing this, we test assumptions supporting the gatekeeper system and 
further strengthening of this gatekeeper system. We asked the respondents to assess the 
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perceived amount of care by sector and type, and used several propositions describing 
factors possibly related to overuse and asked the respondents for opinion. Chapter 4 
describes the development of a list of lower value services identified from 193 Dutch clinical 
practice guidelines, published between 2010 and 2015. The list was developed with the aim 
to provide a comprehensive list of lower value services for Dutch hospital care. Furthermore, 
we compared our list with the original do-not-do – established by NICE in the UK – list on 
several aspects, including types of care and patient groups. Finally, we developed methods 
to prioritize the list on basis of several aspects, including prevalence of the disease and 
disease burden. Chapter 5 presents an interview study after the introduction of cost-
ineffective health technologies in the Netherlands. The aim of this research was to explore 
how Dutch health organizations have dealt with the cost pressure of cost-increasing and 
cost-ineffective health technologies. We conducted six case-studies and interviewed 
84 professionals at all hierarchical levels (practitioners, departments, board of directors, 
insurers, and others) to explore the causality of resource allocation (how does one decision 
leads to another?) and the ultimate effects for individual patients.
 Approach two – which encompasses an exploration of the characteristics and 
utilization of high-cost patients – includes chapter six until chapter eighth. Chapter 6 
presents our systematic review of high-cost patients’ characteristics and healthcare 
utilization. We reviewed 55 studies of high-cost patients’ characteristics and healthcare 
utilization. Andersen’s behavioural model was used to categorize the characteristics of 
high-cost patients into predisposing, enabling and need characteristics. Our analysis 
was aimed at identifying drivers of costs that matter across payer types and countries. 
Chapter 7 presents our Dutch claims database analysis on this issue. We first determined 
characteristics and spending and quantified the share of high-cost beneficiaries that use 
expensive treatments. We then used a beneficiary’s most cost-incurring medical condition 
to examine characteristics and utilization patterns. In addition, we compared utilization 
and conditions across age groups. All analyses were performed for top-1% and top-2-5% 
beneficiaries separately. Chapter 8 presents our second claims database analysis. In this 
study, we study the longitudinal healthcare utilization and characteristics of heart failure 
patients with high costs. We explore the characteristics of CHF patients with high costs 
and identified the determinants associated with high costs using generalized estimation 
equation modelling (GEE).  Furthermore, we explore longitudinal healthcare utilization and 
determine the persistency of high costs within this population. Chapter 9, the discussion, 
summarizes the main findings of the thesis, discusses these findings in comparison with 
other research, and describes the implications of these findings for policy and practice. 
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What is the role of government?
In the Netherlands, the national government has overall responsibility for setting health 
care priorities, introducing legislative changes when necessary, and monitoring access, 
quality, and costs. It also partly finances social health insurance (a comprehensive system 
with universal coverage) for the basic benefit package (through subsidies from general 
taxation and reallocation of payroll levies among insurers via a risk adjustment system) 
and the compulsory statutory health insurance system for long-term care. Prevention and 
social supports are not part of statutory health insurance but are financed through general 
taxation. Municipalities and health insurers are responsible for most outpatient long-term 
services, including personal and home care, and all youth care under a provision-based 
approach (with a high level of freedom at the local level).
Universal coverage
In the Netherlands, health insurance was installed in 1941 according to the German Bismarck 
model of public and private health insurers. Around 63% of the population was covered by 
public health insurance, while more affluent could opt for private insurance or choose to 
remain uninsured. At the turn of the century, concerns of inefficiencies and long waiting 
lists provided momentum for a market oriented reform inspired by the Enthoven proposal of 
managed competition. The 2006 Health Insurance Act (reform) merged the traditional public 
and private insurance into one universal social health insurance with mandatory coverage. 
In 2011, the government started to track down the uninsured. Since then, the number of 
uninsured has steadily declined, and by the end of 2016, 23,000 people (less than 0.2% of the 
population) remain uninsured.
How is the health system financed and who is covered?
Publicly financed health insurance  In 2016, the Netherlands spent 10.5 percent of GDP on 
health care, and 81 percent was collectively financed, consisting of a mixture of insurance 
premiums (21%), copayments (11%), earmarked payroll taxes (46%) and general taxation (22%) 
[1].  All residents (and nonresidents who pay Dutch income tax) are mandated to purchase 
statutory health insurance from private insurers. Uninsured are fined and premiums may 
be levied directly from income. People who conscientiously object to insurance can opt out 
by making mandatory contributions into a health savings account. Active members of the 
armed forces (who are covered by the ministry of defense), are exempt. Insurers are required 
to accept all applicants, and enrolees have the right to change their insurer each year.
 Apart from acute care, long-term care, and obstetric care, undocumented immigrants 
have to pay for most health care themselves (they cannot take out health insurance). 
However, some mechanisms are in place to reimburse costs that undocumented immigrants 
are unable to pay. For political asylum seekers, a separate set of policies has been developed. 
Permanent residents (for more than three months) are obliged to purchase private insurance 
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coverage. Visitors are required to purchase insurance for the duration of their visit if they are 
not covered through their home country.
 Statutory health insurance is financed according to the 2006 Health Insurance Act, through 
a nationally defined, income-related contribution (6.9 percent of up to EUR 54,614 [USD 67,500] 
of annual taxable income) (45%), a government grant for children and youth aged 18 and 
under (5%), and community-rated premiums set by each insurer (45%). Children under 18 are 
automatically covered, while adults choose a policy on an individual basis (no family coverage). 
Adults with the same insurer pay the same premium, regardless of their age or health status. 
However, through employer collectives, lower premiums may be offered. Income taxes and 
government grants are collected in a central health insurance fund, and redistributed among 
insurers in accordance with a risk-adjusted capitation formula that considers age, gender, 
labor force status, region, and health risk (mostly based on past drug and hospital utilization).
 Private, statutory insurers are expected to engage in strategic purchasing, and contracted 
providers are expected to compete on both quality and cost. There are 10 statutory insurers 
in 2018, but the insurance market is dominated by the four largest insurance conglomerates, 
which account for 90 percent of all enrollees. Currently, all insurers are mandated to operate 
as non-profits.
Private (voluntary) health insurance  In addition to statutory coverage, most of the 
population (84%) purchases supplementary voluntary insurance covering a mixture of 
benefits not covered by statutory insurance, such as dental care, alternative medicine, 
physiotherapy, eyeglasses and lenses, contraceptives, as well as reduced copayments for on-
label medicines (excess costs above the limit for equivalent drugs – an incentive for using 
generics). Premiums for voluntary insurance are not regulated; insurers are allowed to screen 
applicants based on risk factors. Nearly all of the insured purchase their voluntary benefits 
from the same (mostly nonprofit) insurer that provides their statutory health insurance. 
People with voluntary coverage do not receive faster access to any type of care, nor do they 
have increased choice of specialists or hospitals. In 2016, voluntary insurance accounted for 
7.0 percent of total health spending.
Safety net  GP care and children’s health care up to the age of 18 are exempt from cost-
sharing. Government also provides subsidies (health care allowances), subject to asset 
testing and income ceilings, to cover community-rated premiums for low-income families: 
singles with annual income less than EUR28,500 (USD35,200) and households with income 
less than EUR35,500 (USD44,000). Over 5 million people, or about 30 percent of the total 
population, receive allowances set on a sliding scale, ranging from EUR4.00 (USD5) to 
EUR94.00 (USD116) per month for singles and from EUR7.00 (USD9) to EUR 176.00 (USD 217) 
for households, depending on income.
What is covered?
Benefit package  The government determines the statutory benefits package, guided by 
advice from the National Health Care Institute. The mandatory benefit package includes, 
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among other things, care provided by general practitioners (GPs), hospitals, and specialists; 
maternal care; dental care (up to age 18); prescription drugs; physiotherapy up to age 18; home 
nursing care; basic ambulatory mental health care for mild-to-moderate mental disorders; and 
specialized outpatient and inpatient mental care for complicated and severe mental disorders. 
Health insurers are legally required to provide these standard benefits. Since 2015, nursing 
home care for elderly and disabled is financed under the Long-Term Care Act (see below).
 Some treatments, such as general physiotherapy and pelvic physiotherapy for urinary 
incontinence, are only partially covered for some people with specific chronic conditions, 
as are the first three attempts at in vitro fertilization. Some elective procedures, such 
as cosmetic plastic surgery without medical indication, dental care above age 18, and 
optometry and other vision care without medical indication, are excluded. A limited number 
of health promotion programs are covered, including smoking cessation and some weight 
management advice. A range of medical devices is covered, including hearing aids and 
orthopedic shoes, but wheelchairs and other walking aids are excluded. The Public Health 
Act describes municipal responsibilities for national prevention programs, vaccinations and 
infectious disease management. Municipalities can install additional prevention programs, 
such as healthy living and obesity reduction programs, but this varies wildly from one 
municipality to another.
 As of 2015, home care is a shared responsibility of the national government, municipalities 
(day care, household services), and insurers (nursing care at home) and is financed through 
the Health Insurance Act and the Social Support Act (Wmo). Hospice care is financed through 
the Long-Term Care Act of 2015. 
Cost-sharing and out-of-pocket spending  For the Health insurance Act, the main form of 
cost sharing is a mandatory deductible of EUR385 (USD440) as of 2018. Children under 18 are 
exempt. In addition, consumers may take on a voluntary deductible of EUR500 (USD570). 
The deductible covers a broad range of health services, including hospital admissions, 
specialist services and prescription drugs. Some services are exempt, such as GP visits and 
preventative services, including most immunizations and breast cancer screening. For some 
selected services, such as on-label medications, physiotherapy, medical transportation or 
medical devices, additional cost sharing may be required via copayments, coinsurance, or 
direct payments. Patients with an in-kind insurance policy may be required to share costs 
of care from a provider that is not contracted by the insurance company. For long-term care, 
an income- and wealth-related copayment up to a maximum of EUR2,332 (USD 2,664) per 
month is required. For municipal home care and social services, most municipalities require 
a small income-related copayment. Out-of-pocket expenses represented 12.2 percent of 
health care spending in 2016.
How is the delivery system organized and how are 
providers financed?
Physicians: medical education and workforce  The number of medical doctors is regulated 
through caps on the number of medical students, both at a national level and at a university 
26 Chapter 2
level. Medical schools are located in private, not-for-profit university medical centers. 
Regular medical students pay a yearly tuition fee of approximately €2,100. The Capacity 
Body (Capaciteitsorgaan) advises the Ministry of Health on all specialized postgraduate 
training programs for medical specialists to assure matching supply and demand. No such 
limitations apply for college level nursing educations. Regional bodies supervise nursing 
training programs, subsidized by the Ministry of Health. There are no national initiatives to 
ensure the supply of medical providers in rural or remote areas. However, in rural areas GPs 
may take over the role of pharmacists for the supply of prescription-only pharmaceuticals [2]. 
Primary care  There were 13,364 registered primary care doctors (GPs) and 32,605 medical 
specialists in 2017. Forty-two percent of practicing GPs worked in group practices of three 
to seven, 40 percent worked in two-person practices, and 18 percent worked solo (2016). 
Most GPs work independently or in a self-employed partnership; one third are employed in a 
practice owned by another GP or are contracted on the basis of short-term contracts.
 The GP is the central figure in the Dutch primary care. The typical practice size is 
approximately 2200 patients per full-time working GPs. Although registration with a GP is 
not formally required, most citizens (over 95%) are registered with one they have chosen, 
and patients can switch GPs as often as they like. GPs have a gatekeeping function; referrals 
are required for both hospital and specialist care.
 Many GP practices employ salaried nurses and primary care psychologists. Primary care 
psychologists constitute specially trained psychologists, nurses and social-caregivers. 
Reimbursement for primary nursing care is received by the GP, so any productivity gains that 
result from substituting a nurse for a doctor accrue to the GP. Chronic care management is 
coordinated through care groups (mostly GP networks). Care groups are legal entities that 
assume clinical and financial responsibility for the chronic disease patients who are enrolled; 
the groups purchase services from multiple providers. To incentivize care coordination, 
bundled payments are provided for certain chronic diseases, such as diabetes, cardiovascular 
conditions, and chronic obstructive pulmonary disease (COPD).
 In 2015, the government introduced a new GP funding model comprising three segments. 
Segment 1 (representing ≈75% of spending) funds core primary care services and consists 
of a capitation fee per registered patient, a consultation fee for GPs (including phone 
consultation), and consultation fees for ambulatory mental health care at the GP practice. 
The Dutch Health Care Authority (Nederlandse Zorgautoriteit) determines national provider 
fees for this segment. Segment 2 (≈15% of spending) consists of funding for programmatic 
multidisciplinary care for diabetes, asthma, and COPD, as well as for cardiovascular risk 
management; prices are negotiated with insurers. Segment 3 (≈10% of spending) provides 
GPs and insurers with the opportunity to negotiate additional contracts – including prices 
and volumes – for pay-for-performance and innovation. Primary care providers are not 
allowed to bill patients extra and above the fee schedule. 
 In 2018, self-employed GPs earn average gross annual income of EUR 135,000 (USD 
167,000) (excluding out-hours care). In 2016, the gross annual incomes of specialists were 
estimated at maximally EUR 160,000 for salaried specialists (USD 197,000; ratio to GPs 1.2:1) 
and EUR 211.000 (USD 260,000; ratio to GPs 1.6:1) for independent specialists. 
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Outpatient specialist care  Nearly all specialists are hospital-based and either part of group 
practices (39%) or on salary (49%, mostly in university clinics; the remaining 12% work both 
on salary and independently). Before 2015, a fixed part of hospital payments was reserved 
for medical specialists. As of 2015, specialist fees are freely negotiable between specialists 
and hospitals. This so-called “integral funding” dramatically changed the relationship 
between medical specialists and hospitals. Hospitals now have to negotiate in allocating 
their financial resources among their specialists. After patients receive referral for specialist 
treatment (in any hospital), patients are free to choose their provider, but insurers may set 
different conditions (e.g., cost-sharing) for different choices within their policies [3]. There 
is a nascent trend toward working outside of hospitals – for example, in growing numbers 
of (mostly multidisciplinary) ambulatory centers – but this shift is marginal, and most 
ambulatory centers remain tied to hospitals. Specialists in ambulatory centers tend to work 
most of the time in academic or general hospitals. 
Administrative mechanisms for paying primary care doctors and specialists  The annual 
deductible (which has to be paid for amongst other specialist physician visits, but not for GP 
visits, see above) is paid to the insurer. The insured have the option of paying the deductible 
before or after receiving health care and may choose to pay all at once or in installments. 
Other copayments – those for drugs or transportation, for example – have to be paid directly 
to the provider.
After-hours care  After-hours care is organized at the municipal level in “GP posts,” which 
are walk-in centers, typically run by a nearby hospital, that provide primary care between 5 
p.m. and 8 a.m. Nearly all GPs work for a GP post. Specially trained doctor assistants answer 
the phone and perform triage; GPs decide whether patients need to be referred to a hospital. 
Doctors are separately compensated at hourly rates for after-hours care (on top of the regular 
income). At least 50 hours of after-hours care must be provided annually to maintain their 
registration as general practitioner. The GP post sends the information regarding a patient’s 
visit to the patient’s regular GP. Since out-of-hours care is typically provided at hospitals, 
there is no national medical telephone hotline advising patients on their nearest out-of-
hours locations.
Hospitals  In 2016, there were 79 hospital organizations, including eight university medical 
centers. All hospitals are private entities but profits may not be distributed to shareholders, 
making the hospital market virtually 100% private non-profit. In 2015, there were 231 
independent private and nonprofit treatment centers whose services were limited to same-
day admissions for non-acute, elective outpatient care (e.g., eye clinics, orthopedic surgery 
centers) covered by statutory insurance. 
 Hospital payment rates, through which doctors are paid, are mostly determined through 
negotiations between each insurer and each hospital over price, quality, and volume. 
The great majority of payments take place through the case-based diagnosis treatment 
combination system (DRG-like) called DBC defined by the Dutch Health Care Authority. 
The rates for approximately 70 percent of DBCs are freely negotiable (DBC-B segment); the 
remaining 30 percent are set nationally by the Dutch Health Care Authority (DBC-A segment). 
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The number of DBCs was reduced from 30,000 to 4,400 in 2012 to reduce administrative 
complexity. Since 2015, independent medical specialist groups negotiate with their hospital 
for their remuneration. Diagnosis treatment combinations cover both outpatient and 
inpatient as well as specialist costs, strengthening the integration of specialist care within 
the hospital organization. 
 A small part of hospital care is reimbursed through so-called add-ons. Add-ons are 
separate payments that have been developed for the reimbursement of expensive drugs and 
intensive care unit admissions. University medical centers receive special allowances (so-
called ‘academic component’) for the adoption of new technologies. 
Mental health care  Mental health care is provided by specially trained psychologists, 
nurses and social caregivers in basic ambulatory care settings, such as GP offices, for mild-
to-moderate mental disorders. In cases of complicated and severe mental disorders, GPs 
will often refer patients to basic mental health care (e.g., a psychologist or an independent 
psychotherapist) or to a specialized mental health care institution. Mental care delivered 
by GP offices or referred by GPs is generally covered as part of the basic benefit package. 
Inpatient mental care is covered as part of the Long-term Care Act. Hospitals provide 
acute mental care. The delivery of preventive mental health care is the responsibility 
of municipalities and is governed by the Social Support Act of 2015. For several years, 
policymakers have been aiming to substitute specialized and basic mental health care for 
primary mental health care, as reflected in the steady increase in the number of GPs who 
employ primary care psychologists.
Long-term care and social support  Long-term care and social support operate as separate 
programs, complementary to the curative health system. Long-term care is financed 
through the Long-Term Care Act of 2015 (Wet langdurige zorg), a statutory social insurance 
scheme for long-term care and uninsurable medical risks and cost that cannot be reasonably 
borne by individuals. It operates nationally, and taxpayers pay a contribution of 9.65% of 
taxable income up to €33.791 in 2017. In 2017, a total of €20.0 billion was spent on long-term 
care under the Long-term Care Act. Home care services, youth care, ancillary services and 
social support services are financed by municipalities through the Social Support Act of 2015 
(Wet maatschappelijke ondersteuning), about 6.5 billion in 2017. Municipalities receive block 
grants from the government, covering all municipal expenses. Municipalities have very 
limited tax-raising abilities. 
 Long-term care encompasses residential care; personal care, supervision, and nursing; 
medical aids; medical treatment; and transport services. Patients in need of permanent 
supervision, or patients who need assistance 24 hours per day to prevent escalation or 
serious harm, are eligible. The Centre for Needs Assessment (Centrum Indicatiestelling Zorg, 
CIZ), a regulatory governmental agency, determines eligibility based on clinical need alone 
(no means-testing). Cost sharing depends on annual income and wealth, age and household 
size. In 2017, 314,220 people used long-term care. 
 The Social Support Act provides funding through a block grant from the national 
government to municipalities, that are responsible for ensuring the provision of household 
services, medical aids, home modifications, services for informal caregivers, preventive 
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mental health care, transport facilities, and other assistance. Municipalities have a great 
deal of freedom in how they organize these services, including needs assessments, and in 
how they support caregivers (e.g., through the provision of respite care or a small allowance).
In 2017, 1,042,790 people used Social Support services funded by municipalities. 
 Long-term care is provided by private, nonprofit organizations. For home care (since 2015 
part of Health Insurance Act and Social Support Act) profits are allowed. Most palliative care, 
including hospice care, is integrated into the health system and can be delivered by general 
practitioners, home care providers, nursing homes, specialists, and volunteer workers. 
Palliative care is financed through a number of sources, but mostly through the Long-Term 
Care Act. 
 Under the Health Insurance Act of 2006, the Social Support Act of 2015 and the Long-Term 
Care Act of 2015, personal budgets are provided for patients to buy and organize their own 
(long-term) care. Under the Health Insurance Act and the Social Support Act, health insurers 
and municipalities are free to set “sufficient” budget rates (typically about 70% of in-kind 
rates), whereas under the Long-Term Care Act, budget rates are set nationally. Municipalities 
have a great deal of freedom in how to support family and informal caregivers, for example, 
through respite care or a small allowance.
FIGURE 1   Organization of the Health System in the Netherlands. Source: J. Wammes, P. Jeurissen, 
and G. Westert, Radboud University Medical Center, 2014.
What are the key entities for health system governance?
Since 2006, the Ministry of Health’s role has been to safeguard health care from a distance 
rather than managing it directly. It is responsible for the preconditions pertaining to access, 
quality, and cost in the health system, has overall responsibility for setting priorities, and 
may, when necessary, introduce legislation to set strategic priorities.
 The Commonwealth Fund116
A policy of further integration of general practice and mental health was agreed on in 2012, with the goals of ensuring that 
patients receive timely care from the right source and reducing the need for specialized care. For several years, 
policymakers have been aiming to substitute outpatient care for inpatient care, as reflected in the steady increase in the 
number of GPs who employ primary care psychologists.
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facilities, and other a sistan e, in accordance with the Social Support Act (Wet maats happelijk  ondersteuning). 
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homes, and nursing homes. Most palliative care is integrated into the health system and delivered by general practitioners, 
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A number of arm’s-length (independent) agencies are responsible for setting operational 
priorities. At the national level, the Health Council advises government on evidence-based 
medicine, health care, public health, and environmental protection. The National Health 
Care Institute advises the government on the components of the statutory benefits package 
and has various tasks relating to quality of care, professions and training, and the insurance 
system (e.g. risk adjustment). The Medicines Evaluation Board oversees the efficacy, safety, 
and quality of medicines. The National Health Care Institute assesses new technologies on 
effectiveness and cost effectiveness, and advises the Minister on uptake into the mandatory 
benefit package. Decisions about the benefits package rest with the health minister. The 
Dutch Health Care Authority (Nederlandse Zorgautoriteit) has primary responsibility for 
ensuring that the health insurance, health care purchasing, and care delivery markets all 
function appropriately – for example, by designing and managing the diagnosis treatment 
combination system and setting prices for 30 percent of diagnosis treatment combinations. 
Meanwhile, the Dutch Competition Authority (Autoriteit Consument en Markt) enforces 
antitrust laws among both insurers and providers. The Health Care Inspectorate supervises 
the quality, safety, and accessibility of care. Self-regulation by medical doctors is also an 
important aspect of the Dutch system [4]. Private insurers are tasked with increasing health 
system efficiency and cost control through prudent purchasing of health services.
 Public engagement and public information are not centralized in one body. The patient 
rights movement consists of a wide range of organizations, some for specific diseases 
and some functioning as umbrella organizations. The patient umbrella organization 
(Patiëntenfederatie Nederland) conducts a range of activities to promote transparency. 
 Health information technology is not centralized in one body. The Union of Providers for 
Health Care Communication (De Vereniging van Zorgaanbieders voor Zorgcommunicatie) is 
responsible for the exchange of data via an information technology (IT) infrastructure. 
 Health equity has not been considered a policy priority by any organization or agency in 
the Netherlands.
What are the major strategies to ensure quality of care?
Private, statutory insurers are expected to engage in strategic purchasing, and contracted 
providers are expected to compete on both quality and cost. At the system level, quality 
is ensured through legislation governing professional performance, quality in health care 
institutions, patient rights, and health technologies. The Dutch Health Care Inspectorate is 
responsible for monitoring quality and safety. In 2014, the National Health Care Institute 
was established to further accelerate the process of quality improvement and evidence-
based practice. As part of the National Health Care Institute, the National Quality Institute 
promotes quality measurement and transparency. Most quality assurance is carried out by 
providers, sometimes in close cooperation with patient and consumer organizations and 
insurers. There are ongoing experiments with disease management and integrated care 
programs for the chronically ill.
 In the past few years, many parties have been working on quality registries. Most 
prominent among these are several cancer registries and surgical and orthopedic (implant) 
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registries. Mechanisms to ensure the quality of care provided by individual professionals 
include registration into a government-based national register, including re-registration 
every 5 years, contingent upon compulsory continuous medical education (the content is 
determined by professional organizations); regular on-site peer assessments by professional 
bodies; and professional clinical guidelines, indicators, and peer review. The main methods 
used to ensure quality in hospitals, nursing homes and other healthcare institutions 
include voluntary accreditation and certification granted by independent organizations); 
compulsory and voluntary performance assessment based on indicators; and national 
quality improvement programs. Furthermore, quality of care is supposed to be enhanced by 
selective contracting (e.g., volume standards for breast cancer treatment).
 Patient experiences are not systematically assessed. Although progress has been 
made, public reporting on quality of care and provider performance is still in its infancy 
in the Netherlands. Patients may report individual experiences with healthcare providers 
and institutions in any sector to the website Zorgkaartnederland.nl on a voluntary basis. 
Furthermore, several websites provide information about institutions (including hospitals 
and nursing homes) and providers in any sector, primarily based on quality indicators 
obtained from the National Quality Institute and the Dutch Healthcare Inspectorate.
What is being done to reduce disparities?
Every four years, variations in health accessibility are measured and published in the 
Dutch Health Care Performance Reports by the National Institute for Public Health and the 
Environment, focusing on socioeconomic differences including ethnicity and education. 
Geographic or regional variation is not measured consistently. Socioeconomic health 
disparities are considerable in the Netherlands, with up to seven years’ difference in life 
expectancy between the highest and lowest socioeconomic groups. Smoking is still a 
leading cause of death. Although monitored by the National Institute for Public Health and 
the Environment (part of the Ministry of Health), the government does not have specific 
policies to overcome health disparities. In 2013, government decided to include diet advice 
and smoking cessation programs in the statutory benefits package.
What is being done to promote delivery system integration 
and care coordination?
A bundled-payment approach to integrated chronic care is applied nationwide for diabetes, 
COPD, and cardiovascular risk management. Under this system, insurers pay a single fee to 
a principal contracting entity – the care group (see above) – to cover a full range of chronic 
disease services for a fixed period. The bundled-payment approach supersedes traditional 
health care purchasing for the condition and divides the market into two segments – one 
in which health insurers contract care from care groups, and another in which care groups 
contract services from individual providers, each with freely negotiable fees [5]. The role 
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of district nurses is currently being strengthened to better coordinate care and help reach 
vulnerable populations.
 Over the last years, a number of pilot studies across the Netherlands have been initiated 
to improve integration and coordination, primarily focusing on health and lifestyle 
improvement, population management and administrative simplification. These initiatives 
have been met with mixed success.
What is the status of electronic health records?
Virtually all general practitioners have a degree of electronic information capacity – for 
example, they use an electronic health record (EHR) and can order prescriptions and receive 
lab results electronically. At present, all hospitals have an electronic health record. Providers 
must allow patients access to their own files upon request, but few hospitals have standard 
online access options for patients. Electronic records for the most part are not nationally 
standardized or interoperable between domains of care. In 2011 legislation to install a national 
electronic health record system failed in congress. Since then, integration of different 
EHR systems between hospitals and between hospitals and other providers has been left 
to the field. In 2011, hospitals, pharmacies, after-hours general practice cooperatives, and 
organizations representing general practitioners set up the Union of Providers for Health 
Care Communication (De Vereniging van Zorgaanbieders voor Zorgcommunicatie), 
responsible for the exchange of data via an IT infrastructure named AORTA; data are not 
stored centrally. Patients must approve their participation in this exchange and have the 
right to withdraw. Aorta uses unique provider identification numbers and patient social 
security numbers, in oversight of the government agency Central Healthcare Information 
and Occupation Access Point. In practice, use of this system is limited. Other initiatives have 
focused on improving data exchange. For example, MedMij is a private organization that 
develops a package of standards and agreements that ensure that portals, provider systems, 
and apps can be linked to safely exchange information.
How are costs contained?
The main approach to controlling costs relies on market forces while regulating competition 
and improving efficiency of care. In addition, provider payment reforms, including a shift 
from a budget-oriented reimbursement system to a performance- and outcome-driven 
approach, have been implemented. In light of the global financial crisis, additional activities 
have been undertaken in order to contain costs. Since 2012, healthcare spending has declined 
from 10.9% to 10.5% of GDP.
 In 2011, an agreement signed by the minister of health, all health care providers, and 
insurers set a voluntary ceiling for the annual growth of spending on hospital and mental 
care. When overall costs exceed that limit, the government has the ability to control spending 
via generic budget cuts. Because of the sector agreements, it has been argued that hospitals 
and insurers de facto negotiate lump sum contracts with budget ceilings as the most 
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important provision. The agreement included an extra 1 percent spending growth allowance 
for primary care practices in 2014 and 1.5 percent in 2015–2017, provided they demonstrate 
that their services are a substitute for hospital care. These agreements were prolonged for 
one year until the end of 2018, and the current Ministry of Health has successfully negotiated 
new agreements that will expire at the end of 2022.
 The pharmaceutical sector is generally considered to have contributed significantly to 
the decrease in spending growth. Average prices for prescription drugs declined in 2014, 
although less than in previous years, with reimbursement caps for the lowest-price generic 
contributing to the decrease in average price. Reimbursement for expensive drugs has to 
be negotiated between hospital and insurer; there is some concern, however, that this and 
other factors may limit access to expensive drugs in the near future. 
 Health technology assessment is gaining in importance and is used mainly for decisions 
concerning the benefit package and the appropriate use of medical devices. The management 
of the basic benefit package also contributes to cost-containment. Based on the advice by 
the Healthcare Institute, the Minister has negotiated lower prices with the manufacturers for 
a range of expensive drugs. The Dutch health minister has formulated an ambitious policy 
proposal aiming in part to limit the pharmaceutical industry’s power over drug pricing. 
During the Dutch European Union presidency in 2016, the topic was successfully put on the 
European Union agenda but the effectiveness of the proposed policies remains to be seen.
 The annual deductible, which accounts for the majority of patient cost sharing, has more 
than doubled between 2008 and 2018, from EUR170 (USD210) to EUR385 (USD475). There are 
some worries that this increase has led to greater numbers of people abstaining from or 
postponing needed medical care.
 Cost containment is most severe in long-term care. Since 2013, people with lower care 
needs are no longer entitled to residential care. In addition, the devolution of services to the 
municipalities as a result of the 2015 Long-Term Care Act was accompanied by substantial 
cuts to the available budgets (on average almost 10%).
 The Federation of University Medical Centers has recently started a program aimed 
at reducing lower-value services. In addition, the Dutch Federation of Medical Specialists 
launched the “Dutch Choosing Wisely” campaign, which is also aimed at reducing lower-
value services.
What major innovations and reforms have been introduced?
Long-term care, including home care, was under separate legislature (the Exceptional 
Medical Expenses Act) up to 2015. In 2015, the major reform placed residential long-term 
care under the newly created Long-Term Care Act, and transferred home care to the Health 
Insurance Act (medical home care and home nursing care) and Social Support Act (ancillary 
home services). The reform program’s main goals were to guarantee fiscal sustainability and 
universal access in the future and to stimulate greater individual and social responsibility. 
The devolution of services to the municipalities as a result of the 2015 Long-Term Care Act 
was accompanied by substantial cuts to the available budgets (on average almost 10%).
 In 2015–2016, initial budget reductions have been retracted, and future budget increases 
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worth €2.1 billion are set aside by the government to alleviate fiscal stress in nursing 
homes [6].
 In curative health care, market reform and regulated competition remain somewhat 
controversial. The government, determined to continue stimulating competition between 
insurers and providers, undertook some measures to that effect, such as requiring insurers 
and providers to assume greater financial risk. Affordability and the accessibility of expensive 
drugs have rapidly become prominent issues [7].
 As of the date of this report, the Health Insurance Act of 2006 has undergone two 
evaluations [8]. The latest evaluation pointed to an imbalance of power, with providers having 
an advantage over insurers.
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Abstract
Background  In the 2012 International Health Policy Survey by the Commonwealth Fund, 
57% of Dutch general practitioners (GPs) indicated that Dutch patients receive too much 
healthcare. This is an unexpected finding, given the clear gatekeeper role of Dutch GPs and 
recent efforts strengthening this role.
Objectives  The study aims to explore where perceived overuse of care prevails and to identify 
factors associated with too much care at the entry point of Dutch healthcare.
Method  An American survey exploring perceptions of the amount of care among primary 
care providers was modified for relevance to the Dutch health system. We further included 
additional factors possibly related to overuse based on twelve interviews with Dutch GPs. 
The survey was sent to a random sample of 600 GPs. 
Results  Dutch GPs (N=157; response rate 26.2%) indicated that patients receive (much) 
too much care in general hospitals, in primary care, in GP cooperatives as well as in private 
clinics. The Dutch responding GPs showed a relatively demand-satisfying attitude, which 
contributed to the delivery of too much care, often leading to deviation from guidelines 
and professional norms. The increasing availability of diagnostic facilities was identified 
as an additional factor contributing to the provision of unnecessary care. Finally, funding 
gaps between primary care and hospitals impede cooperation and coordination, provoking 
unnecessary care.
Conclusion  Our results – most notably regarding the demand-satisfying attitude of 
responding GPs – call into question the classical view of the guidance and gatekeeper role of 
general practitioners in the Dutch healthcare system. 
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Background
57% of Dutch general practitioners (GPs) believe patients receive (much) too much medical 
care. This was one of the main findings of the International Health Policy Survey (IHP), a 
longitudinal international comparative research study in Western countries exploring the 
experiences of general practitioners (GPs) with care. Of the ten countries, only Germany 
scored slightly higher (59%), while on the contrary in New Zealand 39% of GPs felt that 
patients actually received too little care [1].
 The general consensus is that a well-functioning primary care system provides stepped 
care: right care at the right place, on the right time, balancing quality and costs. The GP 
provides care at relatively low cost and avoids costly hospital care [2]. For that reason, in 
various countries policy is aimed at further strengthening the gatekeeper role of primary 
care. Dutch examples are the introduction of GP cooperatives for after-hours care run 
by general practitioners [3], the increased availability of diagnostic facilities in general 
practice, and the promotion of integrated care for the chronically ill through bundled 
payments [4]. In Germany, a nationwide primary care-based and physician-sustained 
disease management program has improved quality of care, while also curbing costs 
[5]. In the United States patient-centred medical homes are considered to be the most 
popular primary care delivery innovation, capable of improving quality of care while 
reducing costs [6]. Recent research indicates that this model also holds a promise for other 
countries [7].
 Meanwhile, a Dutch health policy study suggested an erosion of the role of the general 
practitioner: many patients receive specialized medical care without consulting the 
general practitioner beforehand [8]. We have known for some time that large differences 
exist in care between GP practices, with implications for the effectiveness of GP care [9]. A 
recent study in 31 European countries showed that a strong primary care system is not only 
associated with better population health, but also with higher health spending [10]. 
 To summarize, many countries are strengthening their primary care system, while 
at the same time the effectiveness and consistency of these systems is sometimes 
being questioned. The findings of the IHP survey mentioned above draw attention to a 
remarkable observation: how do we explain the fact that Dutch GPs experience so much 
excess care while working in a health care system with a clear gatekeeper? To find out, 
we conducted an exploratory study among Dutch GPs aiming to 1) understand where this 
perceived care prevails; 2) identify factors that are associated with too much care at the 
entry point of Dutch healthcare. In doing this, we aim to test assumptions supporting the 
gatekeeper system and further strengthening of this gatekeeper system. Therefore, we 
asked the respondents to assess the perceived amount of care by sector and type. Secondly, 
we used clinical cases to gain information about practice patterns and to identify factors/
motivations for choice of policy in that specific clinical case. Furthermore, we used several 
propositions describing factors possibly related to overuse and asked the respondents for 
opinion.
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Methods
We used a previously conducted American questionnaire exploring perceptions about the 
amount of care among primary care providers, as a starting point [11]. This questionnaire 
was translated into Dutch by a certified translation company. We subsequently included 
additional factors possibly related to overuse on the basis of a literature study and interviews 
with twelve Dutch GPs and adapted the questionnaire to the Dutch situation. The aim of 
the interviews was to describe cases of overuse and to identify factors possibly related 
to overuse. The interviews were thematically analyzed by two independent researchers, 
to extract the relevant factors driving overuse in the Dutch healthcare system. A third 
researcher was consulted in case of disagreement. Ultimately, 17 questions were taken from 
the American questionnaire (eg. a clinical case or questions concerning incidental findings 
which for which we changed the clinical case to be applicable in the Netherlands), while 
the remaining 19 questions were formulated on the findings of our interviews. In short, the 
questionnaire consisted of items considering perceived amount of care by sector and type, 
and factors concerning or related to practice policy, the gatekeeper role, referrals, the role of 
the patient, diagnostics, awareness of costs, the health system, and other factors possibly 
related to too much care. Most questions were in the form of propositions describing a factor 
possibly related to overuse (with some in context of a clinical case), with a 5-point likert to 
agree/disagree or alike. The questionnaire was tested for consistency and comprehensibility 
through cognitive interviewing with a GP.
 A random sample of 600 GPs, drawn from the NIVEL database ‘Health professions’, was 
invited to participate by means of an invitational letter. This letter was accompanied by 
a written questionnaire and a postage-paid business reply envelope. Two weeks after the 
first mailing, non-responding GPs received a reminder in the form of a postcard. Four weeks 
after the first dispatch, non-responding GPs  received a new copy of the questionnaire and 
again a freepost return envelope. The results of the questionnaires were analyzed using SPSS 
version 20. Respondents who did not reply to some of the questions were still included in 
the analysis; questions without an answer were considered missing. Below, the most salient 
results will be presented.
Results
Respondent characteristics
A total of 157 GPs (response rate = 26.2%) completed the questionnaire, 100 general 
practitioners (16.7%) indicated that they did not want to participate. Our sample was 
representative for the entire Dutch GP population (Table 1), with a slight over-representation 
of older male GPs as well as GPs in paid employment. Almost 80% indicated that they are 
self-employed and about two-thirds of the respondents reported having a working week of 
more than 40 hours.
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TABLE 1  Characteristics of respondents and national GP population  
Respondents
(N=157)
Dutch GP population1
(N=8831)
Gender Male (%) 60.5% 57.5%
Female (%) 39.5% 42.5%
Age (years) Average 51.2
♂54.5
♀45.8
♂51
♀442
< 35  (%) 3.9% 6.6%
35-44 (%) 21.4% 29.0%
45-54 (%) 29.9% 32.5%
55-64 (%) 44.2% 30.9%
65+ (%) 0.6% 1.0%
Primary practice setting Solo practice (%) 22.5% 25.7%
Two-person practice (%) 29.8% 37.9%
Group practice (%) 29.1% 36.4%
Health care centre (%) 17.2%
Other (%)3 1.4%
Ownership status Self-employed (%) 78.8% 88.9%
Paid employment (%) 21.2% 11.1%
Percentage of patients in 
the practice older than 65 
Under 10% (%) 7.2% Unknown
10 to 25% (%) 46.4% Unknown
26 to 50% (%) 45.1% Unknown
Over 50% (%) 1.3% Unknown
1  Source: www.nivel.nl/databank (All Dutch GPs are included in this databank.)
2  Source: Nivel. Cijfers uit de registratie van huisartsen. Peiling 2010.
3  The results under “other” usually contained digressions on one of the alternatives.
Amount of care by sector and type
A very large majority (81.4%) indicated that in their perception, patients in the Netherlands 
receive (much) too much care (Table 2, in the rest of the article we do not repeat the adjectives 
(much) too much, very or strongly used in our 5-point likerts). Focusing on type of care, a few 
highlights can be observed: over 80% of respondents felt that too much care is delivered in 
private clinics, at GP cooperatives and in hospitals. Moreover, respectively 35.5% and 36.1% 
of the respondents indicated that patients receive much too much care at the GP cooperative 
and in private clinics. More than half of the GPs (58.2%) considered that too much care was 
delivered by general practitioners themselves. In contrast, 63.2% of respondents indicated 
nursing and residential care homes as settings where patients receive too little care. Only 
the amount of palliative care was relatively often perceived as being just right (67.3%). 
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Almost all respondents (90.9%) felt that patients received too much diagnostic care. Also, 
medical treatment (78.7%) as well as monitoring and follow-up (48.7%) are provided too 
much according to the participating GPs.
TABLE 2  Opinion of Dutch GPs on amount of care patients received (by sector and type).
Much 
too little
Too little Just about 
right
Too much Much too 
much
General (IHP-question)1 0.0% 0.7% 17.9% 71.5% 9.9%
Sector
Private clinics2,4 0.0% 1.6% 13.9% 48.4% 36.1%
GP cooperative2 0.0% 1.9% 13.5% 49.0% 35.5%
Hospital2 0.0% 4.5% 11.0% 69.5% 14.9%
Primary mental health care2 0.0% 34.7% 47.9% 14.6% 2.8%
Secondary mental health care2,4 0.7% 40.3% 38.1% 17.2% 3.7%
General practitioner care2 0.0% 5.2% 36.6% 56.9% 1.3%
Home care2 2.6% 37.3% 50.3% 9.2% 0.7%
Nursing and residential care homes2 6.1% 57.1% 30.6% 6.1% 0.0%
Type
Diagnostics3 0.0% 0.6% 8.4% 74.0% 16.9%
Medical treatment3 0.0% 0.0% 22.2% 69.9% 7.8%
Monitoring and follow-up3 0.0% 9.7% 41.6% 43.5% 5.2%
Prevention3 4.6% 48.7% 23.0% 19.7% 3.9%
Rehabilitation3 0.7% 43.1% 52.1% 3.5% 0.7%
Nursing and care3 2.0% 57.8% 38.8% 1.4% 0.0%
Palliative care3 0.0% 32.0% 67.3% 0.7% 0.0%
1   Question from Commonwealth Fund IHP survey: Thinking about all the medical care your 
patients receive – not just from you, but from all their providers, including specialists – what is 
your opinion about the amount of medical care they receive? Is it…? 
2   Thinking about all the medical care your patients receive, what is your opinion about the amount 
of care they receive at the ….
3   Thinking about all the medical care your patients receive, what is your opinion about the amount 
of …….. care they receive. 
4   22 and 35 respondents chose the option ‘Do not know’ for secondary mental health care and 
private clinics respectively. 
 
Clinical cases and variation in treatment by GP
CASE 1   A patient of yours (60-year-old man) has well-controlled hypertension. This is his 
only medical problem.
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To the question ‘In general, how frequently do you schedule routine follow-up visits? Every ... 
months” the largest group responded every 6 months (42.5%), followed by every 12 months 
(30.1%) and every three months (24.8%) (N = 153).
 We presented the respondents with the additional cases 2 and 3 (see boxes and tables 
3 and 4). We asked them to what extent specific factors determined their policy. The three 
cases showed that there is a large variation in practice among the participating GPs. The GPs 
explained that their choice depended on the degree of anxiety and awareness of the patient 
and the degree to which the patient accepts the given explanation. Almost all respondents 
(more than 80%) indicated that this somewhat or substantially played a role in their choice 
of policy. Their choice was further motivated by doing what was indicated “on clinical 
grounds” (62.4%) and “doing what the patient expects him to do” (55.6%). It is also notable 
that there seems to be a division among the participating GPs: 42.9% indicated that the 
clinical indication largely determined their choice, while on the other hand 37.7% stated that 
the clinical indication did not influence their decision.
CASE 2   A mother contacts the practice by phone about her ten-year-old daughter. She has 
been coughing for two days and has a rise in temperature (38.5°) since last night. 
The daughter does not feel like eating, drinks well but started coughing heavily 
again last night. Her mother would like to have a consultation this afternoon. The 
assistant tries to give advice and explain to her that it would not seem to be neces-
sary to visit the practice. Still, the mother continues to ask for a consultation and 
the assistant would like to confer with you.
CASE 3   For many years, your patient has suffered from chronic daily headaches. This 
worries him considerably. You know the patient well, he often visited your practice 
for these complaints. You have never been able to find out the cause. The last med-
ication you prescribed also had no effect. The patient is distraught and asks for a CT 
scan or MRI of the head to be made.
 
TABLE 3  What would be your policy with regard to case 2?  
 
Policy
Tell the assistant that the proposed policy (the assistant informs the mother that it 
is not necessary to come to the practice) is all right and that the demand for office 
visits will not be honored.
5.7%
You ask the assistant to call the mother and ask her to wait for a while. If the fever 
persists for more than three days, she can phone in the morning for an appointment.
35.7%
You offer the mother a consultation by telephone. 22.3%
You let the mother and daughter come to the practice. 36.3%
TABLE 4  What would be your policy with regard to case 3? 
  
Policy
You try to calm the patient and explain that a CT scan or MRI for these complaints 
is not useful.
21.7%
You request a CT scan or MRI for him. 3.9%
You refer the patient to a neurologist. 74.3%
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Patient-provider relationship factors
Nearly all (> 90%) respondents indicated that patients experience health care as a right, and 
that this fact leads to unnecessary care. A comparable proportion indicated that patients 
have a strong need for an explanation and certainty, and that this also leads to unnecessary 
care. Two thirds (66.1%) stated that when patients really wanted to be referred, they would go 
along with this as they prevailed to maintain the relationship with the patient.
Provider decision-making and clinical guideline issues
Pancreatic lipomatosis in an ultrasound for possible cholelithiasis is an example of incidental 
findings in diagnostics. To the question “How often are you faced with such incidental 
findings?” 29.4% of the respondents answered often and 6.5% very often. It is notable that 
one-third (32.2%) of the respondents usually and 4.6% almost always request additional 
tests to clarify incidental findings. Only a minority (38.0%) indicated that they do not bother 
to deviate from the written recommendation of the radiologist when confronted with 
incidental findings. Most GPs indicated that they felt obliged to follow the recommendation 
(23.3%) or deviate from the recommendation only in exceptional circumstances (38.7%). 
Additionally, more than two-thirds (70.9%) found that the availability of diagnostic 
tools (ECG/spirometry) at the practice leads to more investigations, as opposed to these 
investigations having been requested. Moreover, according to 61.6% of the respondents, 
some guidelines prescribe so many monitoring tests that they feel they request these 
required tests unnecessarily.
Issues related to the relationship between primary care and other sectors
According to the respondents, a variety of factors may increase or decrease the number of 
referrals. A lack of time at the moment of referral and fear of making mistakes led to an 
increased number of referrals (more than 60% of the respondents). According to 70.9% of 
the participating GPs, patients are reassured more quickly when he or she refers increasing 
the number of referrals. More than half (54.1%) indicated that it takes a lot of time and effort 
to convince a patient that an additional investigation is not beneficial. This further increased 
the number of referrals. 
 The fact that patients easily receive hospital care without a referral from a general 
practitioner leads to unnecessary care, according to 64.3% of the GPs. Almost 80% of 
respondents indicated that some patients prefer the GP cooperative as an alternative for 
the regular practice-based primary care and that this leads to unnecessary care. Over 80% 
of respondents considered that insurers reimburse care in hospitals that could be provided 
by the GP, which provoked unnecessary care. 70% thought that insurers could more 
actively guide providers to reduce unnecessary care. 72.4% indicated that funding gaps 
between primary care and hospitals impede cooperation and coordination, which provoked 
unnecessary care.
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Discussion
According to the 26% of invited Dutch GPs who responded to this survey, patients receive 
too much care in general hospitals, in primary care, in GP cooperatives as well as in private 
clinics. The Dutch responding GPs’ demand-satisfying attitude and the increased availability 
of diagnostic facilities most saliently contribute to the provision of perceived excess care 
at the entry point of care in the Netherlands. Also misaligned incentives induce that Dutch 
responding GPs do not sufficiently pick up the gatekeeper’s role. Below, these findings are 
discussed more elaborately.  
 Our results show that responding practitioners find it difficult to deny demanding 
patients access to further care, even if they think treatment is unnecessary from a medical 
point of view. This creates an image of responding GPs acting in a demand-satisfying way 
in their referrals and treatment decisions. It is likely that this contributes to the perceived 
amount of overdiagnosis and overtreatment. 
 The demand-satisfying attitude of the responding GPs puts into question the classic, 
possibly simplified, image of the ‘gatekeeper’ impeding access to expensive unnecessary 
hospital care. According to 84.1% of the respondents, too much care is provided at hospitals, 
an indication that the gatekeeper system, originally meant to be a gateway to secondary 
care, is working suboptimal. A recent Dutch study showed a threefold variation in referral 
rates to medical specialists between GPs. This variation was driven by the physician practice 
pattern, not by the patient case mix [12]. Undoubtedly, this variation leaves ample room 
for improvement, although the optimal level of referral is unknown. A myriad of policy 
options is available to reduce referrals, such as tightening or more explicitly defining the 
criteria for referral, implementing (multidisciplinary) guidelines, increasing conversation 
and collaboration between primary and secondary care or benchmarking GPs on referral 
rates [12-15]. 
 The possibility of bypassing the general practitioner in favour of hospital care (for 
example via the emergency department), as well as budget gaps between primary care and 
hospitals and the absence of guiding insurers impede general practitioners in maintaining 
their role of gatekeeper. Our results show that responding GPs themselves are prepared to 
avoid perceived unnecessary hospital care – versus reducing perceived unnecessary care 
in primary care – yet that the preconditions at the level of the health system do not meet. 
Bundled payments or medical specialist consultation at primary care practice may in theory 
(partly) overcome this problem [16].
 The three cases illustrate that there is probably a large variation in practice among Dutch 
responding GPs. Such variation suggests that some patients receive suboptimal care and 
that there is ample room for improvement. Our findings indicate that Dutch responding GPs 
are not determined to their role of commissioners of care. Moreover, responding GPs admit 
to providing a lot of unnecessary care themselves. The combination of a demand-satisfying 
attitude of the Dutch responding GPs, with consumerism among patients (patients 
perceive health care as their right), drives this perception. Shared decision making may be 
a feasible strategy to address both factors. The evidence-based source Clinical evidence 
estimates that only a minority of treatments is ‘beneficial’ (11%) or ‘likely to be beneficial’ 
(24%). The remaining treatments were classified at best as ‘a trade-off between benefits 
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and harms’ (7%) to having an ‘unknown effectiveness’ (50%) [17]. Thus, in many instances an 
evidence base may not be able to provide the best alternative. Rather, two or more medically 
acceptable alternatives may exist, whereby the choice should be dependent on the patients’ 
preferences and the possible harms and benefits of each alternative [18]. Research shows that 
when patients are better informed they tend to opt for a more conservative approach [19]. 
An example of this is the study done by Fleuren et al, who showed that the implementation 
of a shared care guideline for lumbosacral radicular syndrome reduces unnecessary early 
referrals [20]. 
 According to responding GPs, the availability of (access to) new diagnostic facilities in 
primary care leads to added risk of accidental discoveries and follow-up treatments, but 
also to unnecessary diagnostics itself. Therefore, this seems to contribute to perceived 
unnecessary care. Our findings raise the question of how to combine the increased 
possibilities for diagnosis and treatment at primary care with a prudent use. Due to the 
increasing possibilities for diagnosis and treatments, supply-induced demand might 
become a major theme in primary care as well. 
 Remarkably, our study showed that responding GPs sometimes question the necessity 
of care provided and requested at GP cooperatives (which is actually care delivered by 
responding GPs themselves). In 2006, Giesen et al [21] found that more than three quarters 
of all contacts at GP cooperatives did not concern urgent problems, which may explain the 
perceived amount of excess care we found. Both our study and the study by Giesen et al raise 
the question how to practically shape the GP cooperatives. Both observations concerning 
diagnostic facilities and GP cooperatives are relevant, since these are actively encouraged in 
the Netherlands and in many OECD-countries, one of their objectives being the reduction of 
unnecessary care. 
 Finally, we confirmed the finding of Sirovich et al [11] that due to a lack of time responding 
GPs practice in a more active style concerning ordering diagnostic tests and referrals, 
although malpractice concern and clinical performance measures play a less prominent 
role in the Netherlands, as opposed to the USA. In the Netherlands the average numbers of 
inhabitants per GP is 2300, which is relatively high. This may explain the working pressure 
and active practice style.   
Limitations 
The participating GPs were slightly older, did less frequently work in a solo practice, and were 
more often than the national average in paid employment. Given the difference in score on 
the IHP-question (81% in our study compared to 57% in the IHP-survey [1]), response bias 
may have played a role in this study in the sense that more critical GPs may have been more 
likely to respond. Even so, this will not necessarily affect the validity of the identified factors 
that we found to be related to excess or unnecessary care. Moreover, non-response studies 
among physicians have shown no or minimal amounts of response bias, suggesting that 
physician surveys are more resilient to non-response than other types of surveys [22]. Overall, 
we conclude that the low response rate may represent some response bias but given the 
explorative nature of the study and the bold statements made by a substantial group of GPs, 
the results justify further research. 
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Conclusion
This study shows that, according to Dutch responding GPs, a lot of unnecessary care is 
delivered in hospitals, GP cooperatives and in private clinics. According to the responding 
GPs the demand-satisfying attitude of general practitioners contributes to perceived 
unnecessary care, as does the increased availability of diagnostics. The assumption that the 
costs of additional investments in primary care will be automatically paid back by reducing 
unnecessary care at hospitals needs to be further investigated. The various roles of the 
GP – gatekeeper, patient navigator, therapist and navigator – are of interest in this. Shared 
decision making has most potential in addressing both the demand-satisfying attitude of 
GPs and consumerism among patients. However, questions remain regarding the potential 
impact of such a strategy and more research on shared decision making and alternatives 
is needed, because it is still in stage of infancy/a novel phenomenon. Our results indicate 
that further discussion and exploration by GPs and policy makers about the complicated 
and sometimes unintended effects of strengthening primary care and its interactions with 
unnecessary care may be fruitful. Supply-induced demand does not stop beyond medical 
specialists; primary care doctors are ‘vulnerable’ to it as well.
48 Chapter 3
References
1 Schoen C, Osborn R, Squires D, et al. A survey of primary care doctors in ten countries 
shows progress in use of health information technology, less in other areas. Health 
affairs. Dec 2012;31(12):2805-2816.
2 Starfield B, Shi L, Macinko J. Contribution of primary care to health systems and 
health. The Milbank quarterly. 2005;83(3):457-502.
3 Thijssen WA, Wijnen-van Houts M, Koetsenruijter J, Giesen P, Wensing M. The impact 
on emergency department utilization and patient flows after integrating with a 
general practitioner cooperative: an observational study. Emergency medicine 
international. 2013;2013:364659.
4 NZa. Consultatiedocument Eerstelijnsdiagnostiek. Goede beeldvorming beter in 
beeld. 2011.
5 Stock S, Drabik A, Buscher G, et al. German diabetes management programs improve 
quality of care and curb costs. Health affairs. Dec 2010;29(12):2197-2205.
6 Hoff T, Weller W, DePuccio M. The patient-centered medical home: a review of recent 
research. Medical care research and review : MCRR. Dec 2012;69(6):619-644.
7 Faber M, Voerman G, Erler A, et al. Survey Of 5 European Countries Suggests That 
More Elements Of Patient-Centered Medical Homes Could Improve Primary Care. 
Health affairs. Apr 2013;32(4):797-806.
8 Plexus K. Onderzoek naar de effectiviteit van poortwachters in het Nederlandse 
zorgstelsel 2000 – 2010. 2012.
9 Cardol M, Dijk Lv, Jong Jd, Bakker Dd, Westert G. Huisartsenzorg: wat doet de 
poortwachter? : NIVEL. RIVM. ;2004.
10 Kringos DS, Boerma W, van der Zee J, Groenewegen P. Europe’s strong primary care 
systems are linked to better population health but also to higher health spending. 
Health affairs. Apr 2013;32(4):686-694.
11 Sirovich BE, Woloshin S, Schwartz LM. Too Little? Too Much? Primary care physicians’ 
views on US health care: a brief report. Archives of internal medicine. Sep 26 
2011;171(17):1582-1585.
12 van Dijk C, Korevaar J, de Jong J, Koopmans B, van Dijk M, de Bakker D. Ruimte voor 
substitutie? Verschuivingen van tweedelijns- naar eerstelijnszorg. NIVEL;2013.
13 Iacobucci G. GPs put the squeeze on access to hospital care. Bmj. 2013;347:f4432.
14 Katz MH. How can we know so little about physician referrals? Archives of internal 
medicine. JAN 23, 2012 2012;172(2).
15 Dijkstra R, Brugge At. De poortwachtersrol in het licht van toekomstbestendige 
hoogwaardige Gezondheidszorg. Amsterdam: Coincide;2013.
16 Struijs JN, Baan CA. Integrating care through bundled payments--lessons from The 
Netherlands. The New England journal of medicine. Mar 17 2011;364(11):990-991.
17 What conclusions has Clinical Evidence drawn about what works, what doesn’t based 
on randomised controlled trial evidence?  http://clinicalevidence.bmj.com/x/set/
static/cms/efficacy-categorisations.html. Accessed 19 februari, 2014.
18 Stiggelbout AM, Van der Weijden T, De Wit MP, et al. Shared decision making: really 
putting patients at the centre of healthcare. Bmj. 2012;344:e256.
Is the role as gatekeeper still feasible? A survey among Dutch general practitioners 49
19 Stacey D, Legare F, Col NF, et al. Decision aids for people facing health treatment or 
screening decisions. The Cochrane database of systematic reviews. 2014;1:CD001431.
20 Fleuren M, Dusseldorp E, van den Bergh S, et al. Implementation of a shared care 
guideline for back pain: effect on unnecessary referrals. International journal for 
quality in health care : journal of the International Society for Quality in Health Care / 
ISQua. Oct 2010;22(5):415-420.
21 Giesen P, Franssen E, Mokkink H, van den Bosch W, van Vugt A, Grol R. Patients either 
contacting a general practice cooperative or accident and emergency department out 
of hours: a comparison. Emergency medicine journal : EMJ. Sep 2006;23(9):731-734.
22 Flanigan T, McFarlane E, Cook S. Conducting Survey Research among Physicians and 
other Medical Professionals – A Review of Current Literature. Proceedings of the 
Survey Research Methods Section; 2008.

CHAPTER 4
Identifying and prioritizing lower 
value services from Dutch specialist 
guidelines and a comparison with the 
UK do-not-do list
Joost Johan Godert Wammes
M. Elske van den Akker-van Marle 
Eva W Verkerk
Simone A van Dulmen
Gert P Westert
Antoinette DI van Asselt
Tijn Kool
BMC Med. 2016 Nov 25;14(1):196.
52 Chapter 4
Abstract
Background  The term ‘lower value services’ concerns healthcare that is of little or no value 
to the patient and consequently should not be provided routinely, or not be provided at all. 
De-adoption of lower value care may occur through explicit recommendations in clinical 
guidelines. The present study aimed to generate a comprehensive list of lower value services 
for the Netherlands that assesses the type of care, and associated medical conditions. The 
list was compared with the NICE do-not-do list (United Kingdom). Finally, the feasibility of 
prioritizing the list was studied – to identify conditions where de-adoption is warranted. 
Methods  Dutch clinical guidelines (published from 2010-2015) were searched for lower value 
services. The lower value services identified were categorized by type of care (diagnostics, 
treatment with and without medication), type of lower value service (not routinely provided 
or not provided at all) and ICD10-codes (international classification of diseases). The list was 
prioritized per ICD10-code, based on the number of lower value services per ICD10-code, 
prevalence and burden of disease. 
Results  A total of 1366 lower value services was found in the 193 Dutch guidelines included in 
our study. Of the lower value services 30% covered diagnostics, 29% related to surgical and 
medical treatment without drugs primarily and 39% related to drug treatment. The majority 
(77%) of all lower value services was on care that should not be offered at all, whereas the 
other 23% recommended on care that should not be offered routinely. ICD10-chapters 
that included most lower value services were neoplasms and diseases of the nervous 
system. Dutch guidelines appear to contain more lower value services than UK guidelines. 
The prioritization processes revealed several conditions – including back pain, COPD and 
ischaemic heart diseases – where lower value services most likely occur and de-adoption is 
warranted. 
Conclusion  In this study, a comprehensive list of lower value services for Dutch hospital 
care was developed. A feasible method for prioritizing lower value services was established. 
Identifying and prioritizing lower value services is the first of several necessary steps in 
reducing them. 
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Background
Quality of healthcare is reflected by “the degree to which health services for individuals 
and populations increase the likelihood of desired health outcomes and are consistent 
with current professional knowledge” [1]. Conform this definition, evidence-based medicine 
means that good medical practices are replaced by better ones when robust scientific 
evidence becomes available and practices that are outdated or proven invaluable to patients 
will be de-adopted. This ideal world is in sharp contrast with current medical practice [2,3]. 
 Current practice is not always high-value or evidence-based. Lower value or lower quality 
of care may either be classified into misuse, overuse or underuse of health care services [4]. 
The focus of this paper is overuse; which occurs when a health care service is provided under 
circumstances in which its potential for harm exceeds the possible benefit [4]. In our study 
we also include (cost-)ineffective care, inappropriate timing of care or care not in line with 
the patients’ wishes as lower value services. Many questions remain about the size of the 
problem. However, scientific literature suggests that overuse represents between 10% and 
30% of provided services, of which a part is lower value care, resulting in worse outcomes 
including death and unnecessary costs [2,3,5]. We consider these services as lower value 
services, because they have no net value for the patient and de-adoption – a substantial 
reduction of providing or using the service in daily medical practice – is warranted. 
 During the last decade, efforts have been undertaken to de-adopt lower value services. 
UK’s National Institute for Health and Care Excellence (NICE) started working on de-adoption 
in 2005 [6] which resulted in the ‘do-not-do list’ [7]. In the US, the National Physician Alliance 
started developing “Top Five” lists since 2009 and initiated the Choosing Wisely initiative 
in 2012 [8]. Australian activities were centered around the Medicare Benefits Schedule [9]. 
The basis of these programs is usually a (long) list of lower value services and sometimes a 
prioritization process to identify candidates for de-adoption [9,10]. 
 The methods for creating these lists are diverse, and prioritization based on impact 
proves to be difficult. For example, Choosing Wisely lists varied widely in potential impact on 
daily care and spending; and specialist societies tended to list colleague specialties’ services 
as lower value [8]. UK research has shown additional challenges, such as a lack of reliable 
evidence on the clinical merits of many services [11]. A prominent problem in overuse is that 
interventions which are high-value for a given subpopulation are inappropriately applied 
to other populations [12]. Candidate lists tend to be large and the potential gains in health 
and cost vary widely across lower value services. Therefore, as resources for de-adoption are 
limited, prioritization of lower value services for de-adoption is warranted. 
 To conclude, there is need for an objective approach to identify and prioritize lower value 
services for practical de-adoption [11]. This article describes the development of a list of lower 
value services identified from 193 Dutch clinical practice guidelines, published between 2010 
and 2015. The list was developed with the aim to provide a comprehensive list of lower value 
services for Dutch hospital care. Furthermore, our list was compared with the NICE do-not-
do list on several aspects, including types of care, and patient groups. Finally, the feasibility 
of prioritizing the list was studied. We hypothesized the prevalence of a disease and disease 
burden (a rationale for choice of criteria is given in the discussion) could serve as robust 
criteria for prioritization. 
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Methods
Development of lower value services list
Dutch guidelines contain specific recommendations to ensure that lower value care is not 
offered, or only applied to specific subpopulations or under limiting conditions. In the current 
study we identified these do-not-do recommendations. We have limited the analysis to the 
most recent and up to date guidelines published between January 2010 and May 2015 by the 
scientific societies, as Dutch guidelines are recommended to be revised every five years [13]. 
The guidelines were taken from a guideline database hosted by the Dutch Association of 
Medical Specialists (www.kwaliteitskoepel.nl) covering (mental) hospital care. 
 Firstly, we randomly selected eleven guidelines which were fully read by four researchers 
(SD, EV, JW and MEAM) to identify recommendations on care that should not be offered and 
care that should not be offered routinely. For each do-no-do recommendation identified, 
we listed whether the key term identifying the do-not-do recommendation was one of the 
search terms applied by NICE in the ‘do not do’ study (for example, ‘discontinued’, ‘should 
not’, ‘do not’ [14]) or a new term that should be added (e.g. ‘omit’). Recommendations that 
focused on too little use of care (underuse) were not included. For example: “Restraint is 
not necessary when starting opioids and will lead to a substantial deterioration in quality of 
life by the experienced severe shortness of breath” (Guideline Palliative care for people with 
COPD). Finally, recommendations that focus on organization of care were not included. For 
example, “It is not recommended that professionals who have no experience with patients /
offenders with antisocial personality (disorder) address the issue of the committed violence” 
(Guideline Domestic violence in children and adults). A fifth researcher (RBK) was consulted 
in case of no consensus. 
 Furthermore, the specific section of the guideline in which the do-not-do recommendation 
was written was identified. The standard format of guidelines contains five sections: clinical 
question, recommendations, substantiation, considerations and justification. As in the first 
five guidelines all the recommendations were found in the sections ‘recommendations’ and 
‘considerations’ of the guidelines, subsequently only these sections of the electronic/PDF 
copy of a guideline were searched with the terms from Table 1. 
 Another nine guidelines were independently screened by the four researches (SD, MEAM, 
EV and JW) to determine the inter-rater reliability. Inter-rater reliability was analyzed by 
calculating Fleiss’ Kappa (k) for multiple raters [15]. 
 Using this method, the other guidelines were screened (in total 193), and any ambiguities 
were discussed with another researcher until consensus was reached. When guidelines 
were not constructed according to the standard format and therefore did not contain the 
paragraphs with recommendations and considerations, they were fully screened. For 
each do-not-do recommendation identified we assessed whether the care should not be 
offered at all or should not be offered routinely to all patients and what type of care the 
recommendation was about: diagnosis, treatment without medication, treatment with 
medication, and a residual category. 
 Guidelines that have been published in English were screened with English terms. Patient 
versions of guidelines were not included and also addenda to guidelines with original 
publication date before 2010 were excluded. 
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TABLE 1  Shortlist search terms 
Dutch [English translation] English
Niet [Not]
Geen [No]
Stop [Stop]
Onvoldoende [Insufficient]
Zelden [Seldom]
Alleen [Only]
Kosten [Cost]
Vermijd/Vermeden [Avoid]
Achterwege [Omit]
Onnodig [Unnecessary]
Afgeraden [Discourage]
Ontraden [Dissuade]
Staken/Gestaakt [Cease]
Discontinue/discontinuation
Not
No 
Ineffective
Uncertain
Avoid
Rarely
Stop
 
Connection with International Classification of Disease, Tenth Edition 
(ICD10) code
The lower value services described in the do-not-do recommendations were provided with 
an ICD10-code by searching within the ICD10-encoding [16] on the condition in question. 
When necessary, additional information was sought in the guideline the lower value 
service originated from and/or Wikipedia. If the lower value service was related to two (or 
more) conditions the guideline topic was selected for the ICD10-coding. For example, the 
guidance ‘European Guidelines on cardiovascular disease prevention in clinical practice’ 
included the recommendation ‘Beta-blockers and thiazide diuretics are not recommended 
in hypertensive patients with multiple metabolic risk factors increasing the risk of new-
onset diabetes’. This recommendation was categorized to the ICD10-code for hypertensive 
diseases. If the patient population receiving the lower value service could not be related 
to an ICD10-code, for example in the case of prevention in a healthy population, then the 
ICD10-code of the disease prevented was chosen. For example, the lower value service ‘Do 
not use throat swabs when investigating for possible meningococcal disease’ concerns the 
population with suspected meningococcal disease. Since there is no ICD10-code for this 
population, the ICD10-code of meningococcal disease was chosen. Complex cases were 
discussed between two researchers until consensus was reached. ICD10-codes were then 
aggregated to ICD10-chapters, the highest level of categorization in ICD10.
Comparison with NICE do-not-do database
In the development of NICE guidelines, clinical practices were identified which should not 
be used at all or should not be used routinely. These practices have been collected in the 
“do-not-do database” [7]. NICE has made an Excel file of the database (dated September 
29, 2015) available to us upon request. We compared the average number of do-not-do 
recommendations per NICE guideline with the Dutch number. Furthermore, for each 
recommendation from the NICE do-not-do database we assessed whether the care should 
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not be offered at all or should not be offered routinely and what type of care was concerned 
(diagnosis, treatment without medication, treatment with medication). Finally, the same 
procedure with respect to assigning ICD10-codes was followed.
Prioritization
Prioritization of conditions for further research on lower value services for de-adoption was 
done by aggregating the lower value services described in the do-not-do recommendations 
by ICD10-codes, as the data for prioritization were only available at this level of aggregation 
and not for individual lower value services. Per ICD10-code we identified prevalence estimates 
and disease burden as available in the Global Burden of Disease studies [17] (a detailed 
description of the methodology is given in appendix 1). Prioritization was based on the 
number of lower value services per ICD10-code, prevalence and burden of disease (expressed 
in Years Lived with Disabilities (YLD) and Disability Adjusted Life-Years (DALY)). Each criterion 
was categorized in four groups according to level. Per criterion the group with the highest 
levels was assigned four points. Subsequently, the ICD10-codes were prioritized by the sum 
of scores for the number of lower value services, prevalence, YLD and DALY (Method 1), the 
highest score (up to 16) indicating the highest priority for de-adoption. As we were interested 
in the impact of burden of disease measures on prioritization (both YLD and DALY reflect 
burden of disease) we omitted these criteria in sensitivity analyses, and the prioritization 
was repeated for the sum of the number of lower value services and prevalence (Method 2; 
maximum score 8). For the NICE do-not-do database the same prioritization was performed, 
using UK-specific data on prevalence, YLD and DALY. In appendix 1, a full description of the 
prioritization methodology is given. 
Results
Descriptives Dutch list of lower value services
In total, 1366 lower value services were extracted from the 193 Dutch guidelines on (mental) 
hospital care, implying that each guideline contained on average 7.1 (modus=0; median=5; 
maximum=45) lower value services. Of these guidelines 29 did not contain any lower value 
services. The inter-rater reliability was 0.803 (Fleiss k), indicating a substantial agreement [18]. 
Table 2 shows the average number of lower value services per guideline between 2010 and 
2015. The number of guidelines published in 2014 and 2015 was relatively low because of the 
ending of a subsidy program. The majority of lower value services was, if necessary after 
deliberation within the project group, successfully linked to an ICD10-code. In 98 cases 
(<8%), no ICD10-code could be assigned, predominantly because the recommendation was 
ambiguous concerning the patient group, or the patient group was insufficiently specific 
(e.g. ‘essentially, laparoscopic surgery does not require different fluid management than 
open surgery’). 
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TABLE 2  Number of lower value services per year in Dutch guidelines.
Year Number of guide-
lines published
Number of lower 
value services
Average number of lower value 
services per guideline
2010 61 357 5.85
2011 41 249 6.07
2012 44 347 7.89
2013 35 312 8.91
2014 2 45 22.5
2015 6 59 9.83
Of the lower value services, 415 (30%) related to diagnostics, such as ‘There is no place 
for FDG-PET in the detection of micro metastases’ (guideline anus carcinoma, Dutch list). 
399 lower value services (29%) related to non-drug treatment, such as ‘The insertion of a 
pulmonary artery catheter (PAC) in case of acute heart failure is rarely needed’ (guideline 
heart failure, both in Dutch list and NICE database). Finally,  527 lower value services (39%) 
related to drug treatment, such as ‘Methotrexate is not recommended for hidradenitis 
suppurativa’ (guideline acneiform dermatoses, Dutch list). The remaining 25 (2%) lower 
value services did not fit into these categories (e.g. vaccination or recommendations on 
referral and discharge procedures). The majority (77%) of all lower value services concerned 
care that should not be offered at all, whereas the other 23% recommended on care that 
should not be offered routinely.       
 Figure 1 shows the number of lower value services identified per ICD10-chapter. For the 
Dutch guidelines, ‘neoplasms’ and ‘diseases of the nervous system’ are the most frequent 
chapters, followed by ‘symptoms, signs and abnormal clinical and laboratory findings – not 
elsewhere classified’, ‘diseases of the circulatory system’, ‘diseases of the musculoskeletal 
system and connective tissue’ and ‘mental and behavioral disorders’. Relatively few lower 
value services were found in ICD10-chapters ‘external causes of morbidity and mortality’, 
‘conditions originating in the perinatal period’, and ‘diseases of the blood and blood-forming 
organs and certain disorders involving the immune mechanism’. 
Comparison with NICE do-not-do recommendations
The database contained 188 guidelines in which 1006 do-not-do recommendations (lower 
value services) were found. The UK guidelines thus covered relatively few lower value 
services: on average 5.4 (modus=1; median=3; maximum=32) per guideline. UK guidelines 
covered slightly fewer lower value services related to diagnostics (28%) and non-drug 
treatment (25%), and relatively many lower value services related to drug treatment (46%). 
In addition, UK lower value services less likely described care that should not be offered at 
all (68%), whereas the other 32% recommended on care that should not be offered routinely. 
Finally, UK do-not-do recommendations more frequently covered mental and behavioral 
disorders, diseases of the genitourinary system, pregnancy, childbirth and the puerperium 
(see figure 1).        
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FIGURE 1   Number of lower-value services per ICD-10 group for Dutch guidelines and NICE do-not-do list.
Prioritization of Dutch lower value services
As mentioned, the ranking was performed according to two different strategies. The results 
of the ranking by prevalence, DALY, YLD and number of recommendations (method 1) is 
represented in figure 2. Both dorsalgia (back pain) and other chronic obstructive pulmonary 
diseases were assigned the maximum score of 16, followed by other acute ischaemic heart 
diseases, iron deficiency anaemia, lichen planus, and other disorders of bone (in particular the 
complex regional pain syndrome type 1) which each scored 14 points. Furthermore, out of the 
top-25 prioritized ICD10-codes, ten (40%) are in chapter M, i.e. diseases of the musculoskeletal 
system and connective tissue. When the ranking was performed by only prevalence and 
number of recommendations (method 2, figure 3), three diseases obtained the maximum 
score, i.e. dorsalgia, other chronic obstructive pulmonary disease, and lichen planus. 
 Generally speaking, neoplasm ICD10-codes receive a more modest priority when number 
of recommendations and prevalence are the only criteria for prioritization, but receive higher 
priority when burden of disease criteria are included. Ranking results for UK lower value 
services are provided in appendix 2. 
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FIGURE 2  Ranking results from Dutch guidelines (method 1). 
 
 
FIGURE 3  Ranking results from Dutch guidelines (method 2). 
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Discussion
In this study, we developed a comprehensive list of lower value services for Dutch hospital 
care and studied the feasibility of prioritizing the list. In addition, we repeated the descriptive 
analyses and prioritization for the UK do-not-do database. In total, 1366 lower value 
services were extracted from 193 Dutch guidelines. Of the lower value services 30% covered 
diagnostics, 29% related to non-drug treatment and 39% to drug treatment. The majority 
(77%) of all lower value services was on care that should not be offered at all, whereas the 
other 23% recommended on care that should not be offered routinely. ICD10-chapters that 
included most lower value services were neoplasms and diseases of the nervous system. 
Further research and policy aimed at reducing lower value services are highly warranted. 
A recent Dutch study showed avoidable costs are evident in healthcare: about 60 million 
euro can be saved in the Netherlands, when 23 lower value surgical procedures – actual use 
approximately 11,800 in the Netherlands – are not performed anymore [19]. 
 The prioritization processes revealed several ICD10-codes with relatively high prevalence 
and disease burden where lower value services most likely occur and de-adoption is 
warranted, including back pain, chronic obstructive pulmonary diseases, acute ischaemic 
heart diseases, iron deficiency anemia, lichen planus, disorders of bone, and malignant 
neoplasms of bronchus and lung. These findings are relevant, given the corresponding 
opportunities for further research. However, this prioritization should be interpreted with 
caution, it does not prove lower value services are actually provided to these groups. Rather, 
based on robust criteria we recommend further research into the presence of lower-value 
services in these conditions. 
 The Dutch and UK list show similarities as well as differences. Dutch guidelines appear to 
contain more lower value services than the UK guidelines (7.1 on average vs 5.4 respectively). 
These data suggest Dutch guideline developers might be more aware of the existence of lower 
value services or might consider incorporating do-not-do recommendations in guidelines 
more important than their UK colleagues. However, differences in followed methodology 
might have spurred this difference. We only included guidelines published between 2010 
and 2015, whereas NICE started in 2005, and we have shown an increase in number of do-
not-do recommendations per year. Moreover, we also included recommendations from 
consideration-sections. This probably makes the Dutch list more comprehensive. 
 The development of a comprehensive list of lower value services and prioritization is only 
the first of several necessary steps in actually reducing lower value services, starting with 
measuring the actual use of lower value services. As discussed above, many uncertainties 
remain about the prevalence of lower value services. Estimates for the Netherlands date 
back to the ‘90s [3], or have to be gauged from case studies. Like Morgan et al [5] we support 
routine monitoring of potential “outbreaks” in use of diagnostics and treatment methods 
and variation in routine care. Such an approach entails large scale measurements using real 
time administrative data with sufficient clinical detail to assess appropriateness of care and 
risk adjustment; which are not yet available in the Netherlands. De Vries et al [27] recently 
identified 115 lower value care measures, which mainly focused on the cure sector. Apart 
from these indicators, our database could be used for developing new and valid indicators 
for lower value care.     
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Early evidence shows that dissemination of recommendations alone is not sufficient to 
ensure de-adoption, and that additional specific interventions are required. For example, 
a first evaluation of the Choosing Wisely initiative showed marginal reductions of use, if 
any [20], whereas Schwartz et al [30] showed alternative payment models with global budgets 
successfully discouraged overuse. Several papers discuss interventions or provide roadmaps 
for reducing overuse or promoting/advancing de-adoption [5,21,22]. Most notably, Niven et al 
proposed a conceptual model for the process of de-adoption; which shares much of the 
original Knowledge-to-Action Cycle [22,23]. The proposed framework emphasizes in-depth 
analyses of barriers and facilitators, which is deeply grounded in adjacent fields, such as 
implementation science [24]. Paprica et al [25] underlined stakeholders should be involved 
in de-adoption. In their analysis, they point to the trinity by Lomas et al [26] – medical 
effectiveness research (context-free scientific evidence), social science-oriented research 
(context-sensitive scientific evidence), and the expertise, views, values, and realities 
of stakeholders (colloquial evidence) – and show that colloquial evidence has a major 
influence in de-adoption. Local stakeholder involvement is therefore pivotal in de-adoption 
initiatives. In this study, we focused on identifying and prioritizing lower value services. 
This process is central to the Niven framework and is ideally performed concomitant with 
stakeholder engagement. Stakeholders could, for example, participate in choosing and 
weighting prioritization criteria. In addition, expert panels  could be employed to further 
rank our list of lower value services on appropriateness of the services and priority for de-
adoption [29].  
 In the Netherlands, exactly the above formula for reducing lower value care is being 
followed. The Dutch Federation of University Medical Centers recently initiated a four year 
program for reducing lower value services. The current study is the first outcome of this 
project and in June 2016, all eight university hospitals start local de-adoption pilot projects. 
The current list and prioritization contributed to selecting appropriate conditions and lower 
value services for de-adoption. The list will be integrated with the guideline database [31] 
of the Dutch Association of Medical Specialists. On this website, all lower value service 
recommendations will be highlighted, and special attention will be paid to the fact that in 
these cases not acting is a better solution. 
Limitations 
The methodology we developed for this study has a number of limitations, for a large 
part related to ambiguity in guideline recommendations and lacking data. Ambiguity in 
guideline recommendations sometimes made it difficult to discern lower value services, 
or to distinguish between care that should not be offered at all, and care that should 
not be offered routinely. In some cases, it was explicitly mentioned that care was not 
recommended, whereas in others, this was less explicit. For example, “No recommendations 
can be given for the use of tramadol or oxycodone in the emergency medical treatment on 
the basis of the emergency care literature.” (Guideline Pain management in emergency care 
chain). These recommendations have been included as the context shows that application 
is not indicated. To cope with ambiguous recommendations regular meetings were held to 
discuss disputable items until consensus was reached. Nevertheless, ambiguity of guideline 
recommendations or ambiguous populations may have biased our findings. 
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The Dutch list of lower value services was developed to comprehensively cover lower value 
services in Dutch hospital care. We restricted inclusion of guidelines to the period from 
2010 until May 2015, as Dutch guidelines are recommended to be revised every five years [13]. 
As a result, we could not take into account important conditions or diseases covered by 
older guidelines, by guidelines published after May 2015 or not covered by guidelines at 
all. Furthermore, we might have missed some lower value services that lacked one of the 
keywords we identified. We therefore recommend to routinely update the list and to update 
the list of keywords. 
 Ideally, lower value services are prioritized based on the following criteria: the availability 
of evidence that a service is ineffective or harmful, patient safety, potential health and 
cost impact of de-adoption, availability of alternative practices [28] and the actual use 
of the lower value service. Clarifying such information for over a thousand lower value 
services proved impossible and much of such detailed information is currently lacking. 
We therefore developed alternative criteria as close as possible to the criteria proposed by 
Elshaug et al. Notwithstanding the methodological hurdles and data problems, we consider 
the prioritization results robust for singling out new and valid information besides the 
list itself, and both are useful for informing de-adoption programs. Finally, in this study 
stakeholders were not involved which should be a next step in the process of de-adoption. 
The prioritization results may be important input for this consultation step. 
Conclusion
In this study, a comprehensive list of lower value services for Dutch hospital care was 
developed. The majority of lower value services covered care that should not be offered 
at all. Thirty percent of lower value services covered diagnostics, 29% related to non-
drug treatment, and 39% to drug treatment. Comparing the list with its UK counterpart 
revealed that Dutch guidelines appear to contain more lower value services than the UK 
guidelines. Finally, a feasible method for prioritizing lower value services was established. 
The development of a comprehensive list of lower value services and prioritization is only the 
first of several necessary steps in reducing lower value services. 
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Appendix 1. prioritization methodology
4a. Connection with Global Burden of Disease
Since information on prevalence and disease burden by ICD10-code is not systematically 
available in the Netherlands, it was decided to use the Global Burden of Disease (GBD) 
classification. The GBD is a global classification of disease categories including prevalence, 
disability adjusted life years (DALYs), years of life lost (YLL) and years lost due to disability 
(YLD) for each disease category, and is regularly renewed, most recently in 20151 with 2013 
data. Many of the GBD parameters are available online and by country. Also, information was 
available which ICD10-codes are covered by each GBD-category. A GBD-category often covers 
a range of ICD10-codes. For example, the GBD-category “low back pain” consists of a number 
of ICD10-codes from Chapter VI – Diseases of the nervous system (including disorders of 
lumbosacral plexus), but also from Chapter XIII – Illnesses of the musculoskeletal system 
and connective tissue (including instability of spine).
 The ICD10-codes were assigned to GBD-categories. If an ICD10-code fitted in more than 
one GBD category, the category covering the smallest range of ICD10-codes was chosen. Part 
of the ICD10-codes only fitted in the ‘garbage code’ category, which is a very broad group. 
Therefore, for those ICD-10 codes that were assigned to the rest category ‘garbage code’, an 
alternative GBD-category was sought, if possible. If no ICD10-code was assigned to a lower 
value service but an ICD10-group or specialism was known, this information was used to find 
an appropriate GBD-category for the lower value service. Four researchers (MEAM, EV, JW, 
TA) each took a randomly selected part of the list to assign GBD-categories to ICD10-codes. 
Equivocal cases were discussed with another researcher until consensus was reached. Not 
for each GBD-category prevalence figures were known, and to a lesser extent, DALYs and YLDs 
were missing. 
4b. Prioritization of ICD10-codes
To apply a prioritization in the extensive list of lower value services, the following criteria 
were defined per ICD code: number of lower value services, prevalence, LYD and DALYs. For 
each criterion four groups were made that were given a priority score. The classification 
into four groups aimed at having a comparable number of ICD10-codes in each group, as 
well as obtaining rounded categories (i.e. 500-1000 instead of 439-768). This resulted in the 
following classification:
–  Number of lower value services per ICD10-code: >10 (4 points), 5-10 (3 points), 2-5 (2 
points), 1 (1 point);
–  Prevalence (Netherlands 2013;*1000): >1000 (4 points), 500-1000 (3 points), 100-500 (2 
points) , <= 100 (1 point);
–  YLD (Netherlands 2013;*1000): >10 (4 points), 5-10 (3 points), 1-5 (2 points), <=1 (1 point);
–  DALY (Netherlands 2013;*1000): >100 (4 points), 50-100 (3 points), 10-50 (2 points), <=10 
(1 point).
 
 1   Global Burden of disease Study Collaborators 2013; http://ghdx.healthdata.org/global-burden-
disease-study-2013-gbd-2013-data-downloads Global Burden of Disease Study 2013. Global 
Burden of Disease Study 2013 (GBD 2013) Incidence, Prevalence, and Years Lived with Disability 
1990-2013. Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 2015.
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Subsequently, the ICD10-codes were prioritized by the sum of the number of lower value 
services, prevalence, LYD and DALY (Method 1), the highest score (up to 16) indicating the 
highest priority. As YLD is part of the DALY, this provides a high priority for ICD10-codes with a 
high number of YLD. Therefore, the prioritization was repeated for the sum of the number of 
lower value services and DALYs (Method 2; maximum score 8).
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Appendix 2: UK prioritization results
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Abstract
Under the circumstance of a constrained budget, cost-increasing technologies may displace 
funds from existing health services. It is highly uncertain however, what services are 
displaced and how such displacement takes place in practice. In the current research, we 
understood displacement as a process, a total of decisions made after the introduction of 
a new cost-increasing technology; a pathway from new technology to opportunity costs. 
We conducted six case-studies and interviewed 84 professionals with various roles and 
responsibilities (practitioners, departments, board of directors, insurers, and others) to 
investigate how Dutch hospitals have dealt with the cost pressure of cost-increasing health 
technologies. Transcripts were analyzed thematically in Atlas.ti on the basis of an item list.
 Our findings show that the opportunity costs of cost-increasing health technologies 
are not easily identifiable; limited transparency in the internal allocation of funds within 
a hospital contributed to this. Furthermore, we found that the entry of innovations/new 
technologies and cost-containment are two parallel processes that are generally not causally 
linked. The way of financing is pivotal in displacement in the Netherlands, because there is a 
separate budget for expensive drugs. This budget pressure is reallocated horizontally across 
departments, whereas the budget pressure of remaining services is primarily reallocated 
vertically within departments or divisions. Hospitals have reacted to budget pressures 
primarily through a narrowing in the portfolio of their services, and a range of (other) 
efficiency measures. The board of directors is central in these processes, insurers are involved 
only to a limited extent. Direct displacement of high-value care due to the introduction 
of new innovations was rarely observed. Rationing (primarily reducing accessibility) was 
observed mainly in response to cumulative cost pressures, production ceilings and capacity 
problems. Active surveillance of waiting lists is warranted to prevent waiting list driven 
morbidity.
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Introduction
In the Netherlands a broad agreement between stakeholders in the healthcare sector has 
been agreed on, among other things, maximum permitted budgetary growth (1.3% in 2019, 
decreasing to 0% in 2022, excluding wage and price adjustment). Budget pressure is further 
increased by the continuous introduction of cost-increasing health technologies. Decision 
makers, both at local and national levels, therefore have to make choices about how to spend 
their resources. At the national level, the Health Care Institute (ZINL) of the Netherlands 
advises the Minister of Health (MOH) on the contents of the basic benefit package. In 
2016, ZINL advised the MOH not to reimburse two expensive drugs – Pertuzumab (Perjeta®) 
and Pembrolizumab (Keytruda®) – unless their cost-effectiveness would be improved and 
budget impact would be less through price negotiations. The main argument was that, in 
current economic circumstances, reimbursement of these drugs could require displacement 
of more cost-effective services, resulting in a net loss of health benefits at the population 
level [1,2]. Based on this advice, the Minister negotiated lower prices with the manufacturers 
and decided that the drugs would qualify for reimbursement until the end of 2019 [3]. These 
negotiated prices are not revealed in the public domain. 
 In England, Wales and Scotland, research into displacement has mainly focused on 
estimating the cost per QALY threshold [4,5]. Little is known however, about displacement 
in practice, how displacement takes place and what services are displaced to accommodate 
new cost-increasing technologies. We know of only one study of the introduction of 
cost-increasing technologies. This Welsh study investigated how NHS commissioners 
accommodated financial ‘shocks’ originating from Technology Appraisals issued by 
NICE. They found that the ‘displacement assumption’ (existing services are displaced to 
accommodate cost-increasing technologies) generally did not hold; and that financial 
shocks originating from Technology Appraisals were generally accommodated by greater 
efficiency and increased spending. In addition, commissioners sought for savings or 
efficiency measures in response to cumulative cost pressures from multiple sources rather 
than in response to single Technology Appraisals [6]. One limitation of this research was that 
it was limited to decision making of Finance Directors and Medical Directors of Local Health 
Boards in Wales. Although directors may have the best oversight of macro and meso level 
decision making, they may have been unaware of decisions made at lower organisational 
levels in their geographical areas. Besides, their findings may not be representative for 
countries with other organisational and financial structures. 
 In the current research, we understood displacement as a process, a total of decisions 
and resulting consequences made after the introduction of a cost-increasing technology. 
This includes priority setting at higher organisational levels and bedside rationing at lower 
organisational levels. Insight in displacement also requires exploration of the causality of 
resource allocation ((how) does one decision leads to another?) and the ultimate effects for 
individual patients. We defined priority setting as resource allocation decisions between 
different services, patient groups, or elements of care; whereas bedside rationing was 
interpreted as the effects of such decisions on individual patients [7]. Priority setting in 
general has been researched for many years, albeit relatively little attention has been paid to 
the impact on individual patients. 
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The aim of our study was to investigate how Dutch hospitals have dealt with the introduction 
of cost-increasing health technologies, and to investigate the link between the inflow of 
new technologies and outflow of existing technologies. Specifically, we aimed 1) to test 
whether displacement takes place; 2) to identify which services, patient groups or elements 
of care are typically displaced; and 3) to identify the main actors that prioritize and ration 
and to investigate the motives for such decision making. Six case-studies were conducted to 
understand similarities and differences between cases, and to investigate the mechanisms 
of displacement and how these relate to financial and organisational structure. 
Institutional background
In the Netherlands, nearly universal coverage for curative care is achieved through mandatory 
purchase of statutory health insurance from private insurers. The Health Insurance 
Act legally requires health insurers to provide a comprehensive nationally set benefits 
package. Decisions regarding the package rest with the Minister of Health, who relies on 
advice from the National Health Care Institute and its Healthcare Insurance Board [8,9]. 
Coverage of prescription drugs is described in positive lists. Remaining service coverage is 
specified through an open specification with a general (functional) description of benefits, 
and restrictions are expressed in negative lists [10]. The great majority of services enter the 
health system without formal assessment through this ‘open’ specification. 
 The Healthcare Insurance Board uses four criteria to determine whether or not to 
reimburse a new health service: necessity, effectiveness, cost-effectiveness, and feasibility 
for implementation. Adoption of a technology is based on an integral assessment on 
the basis of these criteria, the criteria are not used as knock-out criteria. The criteria are 
continuously refined and improved, and especially the cost-effectiveness criterion is 
debated. In 2006, the RVZ (government advisory body) argued that treatments with a cost-
effectiveness ratio higher than €80.000/QALY should not be included in the basic benefit 
package. The RVZ also stated that the acceptable costs per QALY vary according to burden 
of disease and other factors, such as rarity of the disease [11]. In reality however, treatments 
are rarely excluded from the basic package based on ‘unacceptable’ cost-effectiveness. In 
addition, besides the appraisal criteria several other factors have played a role in defining the 
actual constituents of the basic benefit package, including the desire to control costs and 
the public opinion [12]. 
 The Dutch healthcare system is largely based on the principles of managed competition 
with little central planning. Health care purchasing is considered the centrepiece of the 
system and is the main instrument for stimulating efficiency. Insurers are supposed to 
prudently purchase care for their enrolees. In real life, insurers and hospitals mainly negotiate 
on volumes and prices, while quality of care plays only a minor role in these negotiations. 
In addition, insurers may decide not to contract a provider (selective contracting), but are 
required to offer adequate care for their enrolees. The great majority of hospital care in the 
Netherlands is reimbursed through payment products similar to Diagnosis Related Group 
(DRGs; which cover both in- and outpatient hospital care). About 70% of DRG-prices are freely 
negotiable, the rest of the prices are regulated. A small part of hospital care is reimbursed 
through so-called add-ons. Add-ons are separate payments that have been developed for the 
reimbursement of expensive drugs and intensive care unit admissions. 
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From 2012 onwards, the Minister of Health has made sector agreements with providers and 
insurers that have effectively limited spending growth to 2.5% during 2012 and 2013, 1.5% 
in 2014 and 1% in 2015-2017. Insurers and hospitals negotiate prices and volumes on a yearly 
basis, guided by the terms of the sector agreements. Because of the sector agreements, it 
has been argued that hospitals and insurers de facto negotiate lump sum contracts with 
revenue ceilings as the most important provision. In addition to the ex ante contracts with 
stipulated prices and volumes, a small part of hospital spending – for ‘non-steerable’ and 
very expensive services, including transplant care and expensive drugs – is carved out from 
the revenue ceiling and funded on a fee for service basis. 
Materials and methods
Study design
We chose a multiple qualitative case study design to study displacement in the hospital 
sector of the Netherlands. Case studies are well suited to explore, deconstruct and reconstruct 
social phenomena, which we expected the displacement process to be. The design is based 
on a constructivist paradigm that is built upon the premise of a social construction of 
reality [13]. Our aim was to obtain the experiences and perspectives of a diverse range of 
stakeholders that have been involved in displacement decision making processes. We 
conducted six case studies to be able to understand similarities and differences between 
cases. Prior to this work, a pilot study was conducted to inform and to test the feasibility of 
our approach. Halfway through the project we organized an expert meeting with national 
experts (N=9) in health economics and policy to discuss preliminary findings.
 We purposefully chose six cost-increasing health technologies. First, a stakeholder 
meeting with our funder (ZINL) was held to identify case studies meeting a pre-specified 
set of criteria. In addition, we searched several (government) websites and explored cases 
through our personal networks. Apart from maximum variation, interventions were 
required to meet the following criteria: 1) interventions should be generally considered cost-
ineffective based on current Dutch standards 2) interventions should be provided in hospitals 
3) the reimbursement decisions should have been made some time ago, in order to be able 
to identify possible displacement effects 4) the intervention should have a relatively high 
budget impact. Based on these criteria, we chose intramural oncolytics, robotic (Da Vinci) 
surgery, Left Ventricular Assist Device, endovascular aneurysm repair, population screening 
for colon cancer, and expensive eye injections (Eylea and Lucentis). A short description of the 
interventions is given in table 1. 
Participant selection and recruitment
We purposefully selected key stakeholders (experts for the particular health technology) to 
be interviewed for the case studies. Key stakeholders were initially identified from policy 
documents, websites, the media or from our (funder’s) network. We then asked the initial 
key informants to suggest other participants (snowball sampling). We aimed to take into 
account geographic spread, to recruit a diverse set of relevant stakeholders, with different 
positions and responsibilities, per case study as well as per hospital within a case study. 
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TABLE 1  Description of the case studies. 
Innovation Description
Left ventricular 
assist device (LVAD)
LVADs are devices for assisting cardiac circulation. They have been 
used from 1992 onwards as a ‘bridge to transplant’ for patients with 
advanced heart failure. During the years, the outcomes of the therapy 
have steadily improved, such that LVAD can be used as long term thera-
py (‘destination’, LVAD is not followed up by a heart transplant). 
Fenestrated 
endovascular 
aneurysm repair 
In this procedure an expandable stent graft is placed within the aorta 
to treat aortic disease. This minimally-invasive technique is indicated 
for high-risk patients unfit for open surgery. Fenestrated and branched 
EVAR (FEVAR) are expensive due to its custom-made graft device. 
Expensive oncolytics In recent years, several relatively expensive oncolytics have been 
approved for inclusion in the basic benefit package, including pertu-
zumab, palbociclib, nivolumab, pembrolizumab, atezolizumab, and 
ibrutinib. 
Eylea and Lucentis Avastin, Eylea and Lucentis are all used for the treatment of various 
eye diseases. Eylea and Lucentis are both much more expensive than 
Avastin, but are equally effective for most indications. Eylea and Lucen-
tis are indicated for patients for whom Avastin is not effective, and for 
patients with diabetic macula oedema and vascular occlusion.  
Population screening 
for colon cancer
In 2014, the Netherlands started population screening for colon cancer. 
People with positive test results are advised to get a colonoscopy in the 
hospital. Studies have shown that this surveillance is not cost-ineffec-
tive [14]. 
Robotic surgery Robotic assisted minimally invasive surgery has been performed in the 
Netherlands since 2000, as an alternative to ‘pure’ laparoscopy or open 
procedures for various indications. Despite many studies, there is still 
no clear-cut evidence regarding the cost-effectiveness. 
For example, we aimed to recruit informants from general, specialized as well as academic 
hospitals, and we recruited medical doctors, financial managers, sales managers, board 
members, and health care purchasers (insurers). Participants were invited to participate in 
the study by e-mail. The invitation letter provided a summary of the aim and methodology 
of the study, as well as the time needed for the interview. We sent reminders when we did not 
receive a response within two weeks. 
Data collection
The interviews took place between September 2016 and May 2017. All interviews per 
case study were conducted by one single interviewer. The interviews and analysis were 
undertaken concurrently and iteratively, in order to inform subsequent interviews. The 
interview team met at least monthly during the duration of the study to discuss the findings 
and to coordinate ongoing work. 
 The primary aims of the interviews were to identify the main (financial) consequences 
of the introduction of the particular health technology for the department, hospital or 
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insurer; and to discuss the choices and decisions that were made, as well as the reasons 
for making the decisions. We also more generally discussed displacement processes and the 
mechanisms known to the respondent that were beyond the case study. 
 A semi-structured topic guide was used for the interviews, including the introduction 
process of the health technology; agreements and negotiation processes with third party 
payers; problems encountered (costs, time, facilities, etc) due to the introduction of the health 
technology; what action was taken in response to the problems; the consequences for care 
provision and rationing; and views concerning displacement (the interview guide is presented 
in appendix 1). Rationing was operationalized according to Klein’s rationing strategies, 
including rationing by denial, selection, delay, deterrence, deflection and dilution [7]. 
 The topic guide was based on relevant literature and a pilot study, and adapted based on 
the first five interviews. We made minor amendments to the topic guide for our interviews 
with hospital boards members and health insurers. During these interviews we discussed 
multiple case studies, and more time was devoted to displacement processes and priority 
setting in general.   
 The interviews were predominantly conducted face to face, at the respondent’s office, 
but twenty interviews were conducted by telephone. Interviews ranged 20-60 minutes and 
were audio-recorded and transcribed verbatim. Permission for audio recording was sought 
for and given in every case. The purpose of the interview and the general aim of the study 
were summarized at the start of each interview. We explained that neither findings nor 
quotes would be attributed to individuals or organizations.
Data analysis and presentation
Transcripts were transcribed verbatim and analyzed thematically in Atlas.ti on the basis of an 
item list. This item list was derived from the semi-structured topic guide and literature. We 
made minor modifications to the topic list based on discussions within the broader study 
team. All analyses were performed by the interviewer who held the interview. In case of data 
ambiguity we contacted the respondents to retrieve the meaning of a quote. For the purpose 
of inter-researcher reliability, the interviewers met regularly to discuss themes and data 
categories. In addition, at the start of the analysis, at least one transcript per case study 
was independently coded by two or more researchers and the results were compared. Any 
differences in data interpretation were discussed and resolved. 
 We developed summary tables of the case studies according to the categories of the 
item list and compared the results across the case studies to identify systematic patterns of 
displacement. Based on this information, a narrative summary of the results was made. The 
results are presented according to the flow chart below (figure 1) which follows the budgetary 
flow in the health system and our interview guide. The arrows of the flowchart indicate how 
stakeholders can (re-)allocate the budget pressure, either upwards (left side), or downwards 
(right side). The green circles correspond with the paragraphs in the results section.
 We first present respondent characteristics, and then discuss the introduction process 
of the health technology and actors involved; agreements and negotiations with insurers; 
problems encountered (costs, time, facilities, etc) due to the health technology; decision 
making process in response to the problems; the consequences for care provision and 
rationing; and views concerning displacement. 
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FIGURE 1  Macro model budget pressure, stakeholder model. 
TABLE 2  Interview informants and roles per case study.1
 
1   Informants may be listed on several roles or columns. For example, a medical doctor may be a 
part-time member of the sales team of the hospital, or a member of the board of directors may 
have spoken about two or more case studies. 
2  Including the pilot study.
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Results
Respondents
In total 84 interviews were conducted. Table 2 presents the characteristics of the respondents 
for each of the case studies. A minimum of nine interviews were held per case-study. Medical 
doctors were generally overrepresented among our respondents. However, in each of our 
case studies we interviewed a diverse range of stakeholders, with at least four distinct roles 
and responsibilities in the Dutch health system.
Below the main findings of the interviews are presented. Paragraph A and B provide 
main contextual findings concerning the health technologies; which are essential for 
understanding the displacement mechanisms that will be outlined in paragraph C until E. 
A  Entry to the system and hospital
An elaborate description of our research findings per case study is presented in appendix 
2. All but one of the technologies have been assessed by ZINL for inclusion in the benefit 
package. LVAD-destination and FEVAR were initially not included in the benefit package, but 
were adopted later when new scientific evidence concerning the benefits of the treatments 
became available. ZINL advised the government not to include Lucentis in the benefit 
package, but this advice was not acted upon. The Da Vinci platform was assessed, but not 
formally in- or excluded, because decisions about service coverage concern treatments for a 
given patient population, not the way the treatment is delivered. 
 The entry into hospitals also differed between the cases. In most of the case studies, a 
wide range of stakeholders were involved in decision making processes, including health 
professionals, managers of hospital departments, board of directors, investment or drug 
committees, and in some cases also stakeholders from outside the hospital (medical 
societies, healthcare inspectorate, ZINL, other governmental agencies). However, in case of 
FEVAR, specialists and departments started experimenting with one or a few test procedures, 
before activities were scaled up after which stakeholders at a higher hierarchy level of the 
hospital were involved. LVAD, FEVAR, Lucentis and Eylea were all used at considerable scale 
before they were formally included in the basic benefit package. 
B  Reimbursement, contracts and negotiation with insurers
In the Netherlands, hospitals and insurers negotiate 1) carved out contracts for expensive 
services, using add-on payments based on fee for service and without cap (in Dutch 
“nacalculatie”) and 2) ex ante a revenue ceiling contract based on prices and volumes 
(in Dutch “plafondafspraken”). Although the agreements allow for differentiation in 
percentages growth per hospital, the growth norm is used as a guiding principle for the 
negotiations. During the year, hospitals and insurers discuss new interventions and policy 
on a continuous basis. In autumn, new contracts for the upcoming year(s) are negotiated. 
 The carved out contracts primarily include expensive drugs and expensive procedures 
such as LVADs. The budget for expensive drugs is not part of department budgets, but is 
a separate budget. Hospitals and insurers negotiate the volume and price of expensive 
oncolytics, and sometimes also an ex ante determined capped budget. Generally speaking, 
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the reimbursement of oncolytics is undisputed, and insurers will reimburse on basis of fee 
for service, as they fear for loss of reputation. However, indication extension during the year 
has led to budget overruns in some hospitals that were unable to negotiate extra money. 
There are several requirements for carved out contracts, including guideline adherence, 
transparency, and no margins on the drugs. 
 Negotiations about the ceiled revenue are parallel to, or subsequent to negotiations of 
the carved out contracts. Hospitals generally prepare long lists of investment opportunities, 
and similarly insurers prepare lists of disinvestment opportunities. Occasionally individual 
items of such lists are discussed and accepted or rejected. However, generally speaking, 
hospital and insurer primarily negotiate a revenue ceiling, which is secondarily based on 
prices and volumes. Terms about specific services are not binding, and may be exchanged for 
any other services. Cross-subsidization (services are paid from the margins of other services) 
was widely reported. 
C  Problems encountered
The interviewees reported a wide range of problems they were faced with when the 
intervention was introduced. In case of LVAD and population screening for colon cancer, 
participants reported predominantly capacity problems (increased need for specialized 
personnel, operating room capacity, intensive care beds) and only limited financial 
problems. Below the most important financial problems, and problems intrinsically related 
to displacement, are outlined. 
C1  Investment opportunities exceed the permitted growth 
Both insurers and hospital management generally did not doubt the added value of most 
investment opportunities. However, it was clear that the associated total costs could not 
be accommodated in the current growth path. Many respondents argued that the increase 
in expensive drugs was at the expense of other services. It was hard to say however, at what 
expense exactly.
“If that were not the case, then the rest of the negotiations might have been  
a lot easier. The expensive drugs are the elephant in the room.”  
BOARD OF DIRECTORS
Respondents generally pointed to the totality of budget increases, rather than to the growth 
of individual drugs or services. For example, FEVAR was one of a range of services contributing 
to the cumulative budget overrun. As a result, what could be observed is a competition 
between technologies and services for spending growth.
“Instead, we do complicated things, like FEVAR-prostheses, complicated 
laparoscopic operations and so on. That costs twice as much, but our budget 
does not grow. So at the meso level of the department, there is a continuous 
fight with the Board of Directors.”  
VASCULAR SURGEON
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From the interviews it appeared that the degree of experienced cost pressure differed between 
settings, depending on the financial organisation of the hospital and negotiating power. 
Generally speaking, we found that the cost pressure in surgical departments/divisions was 
more severe than in cardiology/cardiothoracic divisions. In addition, respondents argued 
that smaller hospitals face higher risks for cost pressure due to expensive drugs, as they were 
less likely to negotiate generous contracts with insurance companies. In the eye drugs case, 
specialized eye centres experienced heavier cost pressure, as they had less abilities for cross-
subsidization or abilities to exchange services.
C2 The distribution of flow of funds within a hospital is not transparent 
Especially in larger and academic hospitals, many revenue sources exist, including 
innovations funds, education fees, research funds and others. Consequently, hospitals use 
internal funds in which the various revenue sources are reallocated (services were exchanged, 
or through cross-subsidization). 
“We work with a budget system. We negotiate about how that budget is built, 
but it is up to the healthcare provider how to fill in that budget. A healthcare 
provider always has the possibility to reallocate the money somewhere else 
instead of to that DRG.”  
INSURER
Respondents reported a lack of transparency in the hospital’s internal financing. In the 
current system, negotiated DRG-prices may not represent real prices, and hospitals may 
lack insight in the costs of their DRGs. Negotiations rarely take place on intervention 
or technology level and are mostly based on hospital revenue deals. Consequently, the 
additional costs of an intervention or displacement effects are hardly visible. 
“The system is not so one-dimensional that such effects are immediately 
visible and you get a difficult conversation about the disposables. There are 
many possibilities and sources for substitution.” 
SURGEON
There was a lot of unawareness about negotiations with insurers. Most respondents named 
volumes for services, which were also used for internal planning (they were not necessarily 
contracted). In some hospitals, managers at higher levels were unaware of individual prices 
(or profit margins) for services in their budget, or accepted business-cases.
D   Decision making processes, underlying reasons and contra-mechanisms to 
budgetary pressure 
D1   Decision making differs across types of financing, board of directors are central to 
decision making 
Priority setting and rationing within hospitals differs depending on the type of service and 
type of budget. Expensive drugs requests are assessed by drug committees, before the Board 
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of Directors are involved, who may negotiate additional budget from insurers. Because there 
is a separate budget for expensive drugs, the budget pressure is experienced at the higher 
managerial levels, not only by the department that uses the drugs. This budget pressure 
is accommodated by insurers, and indirectly by departments in the hospital through lower 
department budgets.
 In addition to the budget for expensive drugs, the hospital budget is cut into budgets 
for divisions and (sub-)department. Departments and divisions are relatively free in how 
to spend this budget, but they are kept relatively strictly to this budget. They discuss their 
policy, budgets and activities with the board of directors on a regular basis. 
“Look, if the cardiologists want to grow in the field of interventions, then 
maybe they should not grow in the area of the fast-track outpatient clinics. “ 
BOARD OF DIRECTORS
Departments and divisions may submit business-cases to request additional funding. The 
board of directors (and sales team) are central to this decision making. They may decide 
to include the business-case in negotiations with insurers (external business-cases). In 
exceptional cases (long waiting lists) hospitals have successfully negotiated extra funding. 
Internal business-cases are not discussed with insurers and may be rejected, or funded from 
other sources. Most of the times, the board will request the departments to take austerity 
measures (see paragraph B). In each of the cases, the board of directors were involved in 
introductory decision making or growth. 
D2  Strategic considerations and key topics  
A range of arguments were mentioned for introducing a technology, or to further invest in 
the growth of a particular service. In all case studies, patients were expected to benefit from 
the treatment. In addition, respondents argued that the technology was considered a key 
topic of the department and the hospital. Such emphasis on key topics can take many forms, 
and key topics were chosen at every managerial level (e.g. from high to low: cardiovascular 
centres, vascular surgery, aorta pathology). Generally speaking, such key topics receive more 
funding, at the expense of others.  
“In the coming years in particular that cardiothoracic and vascular domain will 
grow, maybe at the expense of others. That we say in other respects, that is no 
longer for us.” 
BOARD OF DIRECTORS
Besides, several respondents pointed to competition between providers: providers were 
afraid to lose patients, or were afraid to stay behind technologically.  
“If we limit that flow of patients, then we will lose it, then they’ll look for 
someone else. Until today, that was one of the reasons why we accept the 
budget overrun.” 
SURGEON
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Some respondents were critical about the decision making, doubted the benefits of the 
treatment and noted that a clear evidence base was lacking. Cost-effectiveness was rarely 
considered. Besides, respondents argued the industry had ‘pushed’ the innovation too 
much. 
D3  Contra-mechanisms 
We asked the respondents how they dealt with the budget pressure of the new technologies. 
Respondents primarily pointed to their choices in the portfolio of their services. Insurers and 
the board of directors request departments to stop providing services that can be provided 
elsewhere at lower costs. 
“Someone with a minor heart attack, and when treatment has gone 
straightforward, should simply be followed-up elsewhere.”  
CARDIOLOGIST
Some respondents doubted the budget impact of such measures, albeit it effectively reduced 
work load. Hospitals increasingly collaborate in this re-arrangement of service delivery, but 
the degree of collaboration differs considerably across hospitals.   
 A variety of other measures to relieve budget pressure or capacity problems were 
mentioned, including effort to reduce the price of LVADs, FEVAR-stents, and expensive drugs. 
Many doctors stated that they adhered to guideline recommendations more strictly than 
before, or that eligibility criteria for procedures or drugs were redefined. Besides, efforts were 
taken to reduce the length of stay or to technically improve services. Task rearrangements, 
substitution, e-health, and cuts in staff and beds were also mentioned. 
E  Displacement, and impact on regular care 
We asked interviewees directly which services were displaced to accommodate the 
introduction of the innovation, and which effects this had for regular care and for individual 
patients. In case of LVAD, respondents pointed to generous financing, and that problems 
primarily occurred due to capacity constraints. FEVAR was one of the services contributing to 
cumulative cost pressures, and in some hospitals FEVAR was rationed due to cost pressures 
from other services. The budget pressure of expensive drugs was accommodated by insurers 
and the board of directors, who redistributed this to the rest of the departments (horizontal 
reallocation). In the eye drugs case, rationing was widely reported, but cost pressure was only 
one of the several factors that necessitated rationing. Population screening for colon cancer 
was also rationed, but this was primarily due to shortages in GE-specialists. The additional 
costs for Da Vinci surgery were largely unknown, and cross-subsidized from other services. 
 With few exceptions, there was consensus that displacement, and efficiency/austerity 
measures were not causally linked to investments in technologies.
“I cannot but remember that we had to cut costs and look for efficiency gains. 
But I cannot say that this really is at the expense or coincides with that Da 
Vinci. That is a permanent system to level the costs and the revenues.” 
MANAGER UROLOGY
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Although not necessarily related to the technologies, many respondents pointed to current 
pressures in Dutch hospitals, and the necessity to ration care. Below the most important 
mechanisms are outlined.
E1  Rationing is usually the result of production ceilings and capacity problems 
Many respondents noted that rationing was the result of cumulative pressure from several 
sources, including aging, reform in long term care, and technological innovation. Shortages 
in personnel and beds further complicated the situation. Occasionally, but not structurally, 
such capacity problems were related to austerity measures. Furthermore, individual 
services were rarely rationed, but rationing occurred rather in larger organizational units, 
such as surgical divisions, or cardiovascular centres. Several respondents blamed the sector 
agreements and argued that insurers do not purchase enough care.  
E2  Hospitals primarily reduce accessibility in response to cost pressure 
Respondents listed all rationing strategies; and rationing by delay was mentioned most 
frequently and was regarded the primary rationing strategy. In case of a budget overrun or 
capacity problems, the board of directors request departments to reduce accessibility. 
“Yes, then we consult with the manager and the head of the department, and 
tell them to increase the waiting lists.”  
BOARD OF DIRECTORS
Rationing strategies were usually combined, especially rationing by delay and selection 
were often used in tandem. Furthermore, patients were prioritized on the basis of medical 
need: malign and acute patients got direct access, while benign and non-acute patients were 
queued. 
“If your operation room time is limited and you have to choose, the oncology 
patient is prioritized, and you are actually displacing the benign patient.”- 
DIRECTOR SURGICAL DIVISION 
Respondents noted that rationing strategies were used strategically to redirect patient 
flow. Hospitals focus their activities to more narrowly defined subpopulations or services. 
Consequently patients with low complexity needs (selection) were denied access, or 
hospitals used long waiting lists (delay) for low complexity services.   
 Rationing by selection was often interpreted as a strategy to improve patient care, rather 
than a method to cut costs. For most respondents it was difficult to discern efficiency 
measures  from rationing. Besides, respondents found it hard to identify the direct 
consequences for their patient’s health. Most respondents mentioned that competing 
hospitals had enough capacity to take over the patient flow. One potentially negative 
consequence for patients was increased travel time, and dissatisfaction due to their inability 
to go to the hospital of their first choice. 
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Discussion 
This paper presents how Dutch hospitals have dealt with the introduction of six cost-
increasing health technologies. The findings show that the opportunity costs of cost-
increasing health technologies are not easily identifiable; limited transparency in the 
allocation of funds downstream within a hospital contributed to this. Furthermore, we 
found that the entry of new innovations and cost-containment are two parallel processes 
that are generally not causally linked. The way of financing is pivotal in displacement in the 
Netherlands, because there is a separate budget for expensive drugs. This budget pressure 
is reallocated horizontally across departments, whereas the budget pressure of remaining 
services is primarily reallocated vertically within departments or divisions. Hospitals have 
reacted to budget pressures primarily through a narrowing in the portfolio of their services, 
and a range of (other) efficiency measures. The board of directors is central in these processes, 
while insurers are involved only to a limited extent. Direct displacement of high-value care 
due to the introduction of new innovations was not observed. Rationing (primarily reducing 
accessibility) was observed mainly in response to cumulative cost pressures, production 
ceilings and capacity problems. Patients were prioritized on the basis of medical need, 
malign and acute patients were prioritized for benign and non-acute patients. It was hard to 
identify the direct consequences for patients’ health.
 Our analysis supports and builds on a relatively new field within health economics, a field 
that concerns identifying displacement effects as a response to the introduction of cost-
increasing services, and estimating implicit threshold values to inform decision making 
concerning the basic benefit package. In line with Karlsberg Schaffer et al, we found that new 
technologies were generally accommodated by greater efficiency and increased spending, 
and that hospitals sought savings or efficiency measures in response to cumulative cost 
pressures rather than in response to single cost-increasing technologies.
 One notable contribution of our research is that we, based on comparative analysis, 
identified two distinct pathways in which new technologies contribute to budget pressure. 
Financing is pivotal here. The first pathway includes funding for expensive drugs, which are 
explicitly appraised for inclusion in the basic benefit package. Once included, such drugs are 
generally generously reimbursed. This budget pressure is partly accommodated by insurers, 
and partly spread horizontally across several departments. The second pathway concerns 
funding for all other (non-pharmaceutical) technologies, which are rarely assessed by ZINL 
before entry, and the costs of which relate to the revenue ceiling. The budget pressure of such 
technologies is generally reallocated vertically within the department or division. Insurers 
only have limited abilities to control such spending, and hospitals have ample opportunity 
for cross-subsidization and to exchange funds. There is, however, generally a lack of clear-cut 
evidence about the value of the services. One risk in such implicit decision making processes 
is that policy be based on arguments that may not be in line with maximizing population 
health. Indeed, personal factors (e.g. the “powerful” medical doctor) and competition 
between providers were named as arguments for approving a business-case. In addition, the 
board of directors may have little insight into activities until costs escalate. 
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In England, Wales and Scotland, research into displacement has mainly focused on 
estimating the cost per QALY threshold [4,5]. If the objective is to maximize population 
health, the adoption of new technologies should depend on this threshold value, that equals 
the opportunity costs of marginal spending. Many questions remain about the assumptions 
underlying threshold estimations [15]. Such approaches vary in whether displacement is 
assumed to be optimal, for example that the least-cost effective program would represent 
the threshold, or the average ICER of all services would represent the threshold; and of the 
objective function of the reimbursement authority. Our approach is complementary to 
opportunity cost approaches. The opportunity cost approach answers the hypothetical 
question about benefits gained or lost due to alternative spending, while our research 
observes what happens in a system with a budgetary constraint when cost-increasing 
technologies enter this system. Our findings indicate that displacement typically does not 
take place at the level of individual technologies, such as assumed in QALY league table 
approaches. On the contrary, hospitals displace a range of low-value services, or services 
that may be provided elsewhere at lower costs, and decrease the volumes across the totality 
of their services. 
 Furthermore, our findings indicate that the opportunity costs vary across services. The 
budget pressure of expensive drugs is reallocated horizontally, and its opportunity costs may 
be equal to the marginal value of spending for the entire hospital. In contrast, the budget 
pressure of remaining services are predominantly reallocated vertically, and the opportunity 
costs thus depends on the efficiency of the particular department or division and the service 
they displace; i.e. the opportunity cost of LVAD (cardiothoracic and cardiology departments/
division) may differ from that of FEVAR (vascular surgery). 
Implications for policy
Our findings indicate that rationing (primarily reducing accessibility) was observed mainly 
in response to cumulative cost pressures, production ceilings and capacity problems. 
Such problems are likely to worsen, given the newly established sector agreement with 
decreasing permitted budgetary growth (1.3% in 2019 to 0% in 2022, excluding wage and 
price adjustment). Active surveillance of waiting lists is warranted to prevent waiting list 
driven morbidity. Possibly, as cost constraints increase, more drastic approaches may be 
applied to accommodate new innovations, which may increase the opportunity costs 
of implementation. This implies that new technology assessment should not be viewed 
separately from the general budget constraints that hospitals face, and that in periods 
of increased cost-containment, new technology assessment might need to be stricter. 
Furthermore, we showed that – albeit many stakeholders are involved – the introduction of 
non-pharmaceuticals is relatively uncontrolled, and that this may have undesirable effects. 
Legislators might consider whether the ‘open’ description of the benefit package for non-
pharmaceuticals could become more ‘closed’. One option might be to extend managed 
entry agreement to non-pharmaceuticals. Besides, relevant stakeholders might join 
efforts to ‘guide’ the introduction of new innovations more prudently, for example through 
establishing minimum quality requirements. Finally, insurers might further develop their 
procurement policies to more effectively limit the entry of low-value innovations. 
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Strength and limitations
One major strength of our study is that we interviewed a wide range of stakeholders with 
diverse positions and responsibilities in the Dutch hospital sector. However, insurers were 
relatively underrepresented. For most respondents it was difficult to discern efficiency 
measures from rationing by dilution, and it proved hard to identify the direct consequences 
of rationing strategies. Other type of research may be needed to further study such effects. 
As with all qualitative research, our findings may not necessarily extend to other settings. 
We purposefully identified six contrasting case studies, other case studies may have led to 
other results. Our analyses primarily concerned academic or relatively large hospitals, as 
most innovations enter the sector in these hospitals. Besides, our findings are dependent 
on the Dutch local context, most notably the way Dutch hospitals are reimbursed. Social 
desirability or selective recall bias may have also influenced our findings. There may be no 
incentives for respondents to reveal displacement in interviews. However, our research 
methods were designed to cope with this problem, as we guaranteed that neither findings 
nor quotes would be attributed to individuals or organizations. Besides, we recruited a large 
number and diverse set of relevant stakeholders – also within hospitals – in order to verify 
and compare statements. 
 More research is needed to identify displacement mechanisms in healthcare domains 
other than the hospital sector. In addition, more research may be needed to further 
substantiate or adapt the currently held threshold values in the Netherlands. Our research 
identified two distinct pathways of displacement effects, which are intrinsically linked 
to financing, and our approach may be fruitful in other countries as well. Furthermore, 
our findings once more point to the plethora of low-value service provision and lack of 
knowledge of the value of many services. More research is warranted in disinvestment of 
low-value services, and of (early) health technology assessment to prevent the introduction 
of promising, but nevertheless low-value services. 
Conclusion
The opportunity costs of cost-increasing health technologies are not easily identifiable. 
Hospitals typically displace a range of low-value services, or services that may be provided 
elsewhere at lower costs, and decrease the volumes across the totality of their services. The 
way of financing is pivotal in displacement in the Netherlands, as the budget pressure of 
expensive drugs is reallocated horizontally across departments, whereas the budget pressure 
of remaining services is primarily reallocated vertically within departments or divisions. 
Hospitals ration mainly in response to cumulative cost pressures, production ceilings and 
capacity problems, and active surveillance of waiting lists is warranted to prevent waiting 
list driven morbidity.
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Appendix 1   Interview scheme 
Introduction
A consortium consisting of Radboudumc, Ecorys, Celsus, Maastricht University and Julius 
Center is conducting research into displacement effects in healthcare at the request of the 
National Health Care Institute. Displacement is described by the Healthcare Institute as 
follows: When assessing whether a treatment should be included in the insured package, it 
is assessed whether the health gain that can be achieved is in a reasonable proportion to the 
costs that have to be incurred (the cost-effectiveness). If this is not the case, the inclusion of 
the new treatment will be at the expense of the reimbursement of another treatment. This is 
based on the fact that the available money can only be used once. In order to map (potential) 
displacement at hospital level, we ask different care professionals and other stakeholders in 
the care for their opinion.
We would also like to discuss this with you during an interview of about 45-60 minutes. The 
goal is twofold:
–  Find out what consequences the introduction of [case] has for your department and / or 
for the hospital and what choices were made as a result
–  In addition, we are also curious about your vision of displacement in healthcare in 
general.
With your approval, the interview will be recorded using a voice recorder.
All data and information provided by you will be used confidentially and exclusively for the 
execution of this research. Do you have any questions or remarks so far?
Financing 
First of all, we would like to gain insight into the way in which [case] is financed within your 
hospital.
–  Could you please estimate the size of the patient group that is treated each year with 
[case] at your department / in the hospital?
–  To what extent is [case] fully reimbursed by health insurers?
–  Do you identify problems in the negotiation with health insurers about [case]?
Impact 
–  Has a horizon scan been carried out with regard to the introduction of [case] within your 
department / hospital?
–  Has [case] led to identifiable problems at the ward / in the hospital?
–  Has [case] led to certain choices that relate to regular care?
 -  Do you recognize one or more rationing strategies [a table with the six strategies was 
given] as a result of [case]?
 - What do you think are the (possible) consequences of this rationing for patients?
 -  To what extent has [case] influenced the possibility of (previously planned) 
investments at your department / in the hospital?
–  What are your expectations regarding the future deployment of [case]?
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Involved actors
Based on literature research and initial interviews, we have developed a model, in which we 
map the way in which displacement may take place in healthcare. I would like to discuss this 
model with you.
–  [Presenting figure 1]
 - Who decides about the financing of [case] in your hospital?
 -  Where is the decision to introduce [case] within your organization most felt and by 
whom specifically?
 -  Do other hospitals in the region suffer from the choices that your hospital makes in 
relation to [case]?
 -  Do you notice shifts in care at national level that occur as a result of the admission of 
[case]?
–  Which external parties are possibly involved in displacement in healthcare and how?
Displacement in healthcare
–  In your opinion has [case] led to the displacement of other care?
–  Has it ever happened that, due to the budget pressure, you were unable to provide the 
care that you would like to? If so, what specifically could you no longer do or did not want?
–  Can you think of an intervention that entails a high risk of displacement?
Closing
–  Do you have any other information or documents that are relevant to this topic?
–  Do you have any suggestions regarding other colleagues that we could discuss?
–  In due course, may we approach you again for any additional questions if we are further in 
the study?
–  Do you have any questions or comments?
Thank you for your time and effort.
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ns
eq
ue
nt
ly
, t
he
y 
co
ul
d 
tr
ea
t 
pa
ti
en
ts
 th
at
 c
ou
ld
 o
th
er
w
is
e 
no
t 
be
 tr
ea
te
d 
du
e 
to
 a
 s
ho
rt
ag
e 
of
 
do
no
r h
ea
rt
s.
 
D
ep
ar
tm
en
ts
 o
r d
iv
is
io
n 
w
ro
te
 
bu
si
ne
ss
-c
as
es
, o
r i
nc
lu
de
d 
gr
ow
th
 
of
 LV
AD
s 
in
 th
ei
r p
ro
du
ct
io
n 
pl
an
s 
fo
r t
he
 c
om
in
g 
ye
ar
. B
ot
h 
w
er
e 
ac
ce
pt
ed
 b
y 
th
e 
bo
ar
d 
of
 d
ire
ct
or
s.
 
In
 2
01
5 
th
e 
in
di
ca
ti
on
 ‘d
es
ti
na
ti
on
 
th
er
ap
y’
 w
as
 a
pp
ro
ve
d 
fo
r t
he
 
be
ne
fi
t p
ac
ka
ge
.
Bo
ar
d 
of
 d
ire
ct
or
s 
us
ed
 to
 
gr
an
t d
ep
ar
tm
en
ts
 a
 b
ud
ge
t 
fo
r L
VA
D
s 
fr
om
 in
no
va
ti
on
 
fu
nd
s,
 o
n 
th
e 
co
nd
it
io
n 
th
at
 
th
e 
de
pa
rt
m
en
ts
 w
ou
ld
 
pu
bl
is
h 
in
 a
ca
de
m
ic
 jo
ur
na
ls
 
ab
ou
t t
he
 LV
AD
s 
an
d 
w
ou
ld
 
en
su
re
 LV
AD
 w
ou
ld
 b
e 
ad
op
te
d 
in
 th
e 
ba
si
c 
be
ne
fi
t 
pa
ck
ag
e.
 
La
te
r, 
LV
AD
s 
w
er
e 
fi
na
nc
ed
 
on
 th
e 
ba
si
s 
of
 fe
e 
fo
r 
se
rv
ic
e,
 a
nd
 c
ar
ve
d 
ou
t 
fr
om
 th
e 
bu
dg
et
 c
ei
lin
gs
 
ne
go
ti
at
io
ns
. B
ec
au
se
 
LV
AD
s 
ar
e 
on
 li
st
 w
it
h 
‘n
on
 
st
ee
ra
bl
e’
 in
te
rv
en
ti
on
s,
 
th
is
 le
d 
to
 n
o 
pr
ob
le
m
s 
in
 
ne
go
ti
at
io
ns
.  
Pr
ic
es
 a
re
 s
et
 n
at
io
na
lly
, n
o 
vo
lu
m
es
 a
re
 n
eg
ot
ia
te
d,
 b
ut
 
es
ti
m
at
io
ns
 a
re
 m
ad
e 
in
 
ad
va
nc
e 
fo
r p
la
nn
in
g 
(a
tt
ra
ct
 
ad
di
ti
on
al
 p
er
so
na
l e
tc
, o
r 
th
at
 in
su
re
rs
 c
an
 a
nt
ic
ip
at
e 
fo
r t
he
 e
xt
ra
 b
ud
ge
t)
. 
In
cr
ea
se
d 
ne
ed
 fo
r:
- S
pe
ci
al
iz
ed
 p
er
so
nn
el
. 
-  I
nt
en
si
ve
 c
ar
e,
 
ca
rd
io
lo
gy
 b
ed
s.
 
-  O
pe
ra
ti
on
 ro
om
 
ca
pa
ci
ty
. 
O
th
er
 o
rg
an
is
at
io
na
l 
an
d 
m
ed
ic
al
 p
ro
bl
em
s.
 
D
ep
ar
tm
en
ts
 w
ro
te
 b
us
in
es
s-
ca
se
s 
fo
r b
oa
rd
 o
f d
ire
ct
or
s 
fo
r m
or
e 
bu
dg
et
 a
nd
 p
er
so
nn
el
. 
N
at
io
na
l w
or
ki
ng
 g
ro
up
 d
ev
el
op
ed
 
in
di
ca
ti
on
 c
rit
er
ia
 a
nd
 q
ua
lit
y 
cr
it
er
ia
. 
M
ot
iv
at
io
n:
 
LV
AD
s 
ar
e 
co
ns
id
er
ed
 a
 p
rio
rit
y 
to
pi
c 
by
 d
ep
ar
tm
en
ts
 a
nd
 
ho
sp
it
al
s.
Co
nt
ra
-m
ec
ha
ni
sm
s:
-  D
is
pl
ac
e 
lo
w
 c
om
pl
ex
it
y 
ca
re
 
fr
om
 u
ni
ve
rs
it
y 
ho
sp
it
al
. 
-  E
ffi
ci
en
cy
 m
ea
su
re
s,
 in
cl
ud
in
g 
re
du
ci
ng
 le
ng
th
 o
f s
ta
y.
 
-  N
eg
ot
ia
ti
on
 to
 re
du
ce
 th
e 
pr
ic
e 
of
 
th
e 
LV
AD
. 
D
el
ay
: o
th
er
 
op
er
at
iv
e 
pr
oc
ed
ur
es
 a
re
 
po
st
po
ne
d.
 
D
en
ia
l o
f p
at
ie
nt
s 
w
it
h 
lo
w
 c
om
pl
ex
it
y 
ne
ed
s.
 
N
o 
fin
an
ci
al
 
di
sp
la
ce
m
en
t 
w
it
hi
n 
th
e 
ho
sp
it
al
, m
ai
nl
y 
be
ca
us
e 
of
 
th
e 
fi
na
nc
in
g 
ar
ra
ng
em
en
t w
it
h 
re
la
ti
ve
ly
 lo
w
 
ris
k 
fo
r p
ro
vi
de
rs
. 
In
 a
dd
it
io
n,
 
th
e 
gr
ow
th
 in
 
nu
m
be
r o
f L
VA
D
s 
st
ay
ed
 b
eh
in
d 
ex
pe
ct
at
io
ns
. 
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Ca
se
 s
tu
dy
En
tr
y 
to
 t
he
 s
ys
te
m
Re
im
bu
rs
em
en
t,
 c
on
tr
ac
ts
, 
ne
go
ti
at
io
ns
D
if
fi
cu
lt
ie
s 
or
 
pr
ob
le
m
s 
en
co
un
te
re
d
D
ec
is
io
n 
m
ak
in
g 
pr
oc
es
s 
an
d 
de
ci
si
on
s,
 m
ot
iv
at
io
n,
 c
on
tr
a-
m
ec
ha
ni
sm
s
Im
pa
ct
 o
n 
re
gu
la
r 
ca
re
D
is
pl
ac
em
en
t?
Fe
ne
st
ra
te
d 
en
do
va
sc
ul
ar
 
an
eu
ry
sm
 re
pa
ir 
Sp
ec
ia
lis
ts
 a
nd
 d
ep
ar
tm
en
ts
 
st
ar
te
d 
ex
pe
rim
en
ti
ng
 e
ar
ly
 2
00
0s
, 
ac
ti
vi
ti
es
 w
er
e 
sc
al
ed
 u
p 
af
te
r 
in
it
ia
l s
uc
ce
ss
. 
In
 2
01
3 
FE
VA
R 
w
as
 a
pp
ro
ve
d 
fo
r t
he
 
be
ne
fi
t p
ac
ka
ge
.
So
m
e 
ho
sp
it
al
s 
st
ar
te
d 
w
it
h 
FE
VA
R 
af
te
r t
he
 a
rr
iv
al
 o
f a
 n
ew
 p
ro
fe
ss
or
 
w
it
h 
ex
pe
rie
nc
e 
in
 F
EV
AR
. B
es
id
es
, 
th
e 
te
ch
no
lo
gy
 im
pr
ov
es
 s
o 
th
at
 
pa
ti
en
ts
 c
an
 b
e 
tr
ea
te
d 
th
at
 c
ou
ld
 
ot
he
rw
is
e 
no
t b
e 
tr
ea
te
d,
 a
nd
 
th
e 
te
ch
no
lo
gy
 is
 in
no
va
ti
ve
/
te
ch
ni
ca
lly
 c
ha
lle
ng
in
g,
 w
hi
ch
 is
 
ap
pr
ec
ia
te
d 
by
 th
e 
m
ed
ic
al
 s
ta
ff
. 
Co
m
pe
ti
ti
on
 b
et
w
ee
n 
ho
sp
it
al
s,
 
ho
sp
it
al
s 
ar
e 
af
ra
id
 to
 s
ta
y 
be
hi
nd
.
So
m
e 
ho
sp
it
al
s 
cr
os
s-
su
bs
id
iz
ed
 F
EV
AR
 fr
om
 o
th
er
 
pr
od
uc
ts
. 
Pr
ic
es
 a
nd
 v
ol
um
es
 a
re
 
ne
go
ti
at
ed
 b
et
w
ee
n 
ho
sp
it
al
 
an
d 
in
su
re
r, 
bu
t t
he
se
 a
re
 n
ot
 
bi
nd
in
g,
 m
ay
 b
e 
ex
ch
an
ge
d 
fo
r a
ny
 o
th
er
 c
ar
e,
 a
s 
lo
ng
 a
s 
th
e 
to
ta
l e
xp
en
di
tu
re
s 
do
 n
ot
 
pa
ss
 th
e 
ne
go
ti
at
ed
 b
ud
ge
t 
ce
ili
ng
. 
Th
us
, h
os
pi
ta
l a
nd
 in
su
re
r 
pr
im
ar
ily
 n
eg
ot
ia
te
 a
 to
ta
l 
bu
dg
et
, w
hi
ch
 is
 s
ec
on
da
ril
y 
su
bs
ta
nt
ia
te
d 
by
 p
ric
es
 a
nd
 
vo
lu
m
es
. 
So
m
e 
ho
sp
it
al
s 
di
d 
no
t h
av
e 
an
y 
co
nt
ra
ct
s 
w
it
h 
in
su
re
rs
 
ab
ou
t F
EV
AR
. 
In
su
re
rs
 ra
re
ly
 c
on
tr
ac
t o
n 
ba
si
s 
of
 q
ua
lit
y 
pr
ot
oc
ol
s,
 o
r 
re
vi
ew
 p
at
ie
nt
 n
ot
es
. 
D
ep
ar
tm
en
ts
/d
iv
is
io
n 
w
ro
te
 
bu
si
ne
ss
-c
as
es
 g
en
er
al
ly
 in
 
re
ac
ti
on
 to
 b
ud
ge
t o
ve
rr
un
s,
 
ra
th
er
 th
an
 p
ro
ac
ti
ve
ly
. 
Bu
dg
et
 o
ve
rr
un
 fo
r 
de
pa
rt
m
en
ts
, d
iv
is
io
ns
, 
ca
rd
io
va
sc
ul
ar
 c
en
tr
e.
 
FE
VA
R 
w
as
 o
ne
 o
f t
he
 
se
rv
ic
es
 c
on
tr
ib
ut
in
g 
to
 
th
e 
cu
m
ul
at
iv
e 
bu
dg
et
 
ov
er
ru
n.
 F
EV
AR
 w
as
 
a 
m
in
or
 c
on
tr
ib
ut
or
, 
ot
he
r s
er
vi
ce
s 
co
nt
rib
ut
ed
 m
or
e 
si
gn
ifi
ca
nt
ly
 to
 th
e 
bu
dg
et
 o
ve
rr
un
.
In
cr
ea
se
d 
ne
ed
 fo
r 
fa
ci
lit
ie
s.
In
 s
om
e 
ho
sp
it
al
s,
 e
xt
ra
 b
ud
ge
t 
w
as
 p
ro
ac
ti
ve
ly
 n
eg
ot
ia
te
d 
w
it
hi
n 
th
e 
de
pa
rt
m
en
t,
 d
iv
is
io
n,
 h
os
pi
ta
l 
(o
ve
rs
pe
nd
, f
ro
m
 re
se
rv
es
) o
r f
ro
m
 
th
e 
in
su
re
r. 
In
 o
th
er
 h
os
pi
ta
ls
, e
xt
ra
 
bu
dg
et
 w
as
 n
eg
ot
ia
te
d 
(b
ot
h 
w
it
h 
an
d 
w
it
ho
ut
 s
uc
ce
ss
) i
n 
re
sp
on
se
 
to
 th
e 
cu
m
ul
at
iv
e 
co
st
 p
re
ss
ur
e.
In
 o
ne
 h
os
pi
ta
l, 
op
er
at
io
n 
ro
om
 
ti
m
e 
w
as
 re
du
ce
d 
to
 li
m
it
 th
e 
nu
m
be
r o
f s
ur
gi
ca
l p
ro
ce
du
re
s 
an
d 
sp
en
di
ng
.
M
ot
iv
at
io
n:
 
-  A
or
ta
 p
at
ho
lo
gy
 is
  c
on
si
de
re
d 
a 
pr
io
rit
y 
to
pi
c 
by
 d
ep
ar
tm
en
ts
 a
nd
 
ho
sp
it
al
s.
-  C
om
pe
ti
ti
on
 b
et
w
ee
n 
pr
ov
id
er
s.
-  L
es
s 
in
va
si
ve
 is
 th
e 
fu
tu
re
 fo
r 
su
rg
er
y.
 
Co
nt
ra
-m
ec
ha
ni
sm
s:
-  N
eg
ot
ia
te
 lo
w
er
 p
ric
es
 fo
r s
te
nt
s.
 
-  D
is
pl
ac
e 
lo
w
 c
om
pl
ex
it
y 
ca
re
 
fr
om
 u
ni
ve
rs
it
y 
ho
sp
it
al
. 
-  E
ffi
ci
en
cy
 m
ea
su
re
s,
 in
cl
ud
in
g 
re
du
ci
ng
 le
ng
th
 o
f s
ta
y.
D
el
ay
: w
ai
ti
ng
 li
st
s 
fo
r s
ur
ge
ry
. 
D
en
ia
l o
r d
efl
ec
ti
on
 
of
 lo
w
 c
om
pl
ex
it
y 
pa
ti
en
ts
.
FE
VA
R 
w
as
 o
ne
 o
f 
th
e 
se
rv
ic
es
 th
at
 
co
nt
rib
ut
ed
 to
 
cu
m
ul
at
iv
e 
co
st
 
pr
es
su
re
s.
 In
 s
om
e 
ho
sp
it
al
s,
 e
xt
ra
 
bu
dg
et
 c
ou
ld
 b
e 
ne
go
ti
at
ed
 to
 
ac
co
m
m
od
at
e 
th
is
 
gr
ow
th
. I
n 
ot
he
r 
ho
sp
it
al
s,
 th
e 
gr
ow
th
 o
f F
EV
AR
 
w
as
 li
m
it
ed
 d
ue
 
to
 c
os
t p
re
ss
ur
es
 
fr
om
 c
om
pe
ti
ng
 
in
no
va
ti
on
s.
  
Lo
w
er
 p
ric
es
 fo
r 
st
en
ts
 re
du
ce
 
th
e 
lik
el
ih
oo
d 
of
 
di
sp
la
ce
m
en
t.
D
ue
 to
 
in
tr
an
sp
ar
en
t 
fi
na
nc
in
g,
 n
o 
di
sp
la
ce
m
en
t 
ef
fe
ct
s 
co
ul
d 
be
 
tr
ac
ed
.
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Ex
pe
ns
iv
e 
on
co
ly
ti
cs
Ex
pe
ns
iv
e 
on
co
ly
ti
cs
 a
re
 
re
im
bu
rs
ed
 a
ft
er
 E
M
A-
re
gi
st
ra
ti
on
, 
a 
po
si
ti
ve
 e
va
lu
at
io
n 
of
 
ef
fe
ct
iv
en
es
s 
by
 a
n 
es
ta
bl
is
he
d 
na
ti
on
al
 o
nc
ol
og
ic
 c
om
m
is
si
on
 
(‘C
om
m
is
si
e 
BO
M
’) 
an
d 
an
 
as
se
ss
m
en
t b
y 
th
e 
H
ea
lt
h 
Ca
re
 
In
st
it
ut
e.
W
it
hi
n 
ho
sp
it
al
s,
 d
ru
g 
co
m
m
it
te
es
 
di
sc
us
s 
ne
w
 d
ru
gs
 a
nd
 n
eg
ot
ia
te
 
ex
tr
a 
bu
dg
et
 fr
om
 th
e 
bo
ar
d 
of
 
di
re
ct
or
s.
Ex
pe
ns
iv
e 
on
co
ly
ti
cs
 a
re
 
re
im
bu
rs
ed
 u
si
ng
 a
dd
-o
n 
pa
ym
en
ts
, m
os
t o
ft
en
 o
n 
th
e 
ba
si
s 
of
 fe
e 
fo
r s
er
vi
ce
, o
r 
ex
 a
nt
e 
de
te
rm
in
ed
 c
ap
pe
d 
bu
dg
et
s.
 
H
os
pi
ta
ls
 n
eg
ot
ia
te
 w
it
h 
in
su
re
rs
 a
bo
ut
 v
ol
um
es
 a
nd
 
pr
ic
es
. I
n 
m
os
t h
os
pi
ta
ls
, 
th
es
e 
ne
go
ti
at
io
ns
 a
re
 c
ar
ve
d 
ou
t f
ro
m
 th
e 
ne
go
ti
at
io
ns
 
gu
id
ed
 b
y 
th
e 
bu
dg
et
 
ce
ili
ng
s.
 
Th
er
e 
ar
e 
se
ve
ra
l 
re
qu
ire
m
en
ts
 fo
r c
ar
ve
d 
ou
t 
co
nt
ra
ct
s.
 In
su
re
rs
 re
qu
ire
 
th
at
 h
os
pi
ta
l a
dh
er
e 
to
 
gu
id
el
in
es
, b
e 
tr
an
sp
ar
en
t 
ab
ou
t c
os
ts
 a
nd
 o
ut
co
m
es
, 
an
d 
al
lo
w
 n
o 
m
ar
gi
ns
 o
n 
th
e 
dr
ug
s 
(w
hi
ch
 u
se
d 
to
 b
e 
th
e 
ca
se
, a
nd
 w
as
 s
pe
nt
 o
n 
ot
he
r c
ar
e)
.
Co
nc
er
ns
 a
bo
ut
 fu
tu
re
 
fi
na
nc
ia
l s
us
ta
in
ab
ili
ty
, 
ex
or
bi
ta
nt
 h
ig
h 
pr
ic
es
, 
an
d 
hi
gh
 p
ro
fi
t m
ar
gi
ns
 
of
 in
du
st
ry
. 
G
ro
w
th
 in
 s
pe
nd
in
g 
fo
r 
ex
pe
ns
iv
e 
on
co
ly
ti
cs
 
ex
ce
ed
s 
th
e 
1%
 
gr
ow
th
 li
m
it
 o
f s
ec
to
r 
ag
re
em
en
ts
. 
Th
us
, g
ro
w
th
 a
llo
ca
te
d 
to
 e
xp
en
si
ve
 d
ru
gs
 
ne
ed
s 
to
 b
e 
re
ta
in
ed
 
fr
om
 th
e 
ot
he
r s
er
vi
ce
s.
N
eg
ot
ia
te
 a
dd
it
io
na
l b
ud
ge
t f
ro
m
 
in
su
re
rs
, b
ef
or
e 
an
d 
du
rin
g 
th
e 
ye
ar
. 
In
su
re
r a
nd
 h
os
pi
ta
l fi
rs
t n
eg
ot
ia
te
 
th
e 
to
ta
l b
ud
ge
t f
or
 th
e 
co
m
in
g 
ye
ar
 (≈
 b
ud
ge
t-
t0
 +
1%
). 
Th
en
 th
is
 
bu
dg
et
 is
 c
ut
 to
 1)
 a
ll 
se
rv
ic
es
 
th
at
 a
re
 c
ar
ve
d 
ou
t,
 a
nd
 2
) o
th
er
 
se
rv
ic
es
, w
hi
ch
 a
re
 fu
rt
he
r c
ut
 in
 
di
ff
er
en
t s
eg
m
en
ts
 o
f s
er
vi
ce
s.
 
Bo
ar
d 
of
 d
ire
ct
or
s 
m
ay
 re
qu
es
t 
de
pa
rt
m
en
ts
 to
 c
ut
 c
os
ts
. O
ng
oi
ng
 
cy
cl
e 
of
 a
us
te
rit
y/
ef
fi
ci
en
cy
 
m
ea
su
re
s 
w
it
hi
n 
th
e 
ho
sp
it
al
, 
in
 li
ne
 w
it
h 
th
e 
po
lic
y 
of
 th
e 
or
ga
ni
sa
ti
on
. 
M
ot
iv
at
io
n:
-  I
ns
ur
er
s 
ar
e 
af
ra
id
 fo
r l
os
s 
of
 
re
pu
ta
ti
on
.
-  O
nc
ol
og
y 
is
 c
on
si
de
re
d 
a 
pr
io
rit
y 
to
pi
c 
in
 h
os
pi
ta
ls
, m
al
ig
n 
is
 
pr
io
rit
iz
ed
 a
bo
ve
 b
en
ig
n.
 
Co
nt
ra
-m
ec
ha
ni
sm
s:
-  N
eg
ot
ia
te
 lo
w
er
 p
ric
es
, t
hr
ou
gh
 
fo
r e
xa
m
pl
e 
co
lle
ct
iv
e 
pu
rc
ha
si
ng
. 
-  P
re
ci
si
on
 m
ed
ic
in
e.
-  E
ffi
ci
en
cy
 m
ea
su
re
s.
 
-  D
is
pl
ac
e 
lo
w
 c
om
pl
ex
it
y 
ca
re
 
fr
om
 u
ni
ve
rs
it
y 
ho
sp
it
al
. 
-  I
nt
ro
du
ct
io
n 
of
 n
ew
 d
ru
gs
 
de
la
ye
d 
to
  n
ex
t c
al
en
da
r y
ea
r.
- C
ut
s 
in
 (s
up
po
rt
) s
ta
ff
.
- C
ut
s 
in
 n
um
be
r b
ed
s.
Ra
ti
on
in
g 
of
 
ex
pe
ns
iv
e 
on
co
ly
ti
cs
 w
as
 n
ot
 
re
po
rt
ed
, h
ow
ev
er
 
se
le
ct
io
n 
(m
or
e 
st
ric
t a
dh
er
en
ce
 to
 
in
di
ca
ti
on
 c
rit
er
ia
 
th
an
 b
ef
or
e)
 w
as
. 
So
m
e 
tr
ea
tm
en
ts
 
m
ay
 b
e 
de
la
ye
d,
 o
r 
pa
ti
en
ts
 w
er
e 
se
nt
 
to
 o
th
er
 h
os
pi
ta
ls
 
(d
efl
ec
ti
on
), 
ho
w
ev
er
 
re
sp
on
de
nt
s 
w
er
e 
su
re
 th
es
e 
ha
d 
no
 
ne
ga
ti
ve
 im
pa
ct
 o
n 
pa
ti
en
t’
s 
he
al
th
. 
Pa
ti
en
ts
 w
it
h 
an
 in
di
ca
ti
on
 
fo
r e
xp
en
si
ve
 
on
co
ly
ti
cs
 w
er
e 
se
nt
 to
 a
nd
 fr
om
 
ot
he
r h
os
pi
ta
ls
 
(d
efl
ec
ti
on
).
In
ve
st
m
en
ts
 w
er
e 
de
la
ye
d.
Ex
pe
ns
iv
e 
on
co
ly
ti
cs
 lo
w
er
 
th
e 
gr
ow
th
 
of
 re
m
ai
ni
ng
 
se
rv
ic
es
. 
Th
e 
bu
dg
et
 
pr
es
su
re
 o
f 
th
e 
dr
ug
s 
w
as
 
ab
so
rb
ed
 b
y 
bo
ar
d 
of
 d
ire
ct
or
s 
an
d 
in
su
re
rs
, w
ho
 
re
di
st
rib
ut
ed
 
th
is
 p
re
ss
ur
e 
to
 
th
e 
re
st
 o
f t
he
 
de
pa
rt
m
en
ts
. 
Be
ca
us
e 
of
 th
is
 
in
di
re
ct
 ro
ut
e 
an
d 
in
tr
an
sp
ar
en
t 
fi
na
nc
in
g,
 it
 
is
 d
if
fi
cu
lt
 to
 
ca
us
al
ly
 li
nk
 
au
st
er
it
y 
m
ea
su
re
s 
or
 b
ud
ge
t c
ut
s,
 
to
 th
e 
bu
dg
et
 
pr
es
su
re
 o
f t
he
 
dr
ug
s.
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 c
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m
ec
ha
ni
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Im
pa
ct
 o
n 
re
gu
la
r 
ca
re
D
is
pl
ac
em
en
t?
Ey
le
a 
an
d 
Lu
ce
nt
is
Lu
ce
nt
is
 h
as
 b
ee
n 
re
im
bu
rs
ed
 
fr
om
 2
00
7 
an
d 
on
w
ar
ds
. 
In
 2
01
2,
 Z
IN
L 
ad
vi
se
d 
to
 e
xc
lu
de
 
Lu
ce
nt
is
 fr
om
 c
ov
er
ag
e.
 
In
 2
01
2 
an
d 
20
14
 re
sp
ec
ti
ve
ly
 
Lu
ce
nt
is
 a
nd
 E
yl
ea
 w
er
e 
in
cl
ud
ed
 
in
 th
e 
po
si
ti
ve
 li
st
 fo
r a
dd
-o
n 
pa
ym
en
ts
. T
he
 d
ru
gs
 w
er
e 
in
it
ia
lly
 
in
di
ca
te
d 
fo
r p
at
ie
nt
s 
w
it
h 
ag
e-
re
la
te
d 
m
ac
ul
a 
ed
em
a.
 
Ey
le
a 
an
d 
Lu
ce
nt
is
 w
er
e 
al
so
 u
se
d 
fo
r p
at
ie
nt
s 
w
it
h 
di
ab
et
ic
 m
ac
ul
a 
ed
em
a 
an
d 
va
sc
ul
ar
 o
cc
lu
si
on
. 
H
ow
ev
er
, t
he
se
 in
di
ca
ti
on
s 
w
er
e 
no
t i
nc
lu
de
d 
on
 th
e 
po
si
ti
ve
 li
st
 fo
r 
ad
d-
on
 p
ay
m
en
ts
 u
nt
il 
M
ar
ch
 2
01
5.
 
W
he
n 
ne
w
 in
di
ca
ti
on
s 
ap
pe
ar
ed
 
on
 th
e 
po
si
ti
ve
 li
st
s 
du
rin
g 
th
e 
ye
ar
, t
he
 b
oa
rd
 o
f d
ire
ct
or
s 
tr
ie
d 
to
 n
eg
ot
ia
te
 e
xt
ra
 b
ud
ge
t f
or
 th
e 
dr
ug
s 
w
it
h 
th
e 
he
al
th
 in
su
re
rs
. 
Ey
le
a 
an
d 
Lu
ce
nt
is
 a
re
 
re
im
bu
rs
ed
 u
si
ng
 a
dd
-o
n 
pa
ym
en
ts
, m
os
t o
ft
en
 o
n 
th
e 
ba
si
s 
of
 c
ar
ve
d 
ou
t c
on
tr
ac
ts
. 
In
 s
om
e 
ho
sp
it
al
s 
ho
w
ev
er
, 
th
es
e 
se
rv
ic
es
 c
ou
nt
ed
 fo
r 
th
e 
bu
dg
et
 c
ei
lin
g.
 
In
 th
e 
pa
st
, e
ye
 in
je
ct
io
ns
 
w
er
e 
fi
na
nc
ed
 fr
om
 D
RG
s 
(A
va
st
in
 w
as
 m
ai
nl
y 
us
ed
 fo
r 
fi
na
nc
ia
l r
ea
so
ns
) o
r f
ro
m
 
in
no
va
ti
on
 fu
nd
s.
 
In
su
re
rs
 a
nd
 p
ro
vi
de
rs
 
ne
go
ti
at
e 
a 
pe
rc
en
ta
ge
 o
f 
Ey
le
a/
Lu
ce
nt
is
 o
f t
ot
al
 e
ye
 
in
je
ct
io
ns
, t
yp
ic
al
ly
 b
et
w
ee
n 
10
-2
0%
. 
In
su
re
rs
 re
qu
ire
 tr
an
sp
ar
en
cy
 
in
 th
e 
pu
rc
ha
si
ng
 a
nd
 u
se
 o
f 
th
e 
ey
e 
dr
ug
s.
In
di
ca
ti
on
 e
xt
en
si
on
 in
 
th
e 
m
id
st
 o
f t
he
 y
ea
r 
le
d 
to
 b
ud
ge
t o
ve
rr
un
s 
in
 h
os
pi
ta
ls
 w
he
re
 a
dd
-
on
 p
ay
m
en
ts
 fo
r t
he
 
dr
ug
s 
di
d 
co
un
t f
or
 th
e 
ce
ile
d 
to
ta
l b
ud
ge
ts
. 
Es
pe
ci
al
ly
 s
pe
ci
al
iz
ed
 
ey
e 
ce
nt
re
s 
ex
pe
rie
nc
ed
 
co
st
 p
re
ss
ur
e 
du
e 
to
 
ex
pe
ns
iv
e 
ey
e 
dr
ug
s.
Th
e 
nu
m
be
r o
f p
at
ie
nt
s 
an
d 
th
e 
pe
rc
en
ta
ge
 
of
 p
at
ie
nt
s 
re
qu
iri
ng
 
Ey
le
a/
Lu
ce
nt
is
 g
ro
w
s.
Fo
r i
ns
ur
er
s 
it
 is
 
di
ffi
cu
lt
 to
 d
et
er
m
in
e 
th
e 
rig
ht
 p
er
ce
nt
ag
e 
of
 
ex
pe
ns
iv
e 
in
je
ct
io
ns
.
So
m
e 
in
su
re
rs
 
re
im
bu
rs
ed
 m
or
e 
ex
pe
ns
iv
e 
ey
e 
in
je
ct
io
ns
 th
an
 o
th
er
s.
  
In
cr
ea
se
 in
 n
um
be
r 
of
 p
at
ie
nt
s,
 in
cr
ea
se
d 
w
or
kl
oa
d.
 
Re
ne
go
ti
at
io
n 
w
it
h 
in
su
re
r.
In
te
rn
al
 re
di
st
rib
ut
io
n 
of
 fu
nd
s 
be
tw
ee
n 
de
pa
rt
m
en
ts
 b
y 
bo
ar
d 
of
 
di
re
ct
or
s.
Cr
os
s-
su
bs
id
is
at
io
n 
fr
om
 o
th
er
 
se
rv
ic
es
 w
it
h 
hi
gh
 p
ro
fi
t m
ar
gi
n.
Bo
ar
d 
of
 d
ire
ct
or
s 
co
nt
ro
l 
th
e 
vo
lu
m
e 
an
d 
bu
dg
et
 o
f 
de
pa
rt
m
en
ts
.
M
ot
iv
at
io
n:
-  B
oa
rd
 o
f d
ire
ct
or
s 
de
ci
de
 a
bo
ut
 
pr
io
rit
y 
to
pi
cs
 th
at
 a
re
 a
llo
ca
te
d 
a 
hi
gh
er
 b
ud
ge
t,
 c
om
pa
re
d 
to
 o
th
er
 
de
pa
rt
m
en
ts
/t
op
ic
s 
th
at
 a
re
 
st
ric
tl
y 
ke
pt
 to
 th
ei
r b
ud
ge
t.
 
Co
nt
ra
-m
ec
ha
ni
sm
s:
-  E
ffi
ci
en
cy
 m
ea
su
re
s,
 in
cl
ud
in
g 
ta
sk
 re
ar
ra
ng
em
en
ts
. 
-  D
is
pl
ac
e 
lo
w
 c
om
pl
ex
it
y 
ca
re
. 
-  I
m
pr
ov
e 
ad
he
re
nc
e 
to
 in
di
ca
ti
on
s,
 
vi
a 
co
m
m
it
te
e 
fo
r e
xp
en
si
ve
 
dr
ug
s.
In
 e
xc
ep
ti
on
al
 
si
tu
at
io
ns
, p
at
ie
nt
s 
w
er
e 
se
le
ct
ed
 o
n 
ba
si
s 
of
 in
su
ra
nc
e 
co
m
pa
ny
. I
n 
ad
di
ti
on
, p
at
ie
nt
s 
w
er
e 
se
le
ct
ed
 o
n 
ba
si
s 
of
 m
ed
ic
al
 
ur
ge
nc
y.
D
efl
ec
ti
on
 o
f 
pa
ti
en
ts
 th
at
 
ne
ed
 e
xp
en
si
ve
 
dr
ug
s 
be
ca
us
e 
of
 
in
ad
eq
ua
te
 b
ud
ge
t.
D
el
ay
 o
f n
on
-a
cu
te
 
ca
re
, o
r d
en
ia
l o
f 
re
fe
rr
ed
 p
at
ie
nt
s.
U
nd
er
 s
pe
nd
 o
n 
in
no
va
ti
on
s/
 
in
ve
st
m
en
ts
/ 
m
ai
nt
en
an
ce
. 
Sp
ec
ia
liz
ed
 
ey
e 
ce
nt
re
s 
ex
pe
rie
nc
ed
 m
os
t 
co
st
 p
re
ss
ur
e,
 
pr
es
um
ab
ly
 
be
ca
us
e 
th
ey
 h
ad
 
le
ss
 a
bi
lit
ie
s 
fo
r 
cr
os
s-
su
bs
id
ia
ti
on
 
an
d 
in
te
rn
al
 
re
di
st
rib
ut
io
n 
of
 
fu
nd
s,
 o
r h
ad
 le
ss
 
m
ar
ke
t p
ow
er
 to
 
ne
go
ti
at
e 
ca
rv
ed
 
ou
t F
FS
 c
on
tr
ac
ts
 
fo
r e
xp
en
si
ve
 
dr
ug
s.
Ra
ti
on
in
g 
by
 d
el
ay
 
an
d 
se
le
ct
io
n 
w
er
e 
w
id
el
y 
re
po
rt
ed
, 
ho
w
ev
er
 th
es
e 
w
er
e 
no
t c
au
sa
lly
 
lin
ke
d 
to
 th
e 
ey
e 
dr
ug
s.
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Po
pu
la
ti
on
 
sc
re
en
in
g 
fo
r 
co
lo
n 
ca
nc
er
H
os
pi
ta
ls
 c
ou
ld
 c
ho
os
e 
to
 
pa
rt
ic
ip
at
e 
in
 th
e 
pr
og
ra
m
. T
hi
s 
w
as
 p
ro
fi
ta
bl
e 
du
e 
to
 1)
 in
cr
ea
se
d 
re
ve
nu
e 
fo
r e
nd
os
co
pi
es
 2
) t
he
 
ex
tr
a 
pa
ti
en
ts
 b
ec
au
se
 o
f r
es
ul
ti
ng
 
tr
ea
tm
en
t o
f p
at
ie
nt
s 
w
it
h 
po
si
ti
ve
 
te
st
 re
su
lt
s.
 H
os
pi
ta
ls
 a
re
 re
qu
ire
d 
to
 tr
ea
t a
 m
in
im
um
 n
um
be
r o
f 
pa
ti
en
ts
 w
it
h 
co
lo
n 
ca
nc
er
. 
Ad
op
ti
on
 o
f p
op
ul
at
io
n 
sc
re
en
in
g 
in
 th
e 
be
ne
fi
t p
ac
ka
ge
 w
as
 b
as
ed
 
on
 a
n 
ad
vi
so
ry
 re
po
rt
 o
f t
he
 D
ut
ch
 
H
ea
lt
h 
Co
un
ci
l.
Sc
re
en
in
g 
en
do
sc
op
ie
s 
w
er
e 
in
it
ia
lly
 re
im
bu
rs
ed
 p
er
 
se
rv
ic
e,
 n
ot
 c
ou
nt
in
g 
fo
r t
he
 
bu
dg
et
 c
ei
lin
g.
 
La
te
r, 
ho
sp
it
al
s 
an
d 
in
su
re
rs
 
ex
pl
ic
it
ly
 n
eg
ot
ia
te
d 
ab
ou
t 
pr
ic
es
 a
nd
 v
ol
um
es
 o
f 
sc
re
en
in
g 
en
do
sc
op
ie
s.
 
U
nd
er
ca
pa
ci
ty
 
ga
st
ro
en
te
ro
lo
gy
 (G
E)
 
de
pa
rt
m
en
ts
, s
ho
rt
ag
e 
of
 G
E-
sp
ec
ia
lis
ts
. 
H
ig
he
r d
em
an
d 
fo
r 
co
lo
no
sc
op
ie
s 
th
an
 
an
ti
ci
pa
te
d.
In
te
rn
al
 re
di
st
rib
ut
io
n 
of
 fu
nd
s 
be
tw
ee
n 
de
pa
rt
m
en
ts
 b
y 
bo
ar
d 
of
 
di
re
ct
or
s.
D
ep
ar
tm
en
ts
 a
nd
 d
iv
is
io
ns
 a
re
 
ge
ne
ra
lly
 h
el
d 
re
sp
on
si
bl
e 
fo
r 
th
ei
r o
w
n 
bu
dg
et
 a
nd
 a
re
 g
iv
en
 
fle
xi
bi
lit
y 
in
 h
ow
 to
 s
pe
nd
 th
e 
bu
dg
et
. 
D
ep
ar
tm
en
ts
, d
iv
is
io
ns
 a
nd
 b
oa
rd
 
of
 d
ire
ct
or
s 
de
te
rm
in
e 
pr
io
rit
y 
to
pi
cs
 fo
r w
hi
ch
 b
ud
ge
ts
 a
re
 
lo
os
en
e d
. 
M
ot
iv
at
io
n:
-  P
rio
rit
y 
to
pi
c 
of
 d
ep
ar
tm
en
ts
 a
nd
 
ho
sp
it
al
. 
-  C
ol
on
 c
an
ce
r a
nd
 o
nc
ol
og
y 
in
 
ge
ne
ra
l w
er
e 
co
ns
id
er
ed
 k
ey
 to
pi
cs
 
in
 s
om
e 
ho
sp
it
al
s.
 
-  C
ol
on
 s
cr
ee
ni
ng
 w
as
 c
on
si
de
re
d 
lo
w
 c
om
pl
ex
it
y 
ca
re
 in
 s
om
e 
ac
ad
em
ic
 c
en
tr
es
.  
-  C
ol
on
 c
an
ce
r p
at
ie
nt
s 
w
er
e 
ge
ne
ra
lly
 p
rio
rit
iz
ed
 a
bo
ve
 p
at
ie
nt
s 
w
it
h 
in
fla
m
m
at
or
y 
bo
w
el
 d
is
ea
se
.
Co
nt
ra
-m
ec
ha
ni
sm
s:
-  H
os
pi
ta
ls
 c
om
m
un
ic
at
e 
th
ei
r 
ca
pa
ci
ty
 fo
r s
cr
ee
ni
ng
 e
nd
os
co
pi
es
 
di
gi
ta
lly
 to
 th
e 
na
ti
on
al
 p
ro
gr
am
. 
As
 s
uc
h,
 th
ey
 w
er
e 
ab
le
 to
 re
du
ce
 
th
e 
vo
lu
m
e 
of
 s
er
vi
ce
s 
an
d 
de
m
an
d 
lo
ca
lly
.  
-  D
is
pl
ac
e 
lo
w
 c
om
pl
ex
it
y 
ca
re
. 
- R
eg
io
na
l p
ar
tn
er
sh
ip
s.
 
- S
ub
st
it
ut
io
n.
- E
-h
ea
lt
h.
 
D
efl
ec
ti
on
 o
f 
pa
ti
en
ts
 to
 o
th
er
 
re
gi
on
s.
 
D
el
ay
: w
ai
ti
ng
 
lis
ts
 fo
r r
eg
ul
ar
 
en
do
sc
op
ie
s 
or
 G
E-
ca
re
 in
 g
en
er
al
.
Se
le
ct
io
n:
 in
 u
rg
en
t 
ca
se
s 
pa
ti
en
ts
 w
er
e 
gi
ve
n 
pr
io
rit
y 
an
d 
w
er
e 
ex
em
pt
ed
 
fr
om
 th
e 
w
ai
ti
ng
 
lis
t.
 V
ar
io
us
 
al
te
rn
at
iv
es
 fo
r 
se
le
ct
io
n 
ba
se
d 
on
 
ur
ge
nc
y.
 
D
en
ia
l o
f r
eq
ue
st
 
fo
r s
ec
on
d 
op
in
io
ns
. A
ca
de
m
ic
 
ho
sp
it
al
s 
de
ny
 
lo
w
 c
om
pl
ex
it
y 
pa
ti
en
ts
. 
M
os
t o
f t
he
 
re
po
rt
ed
 p
ro
bl
em
s 
or
 ra
ti
on
in
g 
w
er
e 
re
la
te
d 
to
 th
e 
pr
e-
ex
is
ti
ng
 s
ho
rt
ag
e 
of
 G
E-
sp
ec
ia
lis
ts
. 
Th
e 
sc
re
en
in
g 
pr
og
ra
m
 p
ut
 
fu
rt
he
r p
re
ss
ur
e 
on
 th
e 
w
ai
ti
ng
 
lis
ts
, b
ut
 th
e 
w
ai
ti
ng
 li
st
s 
w
er
e 
ge
ne
ra
lly
 n
ot
 
lin
ke
d 
to
 a
dv
er
se
 
he
al
th
 o
ut
co
m
es
.  
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 c
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Im
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re
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r 
ca
re
D
is
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em
en
t?
Ro
bo
ti
c 
su
rg
er
y
Th
e 
fi
rs
t D
a 
Vi
nc
i p
la
tf
or
m
 w
as
 
bo
ug
ht
 in
 2
00
0.
 
ZI
N
L 
di
d 
as
se
ss
 D
a 
Vi
nc
i, 
bu
t n
ot
 
fo
rm
al
ly
 in
- o
r e
xc
lu
de
d 
th
e 
se
rv
ic
e 
fr
om
 th
e 
be
ne
fi
t p
ac
ka
ge
, b
ec
au
se
 
de
ci
si
on
s 
ab
ou
t s
er
vi
ce
 c
ov
er
ag
e 
co
nc
er
n 
tr
ea
tm
en
ts
 fo
r a
 g
iv
en
 
pa
ti
en
t p
op
ul
at
io
n,
 n
ot
 th
e 
w
ay
 
th
e 
tr
ea
tm
en
t i
s 
de
liv
er
ed
. 
W
it
hi
n 
ho
sp
it
al
s,
 d
ep
ar
tm
en
ts
 
(p
rim
ar
ily
 u
ro
lo
gy
) r
eq
ue
st
ed
 
th
e 
bo
ar
d 
of
 d
ire
ct
or
s 
to
 b
uy
 th
e 
pl
at
fo
rm
.
Th
e 
pr
oc
ur
em
en
t o
f t
he
 
pl
at
fo
rm
 is
 fi
na
nc
ed
 fr
om
 
in
ve
st
m
en
t-
 o
r i
nn
ov
at
io
n 
bu
dg
et
s.
 
In
su
re
rs
 a
re
 n
ot
 in
vo
lv
ed
 in
 
an
d 
ar
e 
no
t c
on
su
lt
ed
 fo
r t
he
 
pu
rc
ha
se
 o
f t
he
 p
la
tf
or
m
. 
H
os
pi
ta
ls
 a
nd
 in
su
re
rs
 
m
ai
nl
y 
ne
go
ti
at
e 
bu
dg
et
s,
 
an
d 
m
ak
e 
no
 s
pe
ci
fi
c 
ag
re
em
en
ts
 a
bo
ut
 s
pe
ci
fi
c 
pr
oc
ed
ur
es
.
H
ow
ev
er
, i
ns
ur
er
s 
m
ay
 
re
qu
es
t a
 m
in
im
um
 n
um
be
r 
of
 p
ro
ce
du
re
s 
pe
r y
ea
r t
o 
gu
ar
an
te
e 
hi
gh
 q
ua
lit
y 
of
 
ca
re
.  
La
ck
 o
f e
vi
de
nc
e 
fo
r b
en
efi
ts
 o
f t
he
 
pl
at
fo
rm
. 
D
RG
s 
fo
r t
he
 
la
pa
ro
sc
op
ic
 p
ro
ce
du
re
 
ar
e 
no
t s
uf
fi
ci
en
t t
o 
co
ve
r t
he
 c
os
ts
. H
ig
he
r 
re
im
bu
rs
em
en
t h
as
 
be
en
 re
qu
es
te
d,
 b
ut
 
w
er
e 
re
je
ct
ed
 b
y 
th
e 
in
su
re
rs
 b
ec
au
se
 o
f 
th
e 
la
ck
 o
f e
vi
de
nc
e 
co
nc
er
ni
ng
 th
e 
pr
oc
ed
ur
e.
H
ig
h 
pr
ic
e 
of
 th
e 
pl
at
fo
rm
, b
ec
au
se
 o
f 
th
e 
m
on
op
ol
y 
of
 th
e 
m
an
uf
ac
tu
re
r. 
In
tr
an
sp
ar
en
cy
 o
f c
os
ts
 
of
 p
ro
ce
du
re
s 
in
 th
e 
pl
at
fo
rm
, c
om
pa
re
d 
to
 c
on
ve
nt
io
na
l 
pr
oc
ed
ur
es
. I
n 
ge
ne
ra
l: 
lit
tl
e 
in
si
gh
t 
in
 th
e 
co
st
s 
of
 th
e 
or
ga
ni
sa
ti
on
. 
M
ed
ic
al
 s
pe
ci
al
is
ts
, u
ro
lo
gi
st
s 
in
 
pa
rt
ic
ul
ar
, r
eq
ue
st
ed
 th
e 
bo
ar
d 
of
 d
ire
ct
or
s 
to
 b
uy
 th
e 
pl
at
fo
rm
, 
an
d 
w
ro
te
 a
 b
us
in
es
s-
ca
se
. B
oa
rd
 
of
 d
ire
ct
or
s 
ap
pr
ov
ed
 th
e 
re
qu
es
t 
or
 n
ot
. 
H
os
pi
ta
l t
rie
d 
to
 n
eg
ot
ia
te
 e
xt
ra
 
bu
dg
et
 fr
om
 in
su
re
rs
. 
Th
e 
la
pa
ro
sc
op
ic
 p
ro
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Abstract 
Objectives  To investigate the characteristics and healthcare utilization of high-cost patients, 
and to compare high-cost patients across payers and countries.   
Design  Systematic review.
Data sources  Pubmed and Embase databases were searched until October 30th, 2017.
Eligibility criteria and outcomes  Our final search was built on three themes: ‘high-cost’, 
‘patients’, and ‘cost’ and ‘cost analysis’. We included articles that reported characteristics 
and utilization of the top-X% (e.g. top-5%, top-10%) patients of costs of a given population. 
Analyses were limited to studies that covered a broad range of services, across the 
continuum of care. Andersen’s behavioral model was used to categorize characteristics and 
determinants into predisposing, enabling and need characteristics.
Results  The studies pointed to a high prevalence of multiple (chronic) conditions to explain 
high-cost patients’ utilization. Besides, we found a high prevalence of mental illness across 
all studies; and a prevalence higher than 30% in US Medicaid and total population studies. 
Furthermore, we found that high costs were associated with increasing age, but that still 
more than halve of high-cost patients were younger than 65. High costs were associated 
with higher incomes in the US, but with lower incomes elsewhere. Preventable spending was 
estimated at maximally ten percent of spending. The top-10%, top-5% and top-1% high-
cost patients accounted for respectively 68%, 55%, and 24% of costs within a given year. 
Spending persistency varied between 24% and 48%. Finally, we found that no more than 
30% of high-cost patients are in their last year of life. 
Conclusions  High-cost patients make up the sickest and most complex populations and 
their high utilization is primarily explained by high levels of chronic and mental illness. High-
cost patients are diverse populations and vary across payer types and countries. Tailored 
interventions are needed to meet the needs of high-cost patients, and to avoid waste of 
scarce resources.
Key words  health services administration and medicine; high-need high-cost; integrated 
delivery of health care; health care utilization, health care costs
Strengths and limitations of this study
–  Based on an extensive literature search, this review included 55 studies of high-cost 
patients’ characteristics and healthcare utilization. 
–  Andersen’s behavioural model was used to categorize the characteristics of high-cost 
patients into predisposing, enabling and need characteristics.
–  Grey literature was not included in our systematic review. However, we identified 55 
studies and compared high-cost patients’ characteristics and healthcare utilization 
across payers and countries.  
–  We did not assess the quality of the studies because of the methodological diversity of 
the studies.    
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Background
It is widely known that healthcare costs are concentrated among a small group of ‘high-cost’ 
patients [1]. Although they receive substantial care from multiple sources, critical health care 
needs are unmet, and many receive unnecessary and ineffective care [2-5]. This suggests that 
high-cost patients are a logical group to seek for quality improvement and cost reduction.
 Especially in the US, many providers or insurance plans have pursued this logic and 
developed programs for “high-need, high-cost patients”. So far, such programs, including for 
example care coordination and disease management, have had favorable results in quality 
of care and health outcomes, and mixed results in their ability to reduce hospital use and 
costs [6]. Research has shown that the effectiveness and efficiency of the programs increase 
when interventions are targeted to the patients that most likely benefit [2,7,8]. Little is known 
however, about variations in clinical characteristics and care-utilization patterns across 
payer-defined groups or countries [9]. Such insight in the health requirements of high-cost 
patients is prerequisite for designing effective policy or program responses.
 We conducted this systematic review to synthesize the literature on high-cost patients’ 
characteristics and healthcare utilization. Andersen’s behavioral model (see method section) 
was used to organize the findings. Our analysis was aimed at identifying drivers of costs 
that matter across payer types and countries. We aimed to inform the development of new 
interventions and policy, as well as future research in high-cost patients. 
Methods
Our methodology was based on established guidance for conducting systematic reviews 
[10,11]. Our main research questions was ‘Who are the most expensive patients, what health 
care services do they use, what drives these high costs, and what drivers matter across 
payers and countries?’.  
Study selection
A preliminary search in Pubmed was conducted to identify key articles and keywords. On 
the basis of these findings, we developed a search strategy covering the most important 
terms. We then reshaped the search strategy by consulting an information specialist of our 
university. The final search was built on three themes: ‘high-cost’, ‘patients’, and ‘cost’ and 
‘cost analysis’. The sensitivity of the search was verified with the key articles we found earlier. 
We searched Pubmed and Embase at October 30th, 2017. Full details of our search strategy are 
attached in appendix 1. 
Inclusion and exclusion criteria
Articles were reviewed by Author A using title and abstract to identify potentially eligible 
studies. Author B verified a random sample of articles to guarantee specificity and 
sensitivity of the selection process. Only studies from high-income countries – as defined 
by the World Bank [12] – and studies published in 2000 and later were included. Studies not 
written in English and conference abstracts were excluded. In the second step, titles and 
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abstracts were reviewed by Author A to assess whether articles fit within our definition 
of high-cost patients: the article reported characteristics and utilization of the top-X% 
(e.g. top-5%, top-10%) patients of costs of a given population. Author B verified a random 
sample of articles at this selection step. In the third step, full-text articles were retrieved and 
independently screened by Author A and Author B for our inclusion criteria. At this step, we 
aimed for studies covering a broad range of services across the continuum of care at health 
system level, and excluded all studies with a narrow scope of costs (for example: hospital 
costs, pharmaceutical costs) and all studies with a narrow population base (primarily 
disease oriented studies, or studies in children). At each step of this selection process, (in-)
consistencies were discussed until consensus was reached. On basis of the discussions, the 
criteria were refined and the prior selection process was repeated.
Data extraction 
A data extraction form was developed by the research team to ensure the approach was 
consistent with the research question. Author A extracted all data. To guarantee specificity and 
sensitivity of data extraction, Author B and Author C both independently extracted the data of 
five random articles. A meeting was held to discuss (in-)consistencies in extraction results. 
On basis of this discussion, the data extraction form was refined and the prior data extraction 
was repeated. Per article the following key elements were extracted: author, year, country, 
definition of high-cost patients, in- and exclusion criteria of the study population, cost data 
used to determine total costs, characteristics of the high-cost patients such as diagnoses, 
age, gender, ethnicity, determinants for high costs including associated supply side factors 
(concerning the supply of health services), subpopulations, and health care use and costs (per 
subpopulation). We also made a narrative summary of the findings per article (provided in 
appendix 2). To identify the most important medical characteristics, only those diseases with 
a high prevalence (≥10%) among high-cost patient populations or medical characteristics 
overrepresented in high-cost populations were extracted. Medical characteristics (prevalent 
diseases) were categorized and presented at the level of ICD10-chapters. 
Data synthesis
Andersen’s behavioural model was used to categorize characteristics and determinants for 
high costs into predisposing, enabling and need characteristics. Andersen’s model assumes 
that healthcare use is a function of 1) characteristics that predispose people to use or not 
to use services, although such characteristics are not directly responsible for use (e.g. age, 
gender, education, ethnicity, beliefs) 2) enabling characteristics that facilitate or impede 
use of services (income/wealth/insurance as ability to pay for services, organization 
of service provision, health policy) 3) needs or conditions that laypeople or health care 
providers recognize as requiring medical treatment. The model also distinguishes between 
individual and contextual (measured at aggregate level, such as measures of community 
characteristics) determinants of service use. Andersen hypothesized that the variables 
would have differential ability to explain care use, depending on the type of service. For 
example, dental care (and other discretionary services) would be explained by predisposing 
and enabling characteristics, whereas hospital care would primarily be explained by needs 
and demographic characteristics [13,14]. 
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FIGURE 1  Selection process. 
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We presented all data according to five general categories, including study characteristics, 
predisposing characteristics, enabling characteristics, need characteristics, and expenditure 
categories and health care utilization. We presented summary tables of results, extracted 
central themes and topics from the studies, and summarized them narratively. All studies 
were analyzed according to payer and country to identify the most important drivers across 
settings. 
Patient and Public Involvement
Patients and or public were not involved in the conduct of this study.
Results
General information
Our search strategy resulted in 7905 articles. After first broad eligibility assessment 767 
articles remained. After screening of titles and abstracts, 190 articles remained for full-text 
screening, from which 55 were ultimately included (figure 1). 
 A description of the studies is given in table 1. The majority of the studies were conducted 
in the United States (N=42). The remaining studies were conducted in Canada (N=9), Germany 
(N=1), Denmark (N=1), the Netherlands (N=1), and Taiwan (N=1). All were retrospective cohort 
studies, and descriptive and logistic regression analysis were the main analytic approaches 
used. The study period ranged from six months to thirty years. The most frequent observation 
period was one year.
 A range of definitions for high-cost patients were used, and some studies used more 
than one definition to distinguish between age groups, between high- and very high-cost 
patients, or to study persistently high-cost patients (>1 year high costs). In general, patients 
belonging to the top-1%, top-5%, top-10%, or top-20% of spending were considered high-
cost patients. 
 The study population differed between the studies. We categorized eighteen studies as 
‘total population’ studies, including studies in universal insurance schemes (of all ages; nine 
Canadian studies, one Dutch, one German, and one Danish study), studies that combined 
data of different payers, or survey studies. Respectively nine, seven and fourteen studies 
were among US Medicare, US Medicaid or US commercial populations. The remaining studies 
compared high-cost patients in multiple US payers, or were among US dual eligibles (eligible 
for both Medicare and Medicaid), US Veterans Affairs (VA)-beneficiaries, or among elderly 
in the Taiwanese insurance system. Some studies used additional criteria to determine 
the population. Age, healthcare use, or insurance were most frequently used as secondary 
condition to determine the population. 
 In fifty studies, total costs per patient were based on the insurance plan or public 
program. In the remaining studies, total costs were based on a survey or identified from a 
variety of sources. 
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 t
es
ts
, a
nd
 
pr
es
cr
ip
ti
on
 d
ru
gs
. 
Ch
ar
ls
on
 e
t 
al
. [
24
], 
U
ni
te
d 
St
at
es
Q
ua
nt
ile
 re
gr
es
si
on
20
09
-2
01
0
To
p-
5%
, t
op
-1
0%
U
ni
on
 o
f h
ea
lt
h 
an
d 
ho
sp
it
al
 w
or
ke
rs
 in
 t
he
 
N
or
th
ea
st
, t
ho
se
 w
ho
 w
er
e 
co
ns
is
te
nt
ly
 e
lig
ib
le
 
fo
r b
en
efi
ts
 o
ve
r a
t 
le
as
t 
22
 m
on
th
s 
in
 2
00
9 
an
d 
20
10
 (s
el
f-
in
su
re
d 
tr
us
t 
fu
nd
), 
w
ho
 a
ls
o 
re
ce
iv
ed
 
D
CG
 c
od
es
.
In
pa
ti
en
t,
 o
ut
pa
ti
en
t,
 e
m
er
ge
nc
y 
ro
om
, 
la
bo
ra
to
ry
 t
es
ts
, b
eh
av
io
ra
l h
ea
lt
h 
an
d 
pr
es
cr
ip
ti
on
 d
ru
gs
. 
Ch
ec
hu
lin
 e
t 
al
. [
25
], 
Ca
na
da
Lo
gi
st
ic
 re
gr
es
si
on
20
07
/0
8-
20
10
/1
1
To
p-
5%
A
ll 
O
nt
ar
io
 re
si
de
nt
s 
se
rv
ic
ed
 b
y 
th
e 
O
nt
ar
-
io
 h
ea
lt
hc
ar
e 
sy
st
em
 d
ur
in
g 
th
e 
fi
sc
al
 y
ea
r 
20
09
/1
0.
 P
at
ie
nt
s 
un
de
r fi
ve
, o
r w
ho
 d
ie
d 
du
ri
ng
 
th
is
 y
ea
r w
er
e 
ex
cl
ud
ed
To
ta
l h
ea
lt
h 
sy
st
em
 c
os
ts
 (i
nc
lu
di
ng
 L
TC
), 
ex
cl
ud
in
g 
ou
tp
at
ie
nt
 o
nc
ol
og
y,
 o
ut
pa
-
ti
en
t 
di
al
ys
is
, a
nd
 o
ut
pa
ti
en
t 
cl
in
ic
.  
Co
he
n 
et
 a
l. 
[2
6]
, 
U
ni
te
d 
St
at
es
Lo
gi
st
ic
 re
gr
es
si
on
19
96
-2
00
2
To
p-
10
%
,
N
at
io
na
lly
 re
pr
es
en
ta
ti
ve
 s
am
pl
e 
of
 t
he
 M
ed
ic
al
 
Ex
pe
nd
it
ur
e 
Pa
ne
l S
ur
ve
y
A
ll 
di
re
ct
 p
ay
m
en
ts
 t
o 
pr
ov
id
er
s 
by
 
in
di
vi
du
al
s,
 p
ri
va
te
 in
su
ra
nc
e,
 M
ed
ic
ar
e,
 
M
ed
ic
ai
d,
 a
nd
 o
th
er
 p
ay
m
en
t 
so
ur
ce
s 
fo
r:
 
in
pa
ti
en
t 
an
d 
ou
tp
at
ie
nt
 c
ar
e;
 e
m
er
ge
n-
cy
 ro
om
 s
er
vi
ce
s,
 o
ffi
ce
-b
as
ed
 m
ed
ic
al
 
pr
ov
id
er
 s
er
vi
ce
s,
 h
om
e 
he
al
th
ca
re
, p
re
-
sc
ri
pt
io
n 
m
ed
ic
in
es
, a
nd
 o
th
er
 m
ed
ic
al
 
se
rv
ic
es
 a
nd
 e
qu
ip
m
en
t.
 
Co
ug
hl
in
 e
t 
al
. [
27
], 
U
ni
te
d 
St
at
es
D
es
cr
ip
ti
ve
20
06
-2
00
7 
(1
 y
ea
r)
To
p-
10
%
M
ed
ic
ar
e 
be
ne
fi
ci
ar
ie
s 
an
d 
du
al
 e
lig
ib
le
s
Sp
en
di
ng
 p
ai
d 
fo
r b
y 
th
e 
pu
bl
ic
 p
ro
gr
am
s 
Co
ug
hl
in
 a
nd
 L
on
g 
[2
8]
, U
ni
te
d 
St
at
es
 
D
es
cr
ip
ti
ve
20
02
-2
00
4
Va
ri
ou
s.
 T
op
-1
%
, 
To
p-
5%
, T
op
-1
0%
, 
To
p-
25
%
, T
op
-5
0%
20
02
 n
at
io
na
l M
ed
ic
ai
d 
po
pu
la
ti
on
 (l
iv
in
g 
in
 
in
st
it
ut
io
ns
 a
nd
 c
om
m
un
it
y)
. 
Ex
cl
ud
in
g:
 w
ho
 re
ce
iv
ed
 o
nl
y 
SC
H
IP
 c
ov
er
ag
e 
or
 
ne
ve
r f
ul
l b
en
efi
ts
. T
op
-0
.1%
 o
f s
pe
nd
er
s.
M
ed
ic
ai
d 
Cr
aw
fo
rd
 e
t 
al
. [
29
], 
U
ni
te
d 
St
at
es
N
eu
ra
l n
et
w
or
k 
m
od
el
in
g
19
99
-2
00
1
To
p-
15
%
M
em
be
rs
 o
f a
 h
ea
lt
h 
pl
an
, w
he
re
 A
m
er
ic
an
 
H
ea
lt
hw
ay
s,
 in
c.
 p
ro
vi
de
d 
di
se
as
e 
m
an
ag
em
en
t 
se
rv
ic
es
. O
nl
y 
m
em
be
rs
 w
it
h 
24
 m
on
th
s 
co
nt
in
-
uo
us
 e
nr
ol
lm
en
t 
w
er
e 
in
cl
ud
ed
. 
H
ea
lt
h 
pl
an
 c
os
ts
.
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D
eL
ia
[3
0]
, U
ni
te
d 
St
at
es
D
es
cr
ip
ti
ve
, m
ul
ti
no
-
m
ia
l r
eg
re
ss
io
n
20
11
-2
01
4
To
p-
1%
, t
op
-2
-1
0%
,
Pe
rs
is
te
nt
ly
 e
xt
re
m
e:
 4
 
ye
ar
s 
 t
op
-1
%
Pe
rs
is
te
nt
ly
 h
ig
h:
 4
 y
ea
rs
 in
 
to
p-
10
%
M
ed
ic
ai
d/
CH
IP
 b
en
efi
ci
ar
ie
s 
in
 N
ew
 Je
rs
ey
, 
ne
w
ly
 c
ov
er
ed
 in
di
vi
du
al
s 
un
de
r t
he
 A
C
A
 (2
01
4)
 
w
er
e 
ex
cl
ud
ed
, M
ed
ic
ai
d/
M
ed
ic
ar
e 
du
al
 e
lig
ib
le
s 
w
er
e 
ex
cl
ud
ed
 
M
ed
ic
ai
d 
FF
S 
cl
ai
m
s 
an
d 
m
an
ag
ed
 c
ar
e 
en
co
un
te
rs
 a
nd
 C
H
IP
de
 O
liv
ei
ra
 e
t 
al
. [
31
], 
Ca
na
da
D
es
cr
ip
ti
ve
20
12
To
p-
10
%
, t
op
-5
%
, t
op
-1
%
. 
M
en
ta
l h
ea
lt
h 
H
C 
pa
ti
en
ts
: 
m
en
ta
l h
ea
lt
h 
>5
0%
 o
f 
to
ta
l c
os
ts
. 
A
ll 
ad
ul
t 
pa
ti
en
ts
 (1
8 
an
d 
ol
de
r)
 w
ho
 h
ad
 a
t 
le
as
t 
1 e
nc
ou
nt
er
 w
it
h 
th
e 
O
nt
ar
io
 h
ea
lt
h 
ca
re
 s
ys
te
m
 
in
 2
01
2.
Ex
cl
ud
in
g:
 a
ll 
in
di
vi
du
al
s 
w
ho
 d
id
 n
ot
 h
av
e 
a 
va
lid
 O
nt
ar
io
 H
ea
lt
h 
In
su
ra
nc
e 
Pl
an
 n
um
be
r.
M
os
t 
pu
bl
ic
ly
 fu
nd
ed
 h
ea
lt
hc
ar
e 
se
rv
ic
es
. 
Fi
gu
er
oa
 e
t 
al
. [
32
], 
U
ni
te
d 
St
at
es
D
es
cr
ip
ti
ve
, c
hi
-
sq
ua
re
20
12
To
p-
10
%
A
du
lt
s 
18
-6
4 
ye
ar
 w
it
ho
ut
 F
FS
 M
ed
ic
ar
e 
co
ve
ra
ge
 
or
 M
ed
ic
ar
e 
A
dv
an
ta
ge
 c
ov
er
ag
e.
 
M
as
sa
ch
us
et
ts
 A
ll-
Pa
ye
r C
la
im
s 
da
ta
ba
se
; 
ne
ar
ly
 a
 u
ni
ve
rs
al
 a
cc
ou
nt
 o
f a
ll 
he
al
th
 
ca
re
 d
el
iv
er
ed
 in
 t
he
 s
ta
te
 w
it
h 
th
e 
ex
ce
p-
ti
on
 o
f M
ed
ic
ar
e 
FF
S.
  
Fi
gu
er
oa
 e
t 
al
. [
33
], 
U
ni
te
d 
St
at
es
D
es
cr
ip
ti
ve
20
12
To
p-
10
%
A
ll 
M
ed
ic
ar
e 
pa
ti
en
ts
, e
xc
lu
di
ng
 t
ho
se
 w
it
h 
M
ed
ic
ar
e 
A
dv
an
ta
ge
 c
ov
er
ag
e,
 w
ho
 w
er
e 
no
t 
co
nt
in
ua
lly
 e
nr
ol
le
d 
in
 p
ar
t 
A
 a
nd
 B
St
an
da
rd
iz
ed
 M
ed
ic
ar
e 
co
st
s.
 
Fi
tz
pa
tr
ic
k 
et
 a
l. 
[3
4]
, 
Ca
na
da
D
es
cr
ip
ti
ve
, l
og
is
ti
c 
re
gr
es
si
on
20
03
/5
 a
nd
 
fi
ve
 y
ea
rs
 
fo
llo
w
 u
p 
To
p-
5%
Pa
rt
ic
ip
an
ts
 fr
om
 t
w
o 
cy
cl
es
 o
f (
CC
H
S)
 s
ur
ve
ys
, 
re
pr
es
en
ta
ti
ve
 o
f t
he
 p
op
ul
at
io
n 
≥ 
12
 y
ea
rs
 
an
d 
liv
in
g 
in
 p
ri
va
te
 d
w
el
lin
gs
. ≥
 18
 y
ea
rs
. E
x:
 
ba
se
lin
e 
hi
gh
-c
os
t 
O
nt
ar
io
 h
ea
lt
h 
in
su
ra
nc
e 
pl
an
Fl
ei
sh
m
an
n 
[3
5]
, 
U
ni
te
d 
St
at
es
Lo
gi
st
ic
 re
gr
es
si
on
19
96
-2
00
3
To
p-
10
%
, t
op
-5
%
N
at
io
na
lly
 re
pr
es
en
ta
ti
ve
 s
am
pl
e 
of
 t
he
 M
ed
ic
al
 
Ex
pe
nd
it
ur
e 
Pa
ne
l S
ur
ve
y
A
ll 
di
re
ct
 p
ay
m
en
ts
 t
o 
pr
ov
id
er
s 
by
 
in
di
vi
du
al
s,
 p
ri
va
te
 in
su
ra
nc
e,
 M
ed
ic
ar
e,
 
M
ed
ic
ai
d,
 a
nd
 o
th
er
 p
ay
m
en
t 
so
ur
ce
s 
fo
r:
 
in
pa
ti
en
t 
an
d 
ou
tp
at
ie
nt
 c
ar
e;
 e
m
er
ge
n-
cy
 ro
om
 s
er
vi
ce
s,
 o
ffi
ce
-b
as
ed
 m
ed
ic
al
 
pr
ov
id
er
 s
er
vi
ce
s,
 h
om
e 
he
al
th
ca
re
, p
re
-
sc
ri
pt
io
n 
m
ed
ic
in
es
, a
nd
 o
th
er
 m
ed
ic
al
 
se
rv
ic
es
 a
nd
 e
qu
ip
m
en
t.
G
an
gu
li 
et
 a
l. 
[3
6]
, 
U
ni
te
d 
St
at
es
D
es
cr
ip
ti
ve
, r
et
ro
-
sp
ec
ti
ve
 c
ha
rt
 re
vi
ew
, 
in
te
rv
ie
w
 a
na
ly
si
s
20
05
-2
01
1
Fi
ve
 a
rc
he
ty
pa
l p
at
ie
nt
s 
am
on
g 
th
e 
50
 c
os
tl
ie
st
 /
 
15
00
 h
ig
he
st
 c
os
t 
pa
ti
en
ts
Pa
ti
en
ts
 s
el
ec
te
d 
by
 c
os
ts
 a
nd
 a
 p
ro
sp
ec
ti
ve
 ri
sk
 
sc
or
e 
to
 p
ar
ti
ci
pa
te
 in
 a
 C
en
te
rs
 fo
r M
ed
ic
ar
e 
an
d 
M
ed
ic
ai
d 
ca
re
 m
an
ag
em
en
t 
pr
oj
ec
t,
 >
18
 
ye
ar
s 
an
d 
ha
d 
su
ffi
ci
en
t 
co
gn
it
iv
e 
ca
pa
ci
ty
 t
o 
pa
rt
ic
ip
at
e 
in
 a
n 
in
te
rv
ie
w
, o
r i
f d
ec
ea
se
d 
ha
d 
fa
m
ily
 m
em
be
rs
 w
ho
 w
er
e 
ab
le
 t
o 
gi
ve
 s
uf
fi
-
ci
en
t 
in
fo
rm
at
io
n.
 
To
ta
l M
ed
ic
ar
e 
pa
ym
en
ts
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A
ut
ho
r(
s)
, 
co
un
tr
y
M
et
ho
do
lo
gi
ca
l 
ap
pr
oa
ch
St
ud
y 
pe
ri
od
D
efi
ni
ti
on
 h
ig
h-
co
st
St
ud
y 
po
pu
la
ti
on
: i
n-
 a
nd
 e
xc
lu
si
on
 c
ri
te
ri
a
Co
st
 d
at
a 
G
ra
ve
n 
et
 a
l. 
[3
7]
, 
U
ni
te
d 
St
at
es
D
es
cr
ip
ti
ve
20
11
-2
01
3
To
p-
10
%
, 
Ep
is
od
ic
al
ly
 h
ig
h-
co
st
, 
pe
rs
is
te
nt
ly
 h
ig
h-
co
st
A
du
lt
s 
ag
es
 19
 a
nd
 o
ve
r, 
en
ro
lle
d 
in
 O
re
go
n 
M
ed
ic
ai
d,
 c
om
m
er
ci
al
 o
r M
ed
ic
ar
e 
A
dv
an
ta
ge
 
pr
og
ra
m
s.
 O
nl
y 
th
os
e 
w
it
h 
co
nt
in
uo
us
 e
nr
ol
l-
m
en
t 
in
 2
01
1 a
nd
 2
01
2 
w
er
e 
in
cl
ud
ed
. E
x:
 d
ua
l 
el
ig
ib
le
s,
 a
nd
 in
di
vi
du
al
s 
w
ho
 h
ad
 ‘c
oo
rd
in
at
io
n 
of
 b
en
efi
t’
-c
la
im
s 
or
 w
it
h 
ne
ga
ti
ve
 t
ot
al
 s
pe
nd
-
in
g 
in
 a
ny
 o
f t
he
 q
ua
rt
er
s.
To
ta
l M
ed
ic
ai
d,
 c
om
m
er
ci
al
 o
r M
ed
i-
ca
re
 A
dv
an
ta
ge
 p
ay
m
en
ts
  (
ac
ut
e 
ca
re
 
ex
pe
nd
it
ur
es
), 
ex
cl
ud
in
g 
sp
en
di
ng
 o
n 
pr
es
cr
ip
ti
on
 d
ru
gs
G
ui
lc
he
r e
t 
al
. [
38
], 
Ca
na
da
D
es
cr
ip
ti
ve
1 A
pr
il 
20
10
 
– 
31
 M
ar
ch
 
20
11
To
p-
5%
A
ll 
pe
rs
on
s 
el
ig
ib
le
 fo
r p
ro
vi
nc
ia
l h
ea
lt
h 
in
su
r-
an
ce
 re
si
di
ng
 in
 t
he
 c
om
m
un
it
y,
 w
ho
 h
ad
 a
t 
le
as
t 
on
e 
in
te
ra
ct
io
n 
w
it
h 
th
e 
sy
st
em
 in
 t
he
 la
st
 
fi
ve
 y
ea
rs
A
ll 
pu
bl
ic
ly
 fu
nd
ed
 h
ea
lt
hc
ar
e 
in
 a
 u
ni
ve
r-
sa
l p
ub
lic
 h
ea
lt
hc
ar
e 
sy
st
em
G
uo
 e
t 
al
. [
39
], 
U
ni
te
d 
St
at
es
D
es
cr
ip
ti
ve
, l
og
is
ti
c 
re
gr
es
si
on
19
99
-2
00
0
To
p-
10
%
 o
f a
ve
ra
ge
 
m
on
th
ly
 e
xp
en
se
s
M
ed
ic
ai
d,
 F
FS
 re
ci
pi
en
ts
 y
ou
ng
er
 t
ha
n 
65
. 
Ex
cl
ud
in
g:
 n
ur
si
ng
 h
om
e 
re
ci
pi
en
ts
M
ed
ic
ai
d 
co
st
s
H
ar
tm
an
n 
et
 a
l. 
[4
0]
, 
G
er
m
an
y
Lo
gi
st
ic
 re
gr
es
si
on
20
10
-2
01
1
To
p-
10
%
En
ro
lle
es
 18
 y
ea
rs
 a
nd
 o
ld
er
 o
f A
O
K 
Lo
w
er
 
Sa
xo
ny
, G
er
m
an
y’
s 
10
th
-l
ar
ge
st
 s
ta
tu
to
ry
 h
ea
lt
h 
in
su
re
r
In
- a
nd
 o
ut
pa
ti
en
t 
ca
re
, s
ic
kn
es
s 
be
ne
fi
ts
, 
re
ha
bi
lit
at
io
n,
 h
om
e 
nu
rs
in
g,
 a
m
bu
la
-
to
ry
 d
ru
g 
su
pp
ly
, p
re
sc
ri
be
d 
th
er
ap
eu
ti
c 
ap
pl
ia
nc
es
 a
nd
 re
m
ed
ie
s.
 
H
en
se
l e
t 
al
. [
41
], 
Ca
na
da
D
es
cr
ip
ti
ve
, l
og
is
ti
c 
re
gr
es
si
on
 
1 A
pr
il 
20
11
 
– 
31
 M
ar
ch
 
20
12
To
p-
1%
, t
op
-2
-5
%
, t
op
-6
-
50
%
, b
ot
to
m
-5
0%
, a
nd
 
ze
ro
-c
os
t 
re
fe
re
nt
 g
ro
up
A
ll 
O
nt
ar
io
 re
si
de
nt
s,
 w
it
h 
a 
va
lid
 O
nt
ar
io
 h
ea
lt
h 
ca
re
, 1
8 
ye
ar
s 
of
 a
ge
 o
r o
ld
er
, a
nd
 m
ed
ic
al
 c
ar
e 
co
st
s 
gr
ea
te
r t
ha
n 
ze
ro
O
nt
ar
io
 h
ea
lt
h 
in
su
ra
nc
e 
pl
an
, f
or
 a
ll 
ho
s-
pi
ta
l a
nd
 h
om
e 
ca
re
 s
er
vi
ce
s,
 in
cl
ud
in
g 
ph
ys
ic
ia
n 
ca
re
, c
os
ts
 re
la
te
d 
to
 o
ut
pa
ti
en
t 
ph
ys
ic
ia
n 
se
rv
ic
es
 w
er
e 
no
t 
in
cl
ud
ed
H
ir
th
 e
t 
al
. [
42
], 
U
ni
te
d 
St
at
es
D
es
cr
ip
ti
ve
, l
og
is
ti
c 
re
gr
es
si
on
20
03
-2
00
8
H
ig
h:
 t
op
-1
0%
M
od
er
at
e:
 t
op
-1
0%
-3
0%
Lo
w
: b
ot
to
m
-7
0%
U
su
al
ly
 lo
w
 
Lo
w
/m
od
er
at
e 
So
m
et
im
es
 h
ig
h 
O
ft
en
 h
ig
h 
U
su
al
ly
 h
ig
h 
U
nd
er
-6
5 
po
pu
la
ti
on
 (T
ru
ve
n 
H
ea
lt
h 
M
ar
ke
tS
ca
n 
da
ta
ba
se
); 
en
ro
lle
es
 a
nd
 d
ep
en
de
nt
s 
of
 m
or
e 
th
an
 10
0,
 m
ai
nl
y 
se
lf
-i
ns
ur
ed
, m
ed
iu
m
 a
nd
 la
rg
e 
em
pl
oy
er
s
O
nl
y 
pe
op
le
 e
nr
ol
le
d 
co
nt
in
uo
us
ly
 a
re
 in
cl
ud
ed
.
A
tt
ri
ti
on
 (a
 m
in
or
it
y 
w
as
 e
nr
ol
le
d 
ea
ch
 y
ea
r)
 d
ue
 
to
 s
ev
er
al
 re
as
on
s:
 d
ea
th
, r
et
ir
em
en
t,
 c
hi
ld
re
n 
ag
in
g 
ou
t 
of
 d
ep
en
de
nt
 s
ta
tu
s 
et
c.
.
D
at
a 
fr
om
 a
ll 
ca
rv
e-
ou
ts
 (e
.g
., 
pr
es
cr
ip
-
ti
on
 d
ru
g,
 m
en
ta
l h
ea
lt
h)
, i
nc
lu
di
ng
 
cl
ai
m
s 
fo
r w
hi
ch
 t
he
 d
ed
uc
ti
bl
e 
is
 im
-
po
se
d.
 A
ll 
sp
en
di
ng
 w
as
 a
dj
us
te
d 
to
 2
00
8 
do
lla
rs
 u
si
ng
 t
he
 m
ed
ic
al
 c
os
t 
Co
ns
um
er
 
Pr
ic
e 
In
de
x.
 
Ex
cl
ud
in
g:
 O
ut
-o
f-
pl
an
 s
pe
nd
in
g 
(e
.g
., 
O
TC
 d
ru
gs
, t
ra
ve
l c
os
ts
).
H
un
te
r e
t 
al
. [
43
], 
U
ni
te
d 
St
at
es
D
es
cr
ip
ti
ve
, l
in
ea
r 
re
gr
es
si
on
Fi
sc
al
 y
ea
r 
20
10
 
To
p-
5%
Co
ho
rt
 fr
om
 V
et
er
an
s 
A
ff
ai
rs
 a
dm
in
is
tr
at
iv
e 
re
co
rd
s,
 w
ho
 w
er
e 
el
ig
ib
le
 fo
r a
nd
 re
ce
iv
ed
 c
ar
e 
in
 s
tu
dy
 p
er
io
d.
 E
x:
 in
di
vi
du
al
s 
w
it
h 
 s
ch
iz
op
hr
e-
ni
a,
 b
ip
ol
ar
 d
ep
re
ss
io
n,
 o
th
er
 p
sy
ch
os
is
, a
lc
oh
ol
 
de
pe
nd
en
ce
 a
nd
 a
bu
se
, d
ru
g 
de
pe
nd
en
ce
 a
nd
 
ab
us
e,
 P
TS
D
, a
nd
/o
r d
ep
re
ss
io
n.
In
pa
ti
en
t,
 o
ut
pa
ti
en
t,
 p
ha
rm
ac
y,
 a
nd
 
no
n-
VA
 c
on
tr
ac
t 
ca
re
. 
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H
w
an
g 
et
 a
l. 
[4
4]
, 
U
ni
te
d 
St
at
es
D
es
cr
ip
ti
ve
, l
og
is
ti
c 
re
gr
es
si
on
20
08
-2
01
1
To
p-
10
%
Em
pl
oy
ee
s 
fr
om
 a
 la
rg
e 
em
pl
oy
er
 in
 P
en
ns
yl
ve
-
ni
a 
an
d 
th
e 
em
pl
oy
ee
s’
 d
ep
en
de
nt
s.
 O
nl
y 
th
os
e 
co
nt
in
uo
us
ly
 e
nr
ol
le
d.
 
A
m
ou
nt
 p
ai
d 
by
 t
he
 in
su
re
r a
nd
 t
he
 
am
ou
nt
 o
f c
os
t 
sh
ar
in
g 
pa
id
 b
y 
in
di
vi
d-
ua
ls
.
Iz
ad
 S
he
na
s 
[4
5]
, 
U
ni
te
d 
St
at
es
D
at
a 
m
in
in
g 
te
ch
-
ni
qu
es
 /
 p
re
di
ct
iv
e 
m
od
el
in
g
20
06
-2
00
8
To
p-
5%
, t
op
-1
0%
, t
op
-2
0%
N
at
io
na
lly
 re
pr
es
en
ta
ti
ve
 s
am
pl
e 
of
 t
he
 M
ed
ic
al
 
Ex
pe
nd
it
ur
e 
Pa
ne
l S
ur
ve
y,
 h
ou
se
ho
ld
 in
di
vi
du
-
al
s 
≥ 
17
 y
ea
rs
 (r
ed
un
da
nt
 re
co
rd
s,
 o
r w
it
h 
ze
ro
 
pe
rs
on
al
-l
ev
el
 w
ei
gh
ts
 w
er
e 
re
m
ov
ed
). 
A
ll 
di
re
ct
 p
ay
m
en
ts
 t
o 
pr
ov
id
er
s 
by
 
in
di
vi
du
al
s,
 p
ri
va
te
 in
su
ra
nc
e,
 M
ed
ic
ar
e,
 
M
ed
ic
ai
d,
 a
nd
 o
th
er
 p
ay
m
en
t 
so
ur
ce
s 
fo
r:
 
in
pa
ti
en
t 
an
d 
ou
tp
at
ie
nt
 c
ar
e;
 e
m
er
ge
n-
cy
 ro
om
 s
er
vi
ce
s,
 o
ffi
ce
-b
as
ed
 m
ed
ic
al
 
pr
ov
id
er
 s
er
vi
ce
s,
 h
om
e 
he
al
th
ca
re
, p
re
-
sc
ri
pt
io
n 
m
ed
ic
in
es
, a
nd
 o
th
er
 m
ed
ic
al
 
se
rv
ic
es
 a
nd
 e
qu
ip
m
en
t.
Jo
yn
t 
et
 a
l. 
[4
6]
, 
U
ni
te
d 
St
at
es
D
es
cr
ip
ti
ve
20
11
 a
nd
  
20
12
 
To
p-
10
%
A
ll 
M
ed
ic
ar
e 
pa
ti
en
ts
, e
xc
lu
di
ng
 t
ho
se
 w
it
h 
M
ed
ic
ar
e 
A
dv
an
ta
ge
 c
ov
er
ag
e,
 w
ho
 w
er
e 
no
t 
co
nt
in
ua
lly
 e
nr
ol
le
d 
in
 p
ar
t 
A
 a
nd
 B
, o
r w
ho
 d
ie
d 
du
ri
ng
 t
he
 s
tu
dy
 p
er
io
d
St
an
da
rd
iz
ed
 M
ed
ic
ar
e 
co
st
s.
Jo
yn
t 
et
 a
l. 
[4
7]
, 
U
ni
te
d 
St
at
es
D
es
cr
ip
ti
ve
, l
in
ea
r 
re
gr
es
si
on
 
20
09
-2
01
0
To
p-
10
%
M
ed
ic
ar
e 
> 
65
 p
op
ul
at
io
n.
Ex
: d
ec
ed
en
ts
, a
ny
 M
ed
ic
ar
e 
ad
va
nt
ag
e 
en
ro
ll-
m
en
t,
 n
ot
 c
on
ti
nu
ou
sl
y 
en
ro
lle
d.
In
- 
an
d 
ou
tp
at
ie
nt
 s
er
vi
ce
s.
Kr
au
se
 e
t 
al
. [
48
], 
U
ni
te
d 
St
at
es
Lo
gi
st
ic
 re
gr
es
si
on
20
09
-2
01
1
To
p-
5%
, t
op
-1
%
, >
$1
00
,0
00
En
ro
lle
es
 o
f B
lu
e 
Cr
os
s 
Bl
ue
 S
hi
el
d 
of
 T
ex
as
, o
nl
y 
m
em
be
rs
 18
-6
3,
 w
it
h 
a 
zi
p 
co
de
 in
 T
ex
as
 a
nd
 
co
nt
in
uo
us
 e
nr
ol
lm
en
t 
in
 2
00
9 
w
er
e 
in
cl
ud
ed
.  
To
ta
l c
la
im
s 
ex
pe
ns
e,
 in
cl
ud
in
g 
ex
pe
nd
i-
tu
re
s 
fo
r h
os
pi
ta
l c
ar
e,
 o
ut
pa
ti
en
t 
fa
ci
lit
y 
se
rv
ic
es
, a
nd
 p
ro
fe
ss
io
na
l s
er
vi
ce
s.
 
Ku
 e
t 
al
. [
49
], 
Ta
iw
an
D
es
cr
ip
ti
ve
, g
en
er
-
al
iz
ed
 e
st
im
at
in
g 
eq
ua
ti
on
s
20
05
-2
00
9
To
p-
10
%
, t
op
-1
1-
25
%
Su
rv
ey
 re
sp
on
de
nt
s 
65
 y
ea
rs
 o
f a
ge
 a
nd
 o
ld
er
N
at
io
na
l h
ea
lt
h 
in
su
ra
nc
e 
La
uf
fe
nb
ur
ge
r e
t 
al
. 
[5
0]
, U
ni
te
d 
St
at
es
D
es
cr
ip
ti
ve
, g
ro
up
-
ba
se
d 
tr
aj
ec
to
ry
 
m
od
el
in
g
20
09
-2
01
1
To
p-
5%
Pa
ti
en
ts
 ≥
18
 y
ea
rs
, w
it
h 
co
nt
in
uo
us
 e
lig
ib
ili
ty
 
fo
r t
he
 e
nt
ir
e 
ca
le
nd
ar
 y
ea
r, 
w
it
h 
≥1
 c
al
en
da
r 
ye
ar
 b
ef
or
e 
th
ei
r e
nt
ry
 y
ea
r a
nd
 w
it
h 
≥1
 m
ed
ic
al
 
an
d 
ph
ar
m
ac
y 
cl
ai
m
 in
 b
ot
h 
th
e 
ba
se
lin
e 
an
d 
en
tr
y 
ye
ar
. 
M
ed
ic
al
 a
nd
 p
re
sc
ri
pt
io
n 
da
ta
 o
f A
et
na
, a
 
la
rg
e 
U
S 
na
ti
on
w
id
e 
in
su
re
r
Le
e 
et
 a
l.,
 [5
1]
 U
ni
te
d 
St
at
es
D
es
cr
ip
ti
ve
, c
lu
st
er
 
an
al
ys
is
20
12
To
p-
10
%
M
ed
ic
ar
e 
pa
ti
en
ts
 h
os
pi
ta
liz
ed
 e
xc
lu
si
ve
ly
 a
t 
Cl
ev
el
an
d 
Cl
in
ic
 H
ea
lt
h 
Sy
st
em
 a
nd
 re
ce
iv
ed
 
at
 le
as
t 
90
%
 o
f t
he
ir
 p
ri
m
ar
y 
ca
re
 s
er
vi
ce
s 
at
 a
 
CC
H
S 
fa
ci
lit
y
CC
H
S 
fa
ci
lit
y 
co
st
s,
 p
os
t-
ac
ut
e 
ca
re
 
se
rv
ic
es
 w
er
e 
on
ly
 in
cl
ud
ed
 fo
r t
ho
se
 
pa
ti
en
ts
 w
ho
 w
er
e 
ad
m
it
te
d 
to
 a
 C
CH
S 
po
st
-a
cu
te
 c
ar
e 
fa
ci
lit
y.
 
Le
in
in
ge
r e
t 
al
. [
52
], 
U
ni
te
d 
St
at
es
D
es
cr
ip
ti
ve
, l
og
is
ti
c 
re
gr
es
si
on
20
09
-2
01
0 
(o
ne
 y
ea
r)
To
p-
10
%
N
ew
 e
nr
ol
le
es
 fo
r M
ed
ic
ai
d 
w
ho
 c
om
pl
et
ed
 a
 
se
lf
-r
ep
or
te
d 
he
al
th
 n
ee
ds
 a
ss
es
sm
en
t
M
ed
ic
ai
d 
co
st
s.
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A
ut
ho
r(
s)
, 
co
un
tr
y
M
et
ho
do
lo
gi
ca
l 
ap
pr
oa
ch
St
ud
y 
pe
ri
od
D
efi
ni
ti
on
 h
ig
h-
co
st
St
ud
y 
po
pu
la
ti
on
: i
n-
 a
nd
 e
xc
lu
si
on
 c
ri
te
ri
a
Co
st
 d
at
a 
Li
eb
er
m
an
 e
t 
al
. [
53
], 
U
ni
te
d 
St
at
es
D
es
cr
ip
ti
ve
19
95
-1
99
9
To
p-
5%
 
M
ed
ic
ar
e 
FF
S 
be
ne
fi
ci
ar
ie
s
M
ed
ic
ar
e 
sp
en
di
ng
M
ee
na
n 
et
 a
l. 
[5
4]
, 
U
ni
te
d 
St
at
es
Ri
sk
 m
od
el
in
g.
 
19
95
-1
99
6
To
p-
0.
5%
, t
op
-1
%
En
ro
lle
es
 o
f s
ix
 H
M
O
s,
 e
lig
ib
le
 fo
r s
om
e 
pe
ri
od
 
in
 19
95
 a
nd
 19
96
, a
nd
 w
ho
 h
ad
 a
n 
ou
tp
at
ie
nt
 
ph
ar
m
ac
y 
be
ne
fi
t.
 M
ed
ic
ar
e 
Co
st
 e
nr
ol
le
es
 w
er
e 
ex
cl
ud
ed
. 
To
ta
l c
la
im
s,
 in
cl
ud
in
g 
in
pa
ti
en
t,
 o
ut
-
pa
ti
en
t,
 ra
di
ol
og
y,
 p
ha
rm
ac
y,
 d
ur
ab
le
 
m
ed
ic
al
 e
qu
ip
m
en
t,
 lo
ng
-t
er
m
 c
ar
e,
 
la
bo
ra
to
ry
. 
M
on
he
it
 [5
5]
, U
ni
te
d 
St
at
es
D
es
cr
ip
ti
ve
, l
og
is
ti
c 
re
gr
es
si
on
19
96
-1
99
7
Va
ri
ou
s.
 T
op
-1
%
, 
To
p-
2%
, T
op
-5
%
, 
To
p-
10
%
, T
op
-2
0%
, T
op
-
30
%
, T
op
-5
0%
.
Re
pr
es
en
ta
ti
on
 o
f n
on
-i
ns
ti
tu
ti
on
al
iz
ed
 c
iv
ili
an
 
U
S 
po
pu
la
ti
on
 (s
ur
ve
y 
re
sp
on
de
nt
s)
To
ta
l p
ay
m
en
ts
 (i
nc
lu
di
ng
 O
O
P,
 u
nc
ov
-
er
ed
 s
er
vi
ce
s,
 t
hi
rd
 p
ar
ty
 p
ay
m
en
ts
).
Po
w
er
s 
an
d 
Ch
a-
gu
tu
ru
[9
], 
U
ni
te
d 
St
at
es
D
es
cr
ip
ti
ve
20
14
To
p-
1%
Pa
ti
en
ts
 o
f P
ar
tn
er
s 
H
ea
lt
hC
ar
e 
in
te
gr
at
ed
 
de
liv
er
y 
Sy
st
em
M
ed
ic
ar
e,
 M
ed
ic
ai
d,
 c
om
m
er
ci
al
 a
re
 
co
m
pa
re
d
Pr
it
ch
ar
d 
et
 a
l. 
[5
6]
, 
U
ni
te
d 
St
at
es
D
es
cr
ip
ti
ve
20
11
To
p-
5%
M
an
ag
ed
 c
ar
e 
po
pu
la
ti
on
, o
f a
ll 
ag
es
, w
it
h 
at
 
le
as
t 
18
0 
da
ys
 c
on
ti
nu
ou
s 
en
ro
llm
en
t 
pr
io
r 1
 
Ja
nu
ar
y 
20
11
, p
at
ie
nt
s 
w
it
h 
ga
ps
 in
 e
nr
ol
lm
en
t 
gr
ea
te
r t
ha
n 
30
 d
ay
s 
w
er
e 
ex
cl
ud
ed
 (s
o 
no
 
un
in
su
re
d 
or
 p
at
ie
nt
s 
en
ro
lle
d 
in
 t
ra
di
ti
on
al
 F
FS
 
M
ed
ic
ar
e 
or
 M
ed
ic
ai
d 
pr
og
ra
m
s)
M
ed
ic
al
 a
nd
 p
ha
rm
ac
eu
ti
ca
l c
la
im
s 
fo
r 
m
or
e 
th
an
 8
0 
U
S 
he
al
th
 p
la
ns
, t
he
 t
ot
al
 
am
ou
nt
 re
im
bu
rs
ed
 b
y 
th
e 
in
su
re
r p
lu
s 
th
e 
pl
an
 m
em
be
r’
s 
ou
t-
of
-p
oc
ke
t 
sh
ar
e
Ra
is
 e
t 
al
. [
57
], 
Ca
na
da
D
es
cr
ip
ti
ve
20
09
-2
01
0 
(1
 y
ea
r)
To
p-
5%
Co
st
 c
on
su
m
in
g 
us
er
s 
of
 h
os
pi
ta
l a
nd
 h
om
e 
ca
re
 s
er
vi
ce
s 
at
 t
he
 p
ro
vi
nc
ia
l l
ev
el
. 
H
os
pi
ta
l a
nd
 h
om
e 
ca
re
 s
er
vi
ce
s.
Ex
cl
ud
in
g:
 P
ri
m
ar
y 
ca
re
 a
nd
 lo
ng
 t
er
m
 
ca
re
 u
se
.
Re
id
 e
t 
al
. [
58
], 
Ca
na
da
D
es
cr
ip
ti
ve
19
96
-1
99
7 
(1
 y
ea
r)
To
p-
5%
≥1
8 
ye
ar
s 
an
d 
ol
de
r e
nr
ol
le
d 
in
 t
he
 p
ro
vi
nc
e’
s 
un
iv
er
sa
l h
ea
lt
h 
ca
re
 p
la
n 
M
ed
ic
al
 s
er
vi
ce
s 
co
st
s 
in
 a
 u
ni
ve
rs
al
 
he
al
th
 c
ar
e 
pl
an
 (p
hy
si
ci
an
 a
nd
 h
os
pi
ta
l 
se
rv
ic
es
)
Re
sc
ho
vs
ky
 e
t 
al
. 
[5
9]
, U
ni
te
d 
St
at
es
D
es
cr
ip
ti
ve
, l
og
is
ti
c 
re
gr
es
si
on
20
06
, o
r 1
2 
m
on
th
s 
be
-
fo
re
 d
ea
th
 
To
p-
25
%
M
ed
ic
ar
e 
FF
S 
be
ne
fi
ci
ar
ie
s,
 ≥
1 C
TS
 s
ur
ve
y,
 W
it
h 
U
SO
C 
ph
ys
ic
ia
n.
Ex
cl
ud
in
g:
 E
SR
D
 b
en
efi
ci
ar
ie
s.
St
an
da
rd
iz
ed
 t
ot
al
 c
os
ts
 o
f M
ed
ic
ar
e 
pa
rt
 
A
 a
nd
 B
 
Ri
le
y 
[6
0]
, U
ni
te
d 
St
at
es
D
es
cr
ip
ti
ve
19
75
-2
00
4
To
p-
1%
 
To
p-
5%
 
M
ed
ic
ar
e,
 b
en
efi
ci
ar
ie
s 
en
ti
tl
ed
 t
o 
Pa
rt
 A
 a
nd
 B
M
ed
ic
ar
e 
co
st
s
Ro
bs
t 
[6
1]
, U
ni
te
d 
St
at
es
D
es
cr
ip
ti
ve
, l
og
is
ti
c 
re
gr
es
si
on
20
05
-2
01
0
To
p-
1%
 in
 s
om
e 
ye
ar
s,
 o
r i
n 
si
x 
ye
ar
s
M
ed
ic
ai
d 
be
ne
fi
ci
ar
ie
s 
w
it
h 
fe
e-
fo
r-
se
rv
ic
e 
co
ve
ra
ge
 fo
r a
t 
le
as
t 
6 
m
on
th
s 
in
 a
ll 
6 
ye
ar
s
M
ed
ic
ai
d
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Ro
se
lla
 e
t 
al
. [
62
], 
Ca
na
da
D
es
cr
ip
ti
ve
, m
ul
-
ti
no
m
ia
l l
og
is
ti
c 
re
gr
es
si
on
20
03
-2
00
8
To
p-
5%
 
To
p-
1%
, t
op
-2
%
-5
%
, t
op
-
6-
50
%
O
nt
ar
io
 re
si
de
nt
s.
Pa
rt
ic
ip
an
ts
 o
f t
he
 C
CH
 S
ur
ve
y.
Ex
cl
ud
in
g:
 In
st
it
ut
io
na
liz
ed
. F
ul
l-
ti
m
e 
m
em
be
rs
 
of
 t
he
 C
an
ad
ia
n 
fo
rc
es
. P
er
so
ns
 li
vi
ng
 in
 re
m
ot
e 
ar
ea
s/
 a
bo
ri
gi
na
l r
es
er
ve
s.
 A
ge
s 
12
-1
8.
Th
os
e 
co
ve
re
d 
by
 O
nt
ar
io
’s
 U
ni
ve
rs
al
 
H
ea
lt
h 
In
su
ra
nc
e 
Pl
an
 (O
H
IP
).
Ex
cl
ud
in
g:
 S
om
e 
pr
es
cr
ip
ti
on
 d
ru
g 
co
st
s,
 
al
lie
d 
he
al
th
 s
er
vi
ce
s,
 d
en
ta
l c
ar
e,
 e
ye
 
ca
re
, a
ss
is
ti
ve
 d
ev
ic
es
.
Sn
id
er
 e
t 
al
. [
63
], 
U
ni
te
d 
St
at
es
Lo
gi
st
ic
 re
gr
es
si
on
20
04
-2
00
9
To
p-
20
%
Em
pl
oy
ee
s 
fr
om
 la
rg
e 
U
S 
em
pl
oy
er
s,
 fr
om
 t
he
 
Th
om
so
n 
Re
ut
er
s 
M
ar
ke
ts
ca
n 
Co
m
m
er
ci
al
 
Cl
ai
m
s 
an
d 
En
co
un
te
rs
 d
at
ab
as
e 
w
it
h 
bo
th
 B
M
I 
an
d 
cl
ai
m
s 
in
 a
ny
 g
iv
en
 y
ea
r. 
Pr
eg
na
nt
 w
om
en
 
an
d 
un
de
rw
ei
gh
t 
em
pl
oy
ee
s 
w
er
e 
ex
cl
ud
ed
. 
A
ll 
in
pa
ti
en
t,
 o
ut
pa
ti
en
t,
 a
nd
 p
re
sc
ri
pt
io
n 
cl
ai
m
s.
 
Ta
m
an
g 
et
 a
l. 
[6
4]
, 
D
en
m
ar
k
D
es
cr
ip
ti
ve
, p
re
di
c-
ti
on
 m
od
el
in
g
20
04
-2
01
1
To
p-
10
%
En
ti
re
 p
op
ul
at
io
n 
of
 W
es
te
rn
 D
en
m
ar
k,
 w
it
h 
a 
fu
ll 
ye
ar
 o
f a
ct
iv
e 
re
si
de
nc
y 
in
 y
ea
r 1
D
an
is
h 
N
at
io
na
l H
ea
lt
h 
Se
rv
ic
e
W
am
m
es
 e
t 
al
. [
65
], 
N
et
he
rl
an
ds
D
es
cr
ip
ti
ve
20
13
To
p-
1%
, t
op
-2
-5
%
, b
ot
-
to
m
-9
5%
Be
ne
fi
ci
ar
ie
s 
of
 o
ne
 D
ut
ch
 h
ea
lt
h 
in
su
re
r
D
ut
ch
 c
ur
at
iv
e 
he
al
th
 s
ys
te
m
, b
as
ic
 
be
ne
fi
t 
pa
ck
ag
e 
in
cl
ud
in
g 
vo
lu
nt
ar
y 
co
m
pl
em
en
ta
ry
 in
su
ra
nc
e 
be
ne
fi
ts
.
W
od
ch
is
 e
t 
al
. [
66
], 
Ca
na
da
D
es
cr
ip
ti
ve
A
pr
il 
1, 
20
09
 
– 
M
ar
ch
 3
1, 
20
12
 
To
p-
1%
To
p-
5%
To
p-
10
%
To
p-
50
%
Pe
op
le
 w
it
h 
a 
re
co
rd
ed
 a
ge
 o
f l
es
s 
th
an
 10
5 
ye
ar
s 
w
ho
 w
er
e 
al
iv
e 
on
 A
pr
. 1
 in
 a
ny
 o
f t
he
 t
hr
ee
 
st
ud
y 
ye
ar
s 
an
d 
w
ho
 h
ad
 a
 v
al
id
 O
nt
ar
io
 h
ea
lt
h 
ca
re
 a
t 
an
y 
ti
m
e 
be
tw
ee
n 
A
pr
. 1
 2
00
9 
an
d 
M
ar
ch
 
31
 2
01
2.
 
Co
st
s 
re
fe
r t
o 
he
al
th
 c
ar
e 
ex
pe
nd
it
ur
es
 
th
at
 h
av
e 
be
en
 a
llo
ca
te
d 
to
 p
at
ie
nt
 
en
co
un
te
rs
 fo
r h
ea
lt
h 
ca
re
. 
A
ll 
m
ed
ic
al
ly
 n
ec
es
sa
ry
 c
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Predisposing characteristics
Table 2 presents predisposing, enabling and need characteristics associated with high-cost 
patients. Age was related to high-cost patients in several ways. First, high-cost patients 
were generally older, and higher age was associated with high costs. This held for each payer 
type. Second, persistently high-cost patients were generally older than episodic high-cost 
patients, and higher ages were associated with persistently high costs. Third, the magnitude 
of cost concentration, and the threshold for high costs differed between age groups [66]. As 
younger groups are generally healthier, costs are concentrated among fewer individuals. 
Fourth, clinical diagnoses and utilization patterns varied across age groups [21,65,66], and some 
subgroups were related to particular ages, including mental health high-cost patients among 
younger ages [31]. Finally, although age was related to high costs, total population studies 
showed that approximately half of the high-cost populations were younger than 65 [38,65].  
TABLE 2  Predisposing, enabling and need factors for high-cost patients. 
Variables Number of studies
Predisposing factors
Age 32 [15, 17-20, 22, 25, 26, 28-30, 32, 34, 35, 37, 
39-42, 47-50, 52, 55, 56, 58-60, 62, 63, 65]
Gender = male 9 [25, 30, 31, 39, 47, 51, 59, 61, 65]
Gender = female 16 [17, 19, 20, 26, 28, 30, 32, 37, 38, 42, 46, 55, 
58, 62, 63, 65]
Ethnicity = black /African American 4 [18, 47, 59, 60]
Ethnicity = white 5 [20, 28, 34, 61, 62]
Ethnicity = less likely black or Hispanic 3 [28, 55, 61]
Ethnicity = less likely immigrant 1 [34]
Ethnicity = less likely whites 2 [46, 48]
Region 4 [28, 42, 45, 47] 
Urban residence 6 [18, 38, 39, 46, 47, 49]
Rural residence 2 [25, 42]
Living institutionalized 3 [27, 30, 59]
Employment status: early retiree 1  [42]
Job satisfaction 1 [19]
Marital status: divorced/widow/separated/living alone 2 [26, 49]
Dependents less likely to incur high costs 1 [40]
Receive care in many census divisions 1 [59]
Harmful habits 3 [19, 52, 62]
Union membership 1 [42]
Education: less than a high-school degree (neigboorhod level) 1 [48]
Enabling factors 
Health insurance
Medicare: more likely dual eligible 6 [18, 33, 46, 47, 59, 60]
Medicaid: specific eligibility status 4 [20, 28, 39, 61]
Commercial: increased insurance 2 [17, 42]
Total population: insurance status had no effect 1 [55]
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Type of insurance 1 [40]
Income
Positive relation with high costs 3 [26, 42, 55]
Negative relation 5 [25, 31, 34, 41, 58]
No relation 3 [49, 59, 62]
Organizational enabling factors
Primary care physician supply 1 [47]
Specialist physician supply 1 [47]
Hospital bed supply 1 [47]
Medical specialist as usual source of care 1 [59]
Proportion of physicians who are medical specialists 2 [18, 59]
Inadequate time during office visits 1 [59]
Proportion of providers operating for profit 2 [18, 59]
Teaching hospitals 1 [18] 
Low nurse-to-staffing ratios 1 [18]
Low supply of long term care beds 1 [18]
Regular medical doctor or hospital 1 [52]
Regular medical doctor (negative relation) 1 [62]
Need factors
A00–B99 Certain infectious and parasitic diseases 9 [22, 26, 30, 34, 42, 61, 63, 65, 66]
C00–D48 Neoplasms 21 [18, 25, 34, 37, 42-44, 46-51, 56-58, 60, 63, 
65, 66, 68]
D50–D89 Diseases of the blood and blood-forming organs 
and certain disorders involving the immune mechanism
4 [21, 30, 56, 58]
E00–E90 Endocrine, nutritional and metabolic diseases 32 [16-19, 21, 22, 25, 27-30, 32, 34, 37, 39, 40, 
43, 44, 46, 47, 49-53, 58, 60, 63-65, 67, 68]
F00–F99 Mental and behavioral disorders 34 [9, 18-23, 25, 27, 28, 30, 31, 33, 34, 37, 39-
43, 46, 47, 50-53, 57, 58, 60-62, 65, 66, 68]
G00–G99 Diseases of the nervous system 10 [22, 30, 44, 46, 57, 58, 61, 63-65]
H00–H59 Diseases of the eye and adnexa 5 [34, 39, 57, 58, 65]
I00–I99 Diseases of the circulatory system 36 [9, 16-19, 21, 22, 25, 27, 29-31, 33, 34, 37, 
40, 42-44, 46-53, 56-58, 60, 64-68]
J00–J99 Diseases of the respiratory system 30 [9, 16-18, 21, 22, 25, 26, 28, 30, 32, 34, 
37, 39, 40, 43, 44, 46, 47, 49-52, 57, 58, 60, 
64-67]
K00–K93 Diseases of the digestive system 9 [30, 31, 34, 42, 43, 57, 58, 61, 65]
L00–L99 Diseases of the skin and subcutaneous tissue 5 [30, 34, 39, 58, 65]
M00–M99 Diseases of the musculoskeletal system and 
connective tissue
15 [9, 18, 19, 22, 30, 34, 42, 43, 46, 50, 51, 56, 
58, 65, 68]
N00–N99 Diseases of the genitourinary system 22 [9, 18, 21, 25, 30, 32, 34, 37, 40, 42-44, 46, 
47, 49, 51, 56-58, 60, 64, 65]
O00–O99 Pregnancy, childbirth and the puerperium 5 [23, 33, 39, 58, 66]
Q00–Q99 Congenital malformations, deformations and chro-
mosomal abnormalities
1 [64]
R00–R99 Symptoms, signs and abnormal clinical and labora-
tory findings, not elsewhere classified
6 [19, 34, 39, 51, 58, 65]
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S00–T98 Injury, poisoning and certain other consequences of 
external causes
9 [34, 39, 42, 46, 48, 51, 57, 65, 66]
Z00–Z99 Factors influencing health status and contact with 
health services
3 [34, 57, 65]
Chronic illness 22 [15, 17, 18, 30, 32, 33, 35, 37, 39, 40, 43, 46, 
49, 50, 53, 58, 60, 62, 64-66, 68]
Multimorbidity / burden of comorbid illness 31 [9, 15, 16, 19, 23, 24, 29, 30, 33, 35, 37-40, 
42, 43, 45-47, 50, 56, 58-63, 65, 67, 68]
Decedents / survival 14 [15, 21, 30, 38, 39, 46, 53, 55, 58-60, 64-66]
Activities daily living 7 [17, 26, 27, 35, 45, 49, 55]
Health status 9 [17, 26, 35, 44, 45, 49, 53, 55, 62]
Studies showed inconsistent results for gender. Respectively 9 and 16 studies noted males 
and females were overrepresented in high-cost patients. Besides, gender was associated with 
different segments of the high-cost population, including males in top-1% or persistently 
extreme-cost patients, and females in top-2-5% or persistently high-cost patients [30,65], or 
males in mental health high-cost patients [31]. 
 Eleven studies reported the association between ethnicity and high costs. In two Canadian 
total population studies and three US Medicaid studies whites were overrepresented among 
high-cost populations, whereas in four US Medicare studies Blacks were overrepresented.  
 Socioeconomic status is regarded as both a predisposing characteristic and an enabling 
characteristic in Andersen’s model, and we found evidence for both relationships. One 
Canadian study found that high costs were most strongly associated with food insecurity, 
lower personal income, non-homeownership and living in highly deprived or low ethnic 
concentration neighborhoods [34]. Other studies found that social deprivation seemed to 
increase risk for high costs more than material deprivation [25].
 Ganguli et al studied health beliefs among high-cost US Medicare patients: socioeconomic 
status, social network, patient activation, and relationships with and trust in the clinician 
and the health system all increased or decreased costs, depending on the context. Trust was 
particularly important, and modified the interaction between patient activation and costs: 
when patients trusted their physicians, patient activation was associated with lower costs. 
When trust was lacking, patient activation was associated with higher costs [36].  
 Health behaviors, including underweight, obesity, physical inactivity and former smoking 
were significantly related to high costs [62,63]. 
Enabling characteristics
The studies’ abilities to assess the effect of insurance were limited because most study 
populations were determined by insurance. Nevertheless, the studies indicated that 
increased insurance may have indicated specific or additional care needs. For example, six 
US Medicare studies reported that high-cost patients were more likely dually eligible and 
four US Medicaid studies reported that certain eligibility statuses were associated with high 
costs. In addition, increased insurance was associated with high costs because it lowers 
costs. Two US commercial studies mentioned that high-cost patients were more likely to 
have a health maintenance organization plan, a preferred provider organization plan, or 
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comprehensive insurance compared to high-deductible health plans; and insured status was 
associated with less consideration of costs in decision making [36]. 
 Twelve studies addressed the relationship between income and high costs. In three US 
studies higher incomes were associated with high costs, whereas five Canadian studies 
found that lower incomes were associated with (mental health) high costs. However, one 
US, one Taiwanese, and one Canadian study reported that income was not significantly 
related to high costs. Finally, among high-cost US Medicare patients, personal resources and 
education were  associated with increased use of resources (higher SES was linked to higher 
priced care), but also with lower resources use [36]. 
Organizational enabling factors
The number of primary care physicians, specialists and hospital beds were associated with 
higher per capita preventable costs among high-cost US Medicare patients [47]. Reschovsky 
et al found several weak or insignificant relationships between organizational factors 
and high costs within the high-cost population, but found that high-cost US Medicare 
patients more likely had a medical specialist as usual source of care than a primary care 
physician or surgeon [59]. Finally, high-cost US Medicare patients were only modestly 
concentrated in hospitals and markets (they were widely distributed through the system). 
High concentration hospitals (with relatively many high-cost patients) had a 15% higher 
median cost per claim, were more likely for-profit and teaching hospitals, had lower nurse-
to-patient ratios, were more likely to care for the poor, and had higher 30-day readmission 
rates and lower 30-day mortality rates. High concentration hospital referral regions had 
higher annual median costs per beneficiary, a larger supply of specialists but equal supply 
of total physicians, a lower supply of long term care beds, higher hospital care intensity and 
higher end-of-life spending [18]. 
Need characteristics
Medical characteristics of high-cost patients are presented in table 2. We categorized medical 
characteristics to ICD10-chapters. Circulatory diseases, mental and behavioral disorders, 
endocrine, nutritional and metabolic, diseases of the respiratory system, diseases of the 
genitourinary system, neoplasms and diseases of the musculoskeletal system and connective 
tissue were most frequently reported among high-cost patients. The prevalence of chronic 
disease(s) and multimorbidity were also dominant among high-cost patients. For example, 
Bynum et al showed that over 26.4% of high-cost US dual eligibles suffered from five or more 
chronic conditions [21].
 Two studies presented medical characteristics across US payers. Both studies showed 
that high-cost commercial patients had the lowest numbers of comorbidities and that 
high-cost Medicaid patients had the highest prevalence of mental illness [9,37]. We further 
compared the prevalence of diabetes, congestive heart failure, lung disease, and mental 
disorders across the studies. The prevalence of diabetes, congestive heart failure and lung 
disease was relatively low (≈5%-25%) in US commercial and total population studies. In US 
Medicaid, the prevalence of congestive heart failure and lung disease were relatively high 
(≈15%-40%; one study reported a prevalence of diabetes and lung disease > 60% [32]), and 
the prevalence of mental illness was particularly high (≈30%-75%). In US Medicare, the 
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prevalence of diabetes, congestive heart failure and lung disease were highest (≈20%-
55%) and the prevalence of mental illness more modest (≈10%-25%). In total populations, 
approximately 30-40% of high-cost patients were treated for mental illness. Besides, the 
prevalence of each of the chronic diseases in the Dutch study was comparable with the 
prevalence in other total population studies. Finally, persistent high-cost patients had a 
higher number of comorbidities and a higher prevalence of each of the diseases compared to 
episodic high-cost patients. 
 High-cost patients were more likely to die, and those in the process of dying were 
more likely to incur high costs. The mortality differed between payers, much less between 
countries. The mortality among Danish and Dutch high-cost patients was comparable 
with the mortality in other total population studies. In US Medicare studies the mortality 
ranged from 14.2% to 27.4%, compared to 11.7% in one US Medicaid study and 5% to 13% 
in total populations. In addition, top-1% patients were more likely to die compared to top-
5% patients [55,65] and persistent high-cost patients were more likely to die than episodic 
high-cost patients [64]. Finally, among US dual eligibles, mortality varied much across age 
and residence groups; nearly half of dual eligibles aged 65 and older died [21].  
Expenditure patterns and healthcare utilization 
In each study, costs were heavily concentrated. The top-10% patients roughly accounted for 
about 68% of costs (range: 55%-77%), the top-5% patients accounted for about 55% of costs 
(range: 29%-65%) and top-1% patients for approximately 24% (range: 14%-33%) within a 
given year. Costs were generally less concentrated in US Medicare, and more concentrated in 
total populations.  
 A wide range of parameters were used to describe high-cost patients’ healthcare 
utilization (table 3). Inpatient acute hospital care was most often reported as a primary 
expenditure category for high-cost patients. In line with this, seventeen studies reported 
hospitalizations, admissions or inpatient days as important cost drivers. Lieberman found 
that total spending per beneficiary correlated strongly with the use of inpatient services 
[53], likewise several studies found that increasing levels of use (i.e. top-1% compared to 
top-5%) were associated with increasing proportions of spending on (inpatient) hospital 
care [36,49,56,62,65,66]. Guo et al reported that high-cost users consumed more units of each 
of the service category analyzed, with the exception of laboratory tests [39]; these findings 
were confirmed elsewhere [44,56]. In addition, it was found that 91% of high-cost patients 
received care in multiple care types [57]. Mental care services were listed as expenditure 
category only in studies of total populations, US Medicaid, and US VA. Finally, one study 
determined the frequency use of expensive services among high-cost patients: expensive 
treatments (expensive drugs, intensive care unit treatment, dialysis, transplant care, and 
DRGs >€30,000) contributed to high cost in approximately one third of top-1% patients, and 
in less than ten percent of top-2-5% patients [65].
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TABLE 3  Expenditure patterns and utilization of high-cost patients. 
Spending category
NUMBER OF STUDIES
(Inpatient) hospital care 31 [18, 19, 21, 25, 27-29, 31-33, 36-39, 43, 44, 46, 49, 51-53, 56, 
57, 59, 60, 62-66, 68]
Subacute care / postacute care services  
rehabilitation
11 [9, 25, 27, 28, 32, 33, 46, 56, 57, 59, 66]
Hospitalizations/ admission / patient days/ 
length of stay
17 [19, 29, 31, 33, 36, 38, 39, 43, 45, 47, 50-52, 56, 58, 65, 68]
Emergency department 12 [19, 37-39, 43, 44, 47, 50, 51, 56, 57, 68]
Outpatient (physician) visits 13 [26, 33, 38, 39, 43, 44, 49, 50, 56, 59-61, 68]
Long term care 11  [21, 25, 27, 28, 32, 33, 40, 43, 51, 61, 66]
Mental health 10 [20, 25, 28, 31, 39, 43, 57, 61, 65, 68] 
Physician services 13 [29, 31, 39, 43-45, 56, 58-61, 66, 68]
Intensive care unit 2 [51, 65]
Prescription drugs 16 [22, 26, 28, 29, 32, 36, 38, 39, 44, 46, 50-52, 56, 65, 68]
Persistency
Subsequent use 13 [21, 22, 28, 30, 34, 36, 37, 42, 53, 55, 60, 61, 64]
Prior use 5 [16, 19, 26, 34, 64]
Persistent users 21 [15, 16, 19, 21, 22, 25, 26, 28, 30, 34, 36, 37, 42, 44, 47, 53, 
55, 60, 61, 64, 66]
Prediction of high-cost patients1 16 [16, 17, 19, 23-26, 29, 35, 40, 50, 52, 54, 61, 63, 67]
1   An in-depth discussion of prediction models for high costs is beyond the scope of the article 
(though individual predictors are used throughout the paper). Generally, diagnosis based 
models outperform prior cost models, and combinations accurately predict high-cost patients. 
Besides, comorbidity indices also accurately predict high-cost patients, and self-reported 
health data meaningfully improved existing models. 
Four studies quantified the amount of ‘preventable’ spending (based on preventable 
emergency department visits and preventable (re-)admissions) among high-cost patients. 
As shown above, various supply side characteristics were associated with higher preventable 
costs among high-cost US Medicare patients, and approximately 10% of total costs were 
preventable [47]. Another study found that 4.8% of US Medicare spending was preventable, 
and that high-cost patients accounted for 73.8% of preventable spending. Moreover, 43.8% 
of preventable spending was accounted for by frail elderly, and preventable spending was 
particularly high for heart failure, pneumonia, COPD/asthma and urinary tract infections [33]. 
Figueroa et al found that preventable spending differed by insurance type among US non-
elderly: respectively 3,5%, 2.8% and 1.4% of spending were preventable among US Medicaid, 
US Medicaid managed care and privately insured high-cost patients [32]. Similarly, Graven 
et al found that proportions of preventable spending differed between payers, and that 
persistent high-cost patients had higher proportions of preventable spending [37]. 
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Twenty-one studies reported on the persistency of high costs. We found three approaches for 
studying persistency. First, studies reported prior healthcare use and/or reported posterior 
healthcare use for patients with high costs in a given index year. In other studies, persistent 
high-cost patients were compared to episodic high-cost patients. Spending persistency 
varied between 24% and 48% for top-5% patients, and between 28% and 45% for top-10% 
patients. Spending persistence was relatively high in US Medicaid, and relatively low in US 
Medicare. Increasing persistence was associated with increasing expenditures on all service 
types [44]. 
Discussion
We reviewed 55 studies on high-cost patients’ characteristics and healthcare utilization, 
and made comparisons across payers and countries. The studies consistently point to a high 
prevalence of multiple (chronic) conditions to explain high-cost patients’ utilization. Besides, 
we found a high prevalence of mental illness across all the studies, most notably in US 
Medicaid and total population studies. We found that various health system characteristics 
may contribute to high costs. Preventable spending was estimated at maximally ten percent 
of spending. Furthermore, we found that high costs are associated with increasing age and 
that clinical diagnoses and utilization patterns varied across age groups. However, still more 
than half of high-cost patients are younger than 65 years. High costs were associated with 
higher incomes in the US, but with lower incomes elsewhere. Finally, we confirmed that 
high-cost patients are more likely to die, and decedents are more likely to incur high-costs. 
However, no more than 30% of high-cost patients were in their last year of life. 
Strengths and weaknesses 
This is the first systematic review of scientific literature on high-cost patients’ characteristics 
and healthcare utilization. Future studies might consider inclusion of grey literature. We 
included studies of various payer types and countries, allowing comparisons across settings. 
However, most studies were conducted in the United States and Canada, which limits the 
generalisability of the findings. Although our comparison across countries did not reveal 
large differences in mortality or prevalence of common chronic diseases, these analyses 
were based on a limited number of variables, studies and countries. It is likely that the 
specific characteristics and utilization of high-cost patients vary across localizations due 
to a wide range of epidemiological and health system factors. One limitation is that we, 
because of methodological diversity, did not assess the quality of the included studies, and 
some studies by design did not control for confounding. To our knowledge, no agreed upon 
framework exists for risk of bias assessment of the kind of studies included in our review. 
One limitation in current frameworks for observation/cross-sectional studies is that these 
are primarily designed for studies that aim to assess intervention effects in comparative 
studies. The internal validity of the findings in our included studies is mainly contingent 
upon its ability to control for relevant confounders. However, no consensus exists about 
what factors should reasonably be controlled for. The external validity of the findings of each 
of the studies depend upon the breadth of the population studied, and the scope of the costs 
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considered for establishing total costs. Our study selection process was aimed at identifying 
studies with a broad population studied, and a wide range of costs considered. Finally, the 
studies used various approaches for defining the needs and measuring multimorbidity 
among their populations, which limits the comparability across studies. 
Reflections on our findings
Current research in high-cost patients has focused on care redesign of the treatment of 
patients with multiple chronic morbidities [7,69]. One contribution of our review is our 
identification of notable differences in characteristics and utilization across payers and 
countries. This (clinical) diversity of high-cost patients may even be larger at a local level. 
Segmentation analysis has been suggested as a method to identify homogenous and 
meaningful segments of patients with similar characteristics, needs and behavior, that 
allows for tailored policy [70]. Such segmentation analysis may powerfully inform population 
health management initiatives. Given the multiple needs and cross-sectoral utilization 
of high-cost patients, we suggest such analyses should capture both characteristics and 
utilization as broadly as possible, to fully apprehend high-cost patients care needs and 
utilization. In the context of high-cost patients, multimorbidity complicates segmentation, 
and the usefulness of segmentation may depend on the way multimorbidity is dealt with. 
To illustrate a potent example, Hayes et al defined high-need, high-cost patients as “people 
having three or more chronic conditions and a functional limitation that makes it hard for 
them to perform basic daily tasks” [71].
 Our findings also reveal several supply side factors that contribute to high costs. However, 
no firm conclusions can be drawn about the strength of these effects. The apparent limited 
impact of organizational factors on spending is in line with Andersen’s model predictions, 
where multimorbidity and health status are prime determinants of healthcare costs [72]. 
However, such findings are surprising given the abundance of evidence for supplier induced 
demand and medical practice variation [73]. High-cost populations may be too diverse 
for studying the impact of organizational factors; for such studies more homogenous 
populations may be prerequisite. 
 Four of our included studies estimated the amount of ‘preventable’ spending among 
high-cost patients. Preventable spending was estimated at maximally ten percent of 
spending, which is relatively low compared to the amounts of savings that have been 
reported elsewhere [8]. Preventable spending was mainly defined as preventable emergency 
department visits or preventable (re-)admissions, as such echoing the two primary 
targets of most high-need high-cost programs, including care coordination and disease 
management. The algorithms used were said to be relatively narrow and could have 
included other diagnostic categories [37]. Besides, future studies might consider more broad 
measures of preventable or wasteful spending, and develop algorithms to identify duplicate 
services, contra-indicated care, unnecessary laboratory testing, unnecessary prolonged 
hospitalizations, or any other kinds of lower value services. 
 It was striking that three US studies reported that higher incomes were associated with 
high costs, whereas other studies found that lower incomes were associated with high costs. 
These findings may point to disparities in health, the price that some Americans pay for their 
care, and the reduced accessibility to care of low income patients. This may particularly hold 
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for the uninsured. Besides, these findings suggest tailored interventions for lower income 
patients may be worthwhile.
Policy and research implications
Based on our findings, we deduced four major segments of high-cost patients for which 
separate policy may be warranted, including patients in their last year of life, patients 
experiencing a significant health event who return to stable health (episodically high-
cost patients), patients with mental illness, and patients with persistently high costs 
characterized by chronic conditions, functional limitations and elder age.
 Many interventions have been taken to increase value of end-of-life care. Advance 
care planning has shown to increase the quality of end-of-life care and decrease costs [74-
76]. In addition, health systems might consider strengthening their palliative care systems 
[77]. Increasing value for episodically high-cost patients requires appropriate pricing of 
procedures and drugs, for example through selective contracting of providers, reference 
pricing or competitive bidding [78]. In addition, bundled payments for procedures and 
associated care may improve care coordination and reduce the use of duplicative or 
unnecessary services [79]. Multidisciplinary needs assessment and shared decision making 
may reduce unwarranted variation in expensive procedures. Mental health high-cost 
patients are known for their medical comorbidities, which suggests these patients might 
benefit from multidisciplinary cross-sectoral healthcare delivery, for example through 
collaborative care [80,81]. Finally, persistent high-cost patients might benefit from a variety 
of models, including disease management, care coordination, or ambulatory intensive care 
units, depending on the needs of the population and local circumstances [8,82-84]. Especially 
population health management approaches may be beneficial for these populations. Sherry 
et al. recently examined five community-oriented programs that successfully improved care 
for high-need, high-cost patients. The five programs shared common attributes, including 
a ‘whole person’ orientation, shared leadership, flexible financing and shared cross-system 
governance structures [85].  
 One study addressed health beliefs and patient networks among high-cost patients [36]. 
More of such research is needed as health beliefs may be more amenable to change than 
other drivers of high costs. One study analyzed the use of expensive treatments by high-
cost patients [65]. Better insight in such healthcare utilization patterns is needed to inform 
interventions and policy aimed at high-cost populations. There is a need for segmentation 
variables and logic that is informative at either micro-, meso- and macrolevel. More research 
is needed to identify determinants of preventable and wasteful spending.
 In conclusion, high-cost patients make up the sickest and most complex populations and 
their high utilization is primarily explained by high levels of chronic and mental illness. High-
cost patients are diverse populations and vary across payer types and countries. Tailored 
interventions are needed to meet the needs of high-cost patients, and to avoid waste of 
scarce resources.
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Appendix 1. Final search strategy
Pubmed (restricted to Dutch, English, French and German):
((((((((High-cost*)) OR (high spending)) OR (Costliest)) OR (highest-cost*))) AND 
((((((Patient*)) OR (Individual*)) OR (Benefici*)) OR (Person*)) OR (user*)) NOT medline[sb])) 
OR (((((((“Economics, Hospital”[Mesh]) OR “Economics, Medical”[Mesh]) OR “Health Care 
Sector”[Mesh])) OR (“Costs and Cost Analysis”[Mesh]))) AND (((((((High-cost*)) OR (high 
spending)) OR (Costliest)) OR (highest-cost*))) AND ((((((Patient*)) OR (Individual*)) OR 
(Benefici*)) OR (Person*)) OR (user*))))
Embase:
1  (high-cost* or high spending or Costliest or highest-cost*).mp. [mp=title, abstract, 
subject headings, heading word, drug trade name, original title, device manufacturer, 
drug manufacturer, device trade name, keyword]
2  (patient* or individual* or benefici* or person* or user*).mp. [mp=title, abstract, subject 
headings, heading word, drug trade name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword]
3  “hospital cost”/ or “health care cost”/ or “cost”/ or economic aspect/ or “hospital 
utilization”/ or medicare/ or exp medicaid/
4 1 and 2 and 3
5  ((high-cost* or high spending or Costliest or highest-cost*) adj3 (patient* or individual* 
or benefici* or person* or user*)).mp.
6 4 or 5
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Appendix 2. Supplementary information 
Author(s), country Key points of the article
Aldridge and Kelly, 
United States 
The majority of decedents were in the high-cost group, however the majority of 
high-cost patients were not in their last year of life. Not only is this group small 
(11%), the window of time for a significant impact on costs is limited by the pa-
tients’ life expectancy. Findings confirm the need to focus on those with serious 
chronic illnesses, functional debility, and persistently high costs.  
Ash et al., 
United States
Diagnosis-based risk models are at least as powerful as prior cost for identifying 
people who will be expensive. Combined cost and diagnostic data were even more 
powerful and more operationally useful, especially because the diagnostic infor-
mation identifies the medical problems that may be managed to achieve better 
outcomes and lower costs.
Bayliss et al., 
United States
Self-reported health status, functional limitations, medication use, presence of 
0-4 chronic conditions, self-reported ED use during the prior year, lack of prior 
insurance, age, gender, and deductible-based insurance product were predictive 
for high costs. 
Beaulieu et al.,
United States
High-cost patients are only modestly concentrated in specific hospitals and mar-
kets. The hospitals and markets that disproportionately care for high-cost ben-
eficiaries were markedly different than those that cared for fewer such patients: 
these hospitals were either academic teaching or for-profit institutions operating 
in urban settings and serve a greater proportion of low-income patients. Concen-
trated markets had a greater supply of specialists and a lower supply of long-term 
care beds. Spending in the last 6 months of life was also significantly higher in 
high-cost concentration HRRs. 
Boscardin et al., 
United States
In addition to demographic characteristics and health service use, self-report of 
the presence of specific health conditions were predictive for high costs. 
Buck et al.,
United States
Mental health/substance abuse service users constitute 11% of all Medicaid en-
rollees, but make up nearly a third of high-cost enrollees. Their use of non-mental 
health/substance abuse services is more important than their use of MH/SA 
services in determining their high-cost status. Adults account for two third of this 
high-cost MH/SA group, and they most frequently qualify for Medicaid through 
disability-related eligibility categories. 
Bynum et al., 
United States
High combined Medicare and Medicaid spending are found in two distinct groups 
of high-cost dual eligibles: older beneficiaries who are nearing their end of life, 
and younger beneficiaries with sustained need for functional supports. High-cost 
dual eligibles often use costly inpatient settings, including acute care hospitals 
and inpatient long-term care services, in addition to nursing homes. 57% of high-
cost dual eligibles reside in the community, not in long term care. 
Chang et al., 
United States
Consistent high-cost users had higher total and pharmacy costs, and more chron-
ic and psychosocial conditions than episodic high-cost users. 
Charlson et al., 
United States
The comorbidity index was significantly correlated with the top 5% and top 10% 
of costs for the pooled sample, as well as for adults and children separately. Co-
morbidity can be used to identify beneficiaries most likely to incur high costs. 
Charlson et al., 
United States
Prior year costs, prior year comorbidity, prior year DCG, and prior year hospitaliza-
tions were all evaluated as predictors of upper 5% and upper 10% of subsequent 
(2010) costs in separate models controlling for age, gender and mental health 
diagnosis. In adults, the comorbidity index was equivalent to DCG and prior cost 
in predicting the top 5% and 10% of cost, while prior hospitalization had much 
lower ability to identify such patients.
Chechulin et al., 
Canada
Age was a strong predictor of high costs, and as the material and social depriva-
tion index increases, the risk of becoming high-cost increased. Males were more 
likely to incur high costs, and degree of rurality was also linked to high costs. 
Current and past healthcare utilization were the strongest predictors for high use. 
Several influential were significantly associated with high costs.
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Cohen et al., 
United States
Prior year expenditures, frequency of prescribed medication purchases, the num-
ber of office based provider visits, activity limitations and health status were the 
most significant predictors for high costs. Other measures that were significantly 
related to high costs were age, gender, marital status, family income, living alone, 
and the presence of an infectious or respiratory condition. Predictive capacity of 
models did not suffer when restricted to a single year of prior information.
Coughlin et al., 
United States
20% of dual eligibles account for more than 60% of combined Medicaid and 
Medicare spending on the dual population. Subgroups were found among these 
high-cost population. Fewer than 1% of dual eligibles were in high-cost categories 
for both Medicare and Medicaid. Dual eligibles are a highly diverse group in terms 
of their spending. Being a dual eligible is not necessarily synonymous with high 
spending.  
Coughlin and Long, 
United States 
A high degree of spending persistence was observed: 57.9% of those in the top-
10% remained in the top-10% in the two subsequent years. Two distinct high-cost 
groups were identified, those with persistently high costs and those with episodi-
cally high costs, each with different services driving their costs. 
Crawford et al., 
United States
The following predictive factors, listed in descending order according to the 
magnitude of their importance statistics, were related to high costs: total medical 
costs, physician costs, prescription drug costs, number of unique diagnoses, age, 
number of prescription drug claims, number of unique procedures, hypertension 
symptoms, CAD symptoms, inpatient costs, and diabetes symptoms.
DeLia, 
United States
One forth of extreme spenders remained in that category in the three subsequent 
years. Almost all were blind, disabled and aged, the majority have a develop-
mental disability, central nervous system diagnosis, or psychiatric diagnosis. 
Persistently high spenders were also more likely to be men, >40 years old, living in 
a nursing facility, or having a higher CDPS score.  
de Oliveira et al., 
Canada
Mental health high-cost patients incurred 30% higher costs than other high-cost 
populations. They were younger, lived in poorer neighboorhouds, and had differ-
ent health care utilization patterns. 
Figueroa et al., 
United States
Characteristics and likelihood of high costs vary by major type of insurance. 
Nearly 1 in 5 Mediciad insured patients was likely to be high-cost (top-10%), these 
patients were more likely to be medically complex, with more chronic diseases 
and mental health health/substance abuse problems. Additionally, patterns of 
spending varied by major type of insurance. 
Figueroa et al., 
United States
About 5% of total health care spending incurred by Medicare beneficiaries was 
potentially preventable, and most of this spending was incurred by high-cost 
patients. Large variations existed across high-cost subgroups. The high-cost frail 
elderly group accounted for nearly half of all potentially preventable spending 
after admissions for ACSCs or potentially avoidable ED visits. This spending was 
particularly high for heart failure, pneumonia, chronic obstructive pulmonary 
disease or asthma, and urinary tract infections.
Fitzpatrick et al., 
Canada
Future high costs status was most strongly associated with food insecurity, per-
sonal income, and non-homeownership. Living in highly deprived or low ethnic 
concentration neighborhoods also increased the odds of becoming an HCU.
Fleishmann et al., 
United States
Medical condition information substantially improved prediction of high expen-
ditures beyond gender and age, with the DCG risk score providing the greatest 
improvement in prediction. The count of chronic conditions, self-reported health 
status, and functional limitations were significantly associated with future high 
expenditures, controlling for DCG score.
Ganguli et al.,
United States
Complex medical issues, physical disability/frailty, and mental illness/substance 
was linked with increased costs, while socioeconomic status, social network, 
activation, and trust in clinicians and the health system appeared to increase or 
decrease costs depending on context. Trust seemed to modify the interaction 
between patient activation and cost.
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Graven et al., 
United States
Among the top-10%, 5.6%, 1.9%, and 3.8% was attributable to spending on 
preventable services for Medicaid, commercial, and Medicare Advantage patients, 
respectively. In the third year of spending among persistently high-cost patients 
in Medicaid, commercial and Medicaid advantage programs, cost were decreased 
by 11%, 25.6% and 30.6% respectively. 
Guilcher et al., 
Canada
This study provides a novel methodological approach to categorize high-cost 
health system users into meaningful person-centered episodes. The most com-
mon clinical grouping categories to start a person-centered episode of care were 
Planned Surgical, Unplanned Medical and Post-Acute Admission Events. Inpatient 
acute and inpatient rehabilitation accounted for the largest proportions of costs.
Guo et al., 
United States
High-cost patients not only utilized more costly services, and more units of 
service per recipient, but also had higher per-unit costs for each of the service 
categories. The following groups had the highest odds of being a high-cost users: 
dying, disabled, urban resident, and male.
Hartmann et al., 
Germany
Several predictors were related to high costs, including insurance status (depen-
dent coverage in particular), prior expenditures, home nursing, chronic diseases 
and multimorbidity, mental and behavioral disorders, musculoskeletal disorders, 
respiratory system disorders, cardiovascular diseases, and metabolic diseases.
Hensel et al., 
Canada
Seventeen percent of the most costly users had a prior diagnosis of a psychotic, 
major mood, or substance use disorder, and nearly 40% when anxiety and other 
disorders were included. The rate of mental illness and addiction rose incremen-
tally across increasing user cost categories. 
Hirth et al., 
United States
Individuals’ positions within the spending distribution vary over time, but 
considerable persistence exists, particularly clear at the lower end of the spending 
distribution, but also at the top persistence is considerable. Many characteristics 
retained predictive power for future spending, including age, gender and a variety 
of medical conditions. 
Hunter et al., 
United States
Approximately half of high-cost patients had at least one psychiatric diagnosis, 
and of these 49% had two or more psychiatric diagnoses. Utilization and costs of 
mental health and medical-surgical care differed among various groups of high-
cost patients with mental health conditions. 
Hwang et al., 
United States
Persistent high users had higher overall disease burden due to multiple chronic 
conditions and incurred significantly higher expenses in medication and profes-
sional services. 
Izad Shenas et al., 
United States
Data mining techniques, including neural networks and decision trees, were used 
to identify non-trivial attributes of high-cost patients. Identified attributes were 
overall health perception, age, history of blood cholesterol check, history of physi-
cal/ sensory/ mental limitations, and history of colonic prevention measures.
Joynt et al., 
United States
High-cost beneficiaries were segmented into clinically relevant groups, including
frail elders, those with disabilities or ESRD under the age 65, beneficiaries with 
chronic illnesses, and those who were relatively healthy at baseline. Frail elders 
were most likely to incur high costs,  nearly half of the frail beneficiaries incurred 
high costs, and they comprised 40% of the high-cost population. Overall patterns 
of spending were relatively similar across high-cost segments, with inpatient 
spending contributing the largest share in general.
Joynt et al., 
United States
Approximately 10% of the costs for high-cost Medicare patients were deemed 
potentially preventable. The percentage was slightly higher for the persistently 
high-cost cohort. Hospital referral regions with a higher primary care or physician 
supply had higher annual preventable costs per capita. 
Krause et al., 
United States
Silent-members are members of a medical health plan who submit no claims for 
healthcare services in a benefit year despite 12 months of continuous-enrollment. 
This study found that silent members who seek care in subsequent years have 
a greater probability of becoming high-expenditure claimants than those with 
low-expenditure experience.
Ku et al., Taiwan Of the top-10%, 39% remained high-cost in the year thereafter. NHI expenditure 
percentiles, and all chronic conditions significantly predicted future expenditures. 
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Lauffenburger et al., 
United States
High-cost patients had higher mean comorbidity scores (measured using four risk 
adjustment measures). Trajectory modeling may be a useful way to predict costly 
patients that could be implementable by payers to improve cost-containment 
efforts.
Lee et al., 
United States
Five distinct phenotypes of high-cost patients with diverse drivers of cost were 
identified. Besides, “hot-spotters” (those with four or more admissions) were 
quantified. They accounted for 9% of high-cost patients and 19% of that popu-
lation’s costs. The majority of “hot-spotters” were in the cluster of patients who 
had ‘frequent care’. 
Leininger et al., 
United States
Self reported health measures were meaningful predictors of high costs, this in-
cluded individual conditions, behavioral variables, prescription drug use, previous 
year utilization, and access to care measures. 
Lieberman et al., 
United States
This paper explored the potential of two alternative approaches for reducing 
the rate of growth in Medicare spending. Viewed from a budgetary perspec-
tive, concentration in Medicare spending suggests the importance of focusing 
on high-spending patients. Spending per beneficiary correlated strongly with 
inpatient use. The prevalence of serious chronic conditions is higher among 
high-spending beneficiaries. A high-cost patient was five times more likely to die. 
However, only one fifth died at the end of the year. 
Meenan, 
United States
This study evaluated a variety of risk models to predict high-cost patients. To 
predict top-1% and top-0.5%, ACGs, DCGs, GRAM, and Prior-expense were very 
comparable in overall discrimination (AUCs, 0.83– 0.86). DCGs captured the most 
“high-cost” dollars among enrollees with asthma, diabetes, and depression; pre-
dictive performance among demographic groups (Medicaid members, members 
over 64, and children under 13) varied across models.
Monheit, 
United States
A sizeable minority of high expenditure cases exhibits persistently high expendi-
tures in the short run. However, when all persons in a top expenditure percentile 
are considered, health expenditures do begin to regress to the mean over time as 
a majority of high spenders move to lower positions throughout the expenditure 
distribution. 
Powers and Chaguturu, 
United States
Little is known about variation in clinical characteristics and care-utilization 
patterns among payer-defined groups. The costliest 1% of Medicare patients had 
an average of 8 co-occurring chronic conditions. In Medicaid, high-cost patients 
also had several co-occurring chronic conditions (five on average) but there was 
a striking prevalence of mental health disorders. In commercial populations, high-
cost patients had fewer chronic conditions and were more likely to have disease 
risk factors than end-stage sequelae. Drivers of high costs in this population
included catastrophic injuries, neurologic events, and need for specialty pharma-
ceuticals.
Pritchard et al., 
United States
Spending pattern for high-cost patients differs considerably from the general 
population. The absolute expenditures for each place of service were increased, 
and the share of spending on inpatient services is significantly higher in high-
cost patients, while the share of expenditures attributed to major outpatient 
places of service and pharmacy are lower. Common health conditions, such as 
back disorders and osteoarthritis, contribute a large share of expenditures, but 
other conditions such as chronic renal failure, graft rejection, and some cancers 
accounted for disproportionately higher expenditures in high-cost patients. 
Rais et al., Canada Males are more costly than females. Seniors accounted for the majority of high-
cost users and costs, but the average costs per patients decreased with age. Of the 
different clinical conditions, circulatory system conditions incurred the most costs. 
Reid et al., Canada High-cost users are overwhelmingly characterized by multiple and complex health 
problems. This relatively small group accounted for a disproportionate share of 
primary care and specialist encounters as well as inpatient days. 
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Reschovsky et al., 
United States
Among high-cost patients, health was the predominant predictor of costs, with 
most physician and practice and many market factors (including provider supply) 
insignificant or only weakly associated with high costs. Beneficiaries whose usual 
physician was a medical specialist or reported inadequate office visit time, medi-
cal specialist supply, provider for-profit status, care fragmentation, and Medicare 
fees were associated with higher costs.   
Riley , United States Annual expenditures became less concentrated over time, although the year-
to-year persistence of person-level high costs remained strong. There was an 
increase in the prevalence of chronic conditions among high-cost beneficiaries. 
Spending concentration in Medicare decreased over time, perhaps due to 1) 
trends in longevity and medical expenses (increasing life expectancy has had the 
effect of spreading the same level of healthcare costs over a greater number of 
years; as age of death increases, lifetime Medicare costs increase only slightly), 2) 
expensive technologies are increasingly used on less sick patients, or 3) trends in 
disability. 
Robst, United States High costs were very persistent, as a high percentage of individuals were high-
cost cases for multiple years. In addition, individuals receiving ICF-mental retar-
dation services were very likely to have persistent high costs. Individuals with 1 or 
more inpatient stays in the base year were less likely to remain high cost in the 
future. Most high-cost cases had multiple diagnoses.
Rosella et al., Canada High-cost patients tended to be older with multiple comorbidities and were more 
likely to be white, female and have lower household income. Risky behaviors were 
not overwhelmingly drivers of short term high-cost, but this is likely an artifact.  
Snider et al., 
United States
A logistic model was used to capture the effect of BMI on the risk of high future 
medical spending. Individuals in all obesity classes have higher risk of high medi-
cal spending in the following year compared to normal weight patients (BMI ≤ 25).
Tamang et al., 
Denmark
Cost bloomers (those who move from the lower to the upper percentile in one 
year) represented the majority of high-cost patients. They were younger, had less 
comorbidity, lower mortality and fewer chronic conditions. Diverse population 
health data, in conjunction with modern statistical learning methods for ana-
lyzing large data sets, can improve prediction of future high-cost patients over 
standard diagnosis-based tools, especially for cost-bloom prediction task.
Wammes et al., 
Netherlands
Expensive treatments, most cost-incurring condition and age proved to be infor-
mative variables for studying high-cost patients. Expensive care use (expensive 
drugs, ICU treatment, dialysis, transplant care and DRG >€30 000) contributed to 
high costs in one third of top 1% beneficiaries and in less than 10% of top 2%–5% 
beneficiaries. High-cost beneficiaries were overwhelmingly treated for diseases of 
circulatory system, neoplasms and mental disorders.  More than 50% of high-cost 
beneficiaries were 65 years of age or younger, and average costs decreased sharply 
with higher age within the top 1% population.
Wodchis et al., 
Canada
High health care costs were related to a diverse set of patient health care needs 
and were incurred in a wide array of healthcare settings. Analyses showed mod-
erate stability in health care costs for individuals over a 3-year period. High-cost 
spending patterns and conditions varied across age groups. 
Zhao et al., 
United States
This study evaluated three models to predict high-cost patients, including a 
DCG-model, a prior cost model, and a prior plus DCG-model (combo model). The 
DCG-model and combo model outperformed the prior cost model.
Zulman et al., 
United States
Multisystem morbidity is common in high-cost patients, approximately two-
thirds have chronic conditions affecting three or more body systems. While some 
patients with cancer or mental illness may benefit from disease specific interven-
tions, the majority most likely require programs that address their heterogeneous 
health needs.  
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Abstract
Objective To determine medical needs, demographic characteristics and healthcare 
utilization patterns of the top-1% and top-2-5% high-cost beneficiaries in the Netherlands.
Design  Cross-sectional study using 1-year claim data. We broke down high-cost beneficiaries 
by demographics, the most cost-incurring condition per beneficiary, and expensive 
treatment use. 
Setting   Dutch curative health system, a health system with universal coverage. 
Participants: 4.5 million beneficiaries of one health insurer.
Measures  annual total costs through hospital, intensive care unit use, expensive drugs, 
other pharmaceuticals, mental care, and others; demographics; most cost-incurring and 
secondary conditions; inpatient stay; number of morbidities; costs per ICD10-chapter; and 
expensive treatment use (including dialysis, transplant surgery, expensive drugs, intensive 
care unit and DRGs > €30,000). 
Results The top-1% and top-2-5% beneficiaries accounted for 23% and 26% of total 
expenditures respectively. Among top-1% beneficiaries, hospital care represented 76% 
of spending, of which respectively 9.0% and 9.1% were spent on expensive drugs and ICU 
care. We found that 54% of top-1% beneficiaries were aged 65 or younger, and that average 
costs sharply decreased with higher age within the top-1% group. Expensive treatments 
contributed to high costs in one third of top-1% beneficiaries, and in less than 10% of top-2-
5% beneficiaries. The average number of conditions was 5.5 and 4.0 for top-1% and top-2-5% 
beneficiaries respectively. 53% of top-1% beneficiaries were treated for circulatory disorders, 
but for only 22% of top-1% beneficiaries this was their most cost-incurring condition.
Conclusions  Expensive treatments, most cost-incurring condition, and age proved to be 
informative variables for studying this heterogeneous population. Expensive treatments 
play a substantial role in high-costs beneficiaries. Interventions need to be aimed at 
beneficiaries of all ages; a sole focus on elderly would leave many high-cost beneficiaries 
unaddressed. Tailored interventions are needed to meet the needs of high-cost beneficiaries, 
and to avoid waste of scarce resources.
Strengths and limitations of this study
–  This study presents an in-depth analysis of the medical needs, demographics and 
healthcare utilization of high-cost beneficiaries in the Netherlands.
–  We characterized high-cost beneficiaries and spending patterns using several variables, 
including expensive treatment use (e.g. dialysis, expensive drugs, ICU), most cost-
incurring condition, and age. 
–  Analyses were limited to one large insurer, but its beneficiaries are representative for the 
Netherlands.  
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Introduction
It is known that health care costs are concentrated among small numbers of ‘high-cost’ 
beneficiaries. These high-cost beneficiaries are the sickest and most complex populations. 
Although they receive substantial care from multiple sources, critical health care needs are 
often unmet, and many receive unnecessary and ineffective care [1-4]. Therefore, high-cost 
beneficiaries are a useful group on which to focus efforts of quality improvement and cost 
containment. 
 For effective quality improvement and cost reduction it is necessary to acquire an in-
depth understanding of the characteristics, health care use and other factors that drive the 
costs of these groups of high-cost beneficiaries [5,6]. Current literature suggests that a high 
prevalence of multiple (chronic) conditions may explain high-cost beneficiaries’ excessive 
care use [7,8]. This presence of multimorbidity among high-cost beneficiaries makes them 
difficult to understand: how to characterize patients that suffer from several diseases? 
Lehnert et al [9] found that the number of chronic comorbidities were nearly exponentially 
related to costs: the higher the number of chronic comorbidities, the higher the costs of an 
additional comorbidity. Based on this study, we hypothesized that in high-cost beneficiaries 
the most cost-incurring condition accounts for a disproportionate share of costs, and that 
secondary conditions account for the remainder of costs. 
 A major limitation of current literature is that little is known about patterns in care 
use and characteristics among different age groups [10]. In addition, until today no studies 
have reported the role of expensive treatments (e.g. expensive drugs, transplant surgery, 
intensive care units, dialysis) as drivers of high costs. Further insight in healthcare utilization 
patterns is needed to develop interventions and inform policy aimed at high-need, high-cost 
populations.
 The primary aim of this study was to determine medical needs, demographic 
characteristics and healthcare utilization patterns of high-cost beneficiaries in the 
Netherlands. We first determined characteristics and spending and quantified the share 
of high-cost beneficiaries that use expensive treatments. We then used a beneficiary’s 
most cost-incurring medical condition to examine characteristics and utilization patterns. 
In addition, we compared utilization and conditions across age groups. All analyses were 
performed for top-1% and top-2-5% beneficiaries separately. This distinction is often used in 
literature [11-14] and may improve understanding of high-cost beneficiaries.
Methods
Design and context
We conducted a cross-sectional study using claims data from 2013 in the Netherlands. 
In the Netherlands, the Health Insurance Act legally requires health insurers to provide a 
nationally set benefits package. Nearly universal coverage for curative care is achieved 
through mandatory purchase of statutory private health insurance [15,16]. Analyses were 
done in-house with Zilveren Kruis, a health insurer covering 4.5 million beneficiaries who 
were primarily living in the central, eastern and western parts of the Netherlands. The basic 
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principle of the Dutch curative health system is that insurers compete for beneficiaries, and 
that they act as prudent buyers of services for their beneficiaries. Health insurers operate 
nationwide, are obliged to accept all applicants for basic health plans and are not permitted 
to risk-rate premiums for these basic plans. Every insured person, aged 18 years or older, is 
required to pay an annual deductible (350 euro in 2013), from which some services, such as 
general practice visits, are excluded. In addition to the basic health plan, more than 80% 
of the population buys voluntary insurance. Premiums for voluntary insurance are not 
regulated, and insurers are allowed to screen applicants. The system provides a wide range of 
services, including care provided by general practitioners, hospitals, and specialists; dental 
care through age 18; prescription drugs; physiotherapy through age 18; most mental care; 
medical aids and devices; maternity care; transportation and others. In our study we also 
included private voluntary supplementary insurance which typically covers dental care, 
some allied healthcare (including physiotherapy, occupational therapy, dietary advice, 
speech therapy) and alternative medicine (typically homoeopathy, acupuncture, natural 
medicine, magnetizing and osteopathy).
Data 
All insured in 2013 were included in this study. Several beneficiary characteristics were 
obtained from the insurer’s databases, including gender, socio-economic status based 
on income estimates per postal code, date of birth and date of death (until February 20th, 
2015). Date of death was categorized to four quarters in 2013 and any date post-2013. More 
information about (a predecessor of) this database is provided in Smeets et al [17].
 Total costs per beneficiary were calculated by summing all claims with a starting date 
in 2013. We defined the beneficiaries with the top-1% and the top-2-5% of total costs as 
two groups of high-cost beneficiaries. The remaining 95% were categorized as low-cost 
beneficiaries. All claims were categorized in nine cost groups (health sectors) using a link 
table provided by the Dutch Healthcare Institute. These sectors included: hospital care 
(including care used abroad), mental health care, primary care, maternal care, allied health 
care, outpatient pharmaceutical prescriptions, medical devices, dental care (most dental care 
is reimbursed through complementary insurance benefits), and voluntary complementary 
insurance benefits. 
 Below, we describe how we operationalised the variables that we included in our 
analysis, including the treatment costs per diagnosis, the prevalence of conditions and 
multimorbidity count, and the use of specific (expensive) services.
Treatment cost per diagnosis
We categorized and analyzed hospital and mental care costs, according to the ICD10 
international classification of diseases [18]. Treatment costs were categorized to the level of 
ICD10-chapters (e.g. chapter IX: diseases of the circulatory system) and ICD10-subchapters 
(e.g. subchapter I60-I69 cerebrovascular diseases). 
 The great majority of hospital care in the Netherlands is reimbursed through payment 
products similar to Diagnosis Related Group (DRGs, which cover both in- and outpatient 
hospital care) and so-called add-ons for expensive drugs and treatment at the intensive care 
unit (ICU). To compute treatment costs per diagnosis, the DRGs were categorized using a 
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link table provided by the Dutch Health Care Authority. This link table (version 22 December 
2014) was developed to categorize hospital claims to specific health care needs, following 
the ICD10 classification [18]. For the purpose of our study, we made a few minor corrections 
to the link table. As we found the ICD-subchapter I30-I52 (other circulatory diseases) highly 
prevalent but not informative, we decided to disaggregate this subchapter. Add-ons were 
not used for establishing treatment cost per diagnosis, but are dealt with separately (see 
“use of specific expensive services”).
 In 2013, the Dutch mental care sector consisted of ‘primary’ mental care, such as care 
provided at general practices, by psychologists and psychotherapists, and at ‘secondary’ or 
specialized mental care provided in mental care institutions. Only claims from secondary 
mental health care were used for characterization as these specify information about 
diagnoses and treatment. These claims were categorized to the ICD10-(sub)chapter and 
added to the hospital claims for ICD-10 chapter V: mental and behavioural disorders. 
Additionally, the number of inpatients days in mental care per beneficiary was calculated 
(but not used for establishing treatment cost). 
Prevalence of conditions and multimorbidity count
Prevalence of conditions was established using the same categorization as described above. 
In addition, we used parameters from the Dutch risk-adjustment scheme: pharmaceutical 
cost groups that indicate chronic use of drugs for different conditions. These pharmaceutical 
cost groups were categorized to ICD10-(sub-)chapters and integrated with the former to 
establish prevalence of conditions. A detailed description of the Dutch risk-adjustment 
scheme is provided in van Veen et al [19]. Multimorbidity was operationalised in three ways. 
First, multimorbidity was calculated by counting the number of prevalent ICD10-chapters per 
beneficiary. Second, we counted the number of prevalent ICD10-subchapters per beneficiary. 
Third, the number of pharmaceutical cost groups was counted, reflecting the number of 
chronic multimorbidities.
Use of specific (expensive) services
We developed dummy variables for specific types of care. Beneficiaries were regarded 
‘expensive care users’ if their claims included a minimum of €10,000 for ‘add-ons’ for ICU 
treatment or expensive drugs. We used €10,000 as threshold because in 2013 expensive drugs 
only qualified for add-on reimbursement when average yearly costs per beneficiary exceeded 
this value. ICU treatment as reimbursed through add-ons included ICU treatment days, ICU 
consultations, ICU surcharges for specific services, ICU neonatal and pediatric care, and ICU 
transport services such as inter-clinical transportation services and Mobile Intensive Care 
Unit (MICU). Expensive drugs reimbursed through add-ons included growth hormones, 
antineoplastic agents, TNF-alfa inhibitors, orphan drugs, haemostatics and other expensive 
drugs [20]. The list of drugs and indications that qualify for add-on reimbursement can be 
found at www.farmatec.nl.   
 A separate dummy variable ‘transplant’ was developed, for beneficiaries who received a 
transplant or transplant-related care (both pre- and post transplant). One DRG-description 
that included the word ‘transplant’ was sufficient for a person to qualify as transplant-
beneficiary. Similarly, the variable ‘dialysis’ was created for all beneficiaries receiving dialysis 
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for renal failure (both peritoneal and hemodialysis). In addition, all DRGs with an average 
price > €30,000 were identified and together included as separate binary variable. This price 
was chosen as all top-1% beneficiaries incurred €30,000 or more. Furthermore, two dummy 
variables for mental health use were computed, the first on mental care use (> €0 mental care 
costs) and the second on inpatient stays (> 0 days). The total number of inpatient hospital 
days per beneficiary was estimated using national averages of hospital days per DRG [21]. 
Finally, we used claim data to derive the number of different hospitals, university medical 
centers, and hospital specialisms that beneficiaries were treated at, as well as the number 
of ambulance transportations, and emergency department visits. For full details concerning 
the variable computation, please contact the corresponding author.
Analyses
We explored the composition of expenditures across health sectors for both top-1% and top-
2-5% beneficiaries. Demographics, medical characteristics and (expensive) health care use 
were analyzed using descriptive statistics. 
Most cost-incurring and secondary conditions
For each high-cost beneficiary we identified the most cost-incurring ICD10-(sub)chapter. 
For both top-1% and top-2-5% beneficiaries, we first determined the prevalence of each 
ICD10-subchapter. Second, for both high-cost groups we summed treatment cost per ICD10-
subchapter, and divided this with the sum of total costs.  Third, for each ICD10-subchpater 
we calculated how frequently it was the most cost-incurring condition for the beneficiaries 
in these groups. Fourth, we divided the percentage of beneficiaries with a ICD10-subchapter 
as the most cost-incurring condition by the overall prevalence of the ICD10-subchapter. 
This metric was used to distinguish between ICD10-subchapters that were mainly found as 
most cost-incurring conditions compared to ICD10-subchapters that were mainly found as 
secondary conditions. Fifth, for each beneficiary we divided the treatment cost for the most 
cost-incurring condition by total costs. This figure was averaged for each ICD10-subchapter 
and determines the contribution of these conditions to total costs within the subpopulation. 
Health care use according to most cost-incurring ICD10-chapter and across age groups
To identify patterns in (expensive) health care use, we developed cross-tables with costs per 
ICD10-chapter, (expensive) health care use indicators and demographic characteristics as 
descriptive variables. Beneficiaries were selected by the most cost-incurring ICD10-chapter, 
to prevent that beneficiaries with multimorbidity would be counted several times.
 Finally, we compared utilization patterns and conditions across age groups. We examined 
total costs, spending per sector and we identified the five most cost-incurring ICD10-
chapters per age group.
 All analyses were performed using SAS 9.4, Enterprise Guide 6.1.
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TABLE 1  General characteristics and indicators for health care use for three distinct cost groups.
General characteristics Top-1% Top-2-5% Bottom-95%
Number of beneficiaries 45,207 180,826 4,294,611
Average total costs (SD) €56,424
(€40,830)
€15,780
(€5,208)
€1,345
(€1,773)
Share of total costs 22.8% 25.5% 51.7%
Private spending† (SD) €330 (€172) €335 (€165) €159 (€181)
Gender  Male: 52.3% 44.8% 49.6%
Female: 47.7% 55.2% 50.4%
Mean age (SD) 58.5 (21.6) 58.0 (21.8) 39.2 (23.3)
Median age 64 62 39
Percentage dying in or after study period Q1: 0.7% 0.9% 0.2%
Q2 1.8% 1.6% 0.2%
Q3 3.2% 1.7% 0.1%
Q4 4.2% 1.9% 0.1%
>Q4‡: 12.5% 5.9% 0.7%
Socioeconomic status >15 inhabitants††: 4.5% 3.1% 1.0%
Lowest incomes: 31.1% 31.5% 31.4%
Average income: 37.5% 38.5% 37.7%
High income: 26.8% 26.7% 28.6%
Medical characteristics Top-1% Top-2%-5% Bottom-95%
Average number of comorbidities – ICD-chapter (SD) 4.2 (2.1) 3.3 (1.8) 0.7 (1.1)
    Average number of comorbidities – ICD-subchapter (SD) 5.5 (3.1) 4.0 (2.3) 0.8 (1.2)
    Average number of chronic comorbidities – calculated  
    by pharmaceutical cost groups (SD)
1.1 (1.2) 1.0 (1.1) 0.2 (0.6)
(Expensive) healthcare use Top-1% Top-2%-5% Bottom-95%
Percentage using expensive care > €10,000 24.6% 5.8% 0.0%
    Percentage transplant beneficiaries 3.7% 0.8% 0.03%
    Percentage receiving dialysis 6.1% 0.1% 0.0%
    Percentage receiving DRG > €30,000 4.5% 0.03% 0%
Percentage with >0 inpatient mental health care stays 13.0% 3.3% 0.04%
    Percentage with mental health care costs >€0 23.5% 20.6% 6.4%
    Average number of inpatient mental hospital days‡‡ 54.7 (74.3) 4.0 (11.7) 0.05 (0.8)
    Percent visiting a specialized mental care center 22.5% 19.2% 4.8%
    Average number of hospital specialists involved (SD) 4.2 (2.3) 3.0 (1.8) 0.6 (1.0)
    Average number of hospitals visited (SD) 1.9 (1.0) 1.6 (0.9) 0.5 (0.7)
    Average number of inpatient hospital days (SD) 22.3 (26.0) 7.2 (8.4) 0.4 (1.5)
    Percentage using care at a university hospital 39.7% 25.8% 4.5%
    Average number of ambulance transportations (SD) 1.4 (4.3) 0.5 (1.0) 0.02 (0.17)
    Average number of emergency department visits (SD) 0.7 (1.4) 0.4 (0.7) 0.07 (0.27)
†   Consisting of the compulsory deductible of €350. ‡  Dates of death were recorded until the  
20th of February 2015. 
†† Most of whom are institutionalized. ‡‡ For those with mental health care costs >€0. 
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Results
General breakdown of costs
Average total costs for top-1%, top-2-5% and bottom-95% beneficiaries were €56,424, €15,780 
and €1,345 respectively, representing 22.8%, 25.5% and 51.7% of total spending (table 1). For 
top-1% beneficiaries, hospital care represented 76% of costs, of which respectively 9.0% and 
9.1% were for expensive drugs and ICU care. 12.7% and 6.6% of costs were for mental health 
care and outpatient pharmaceuticals. For top-2-5% beneficiaries, hospital care represented 
59.7% of spending, of which 6.0% and 2.1% were spent on expensive drugs and ICU care. 
9.8% and 11.2% were spent on mental health care and outpatient pharmaceuticals. 
Demographics and (expensive) healthcare use
Table 1 presents demographic and medical characteristics of the study population as well 
as (expensive) healthcare use. Males were overrepresented among top-1% beneficiaries, 
and females were overrepresented among top-2-5% beneficiaries. Top-1% and top-2-
5% beneficiaries were much older than low-cost beneficiaries. Furthermore, high-cost 
beneficiaries were more likely to die: 9.9% and 6.1% of top-1% and top-2-5% beneficiaries 
died. However, 63.7% of beneficiaries in our study who died in 2013 or later did not incur high 
costs in 2013. The average number of morbidities based on ICD10-subchapters for top-1%, 
top-2-5% and bottom-95% beneficiaries was 5.5, 4.0 and 0.8 respectively.
 Table 1 also shows that top-1% and top-2-5% beneficiaries scored higher than low-
cost users for each specific service, and top-1% beneficiaries scored higher than top-2-
5% beneficiaries. Both top-1% and top-2-5% beneficiaries used on average one type of 
drugs (pharmaceutical cost groups) continuously. 24.8% of top-1% and 5.8% of top-2-5% 
beneficiaries incurred more than €10,000 on expensive drugs and ICU. Furthermore, 6.1% of 
top-1% beneficiaries underwent dialysis and 3.7% received transplant care. Top-1% and top-
2-5% beneficiaries were treated in on average 1.9 and 1.6 hospitals, and used on average 22 
and 7 inpatient days respectively. Finally, 13% and 3.3% of top-1% and top-2-5% beneficiaries 
were admitted to mental care institutions, respectively.  
Utilization according to ICD10-subchapters, and most cost-incurring and 
secondary conditions 
Appendix 1 presents five parameters for both high-cost populations. Among those in the 
top-1%, a high prevalence of several cardiovascular diseases, COPD, diabetes mellitus, 
and depression were found. In addition, the total treatment costs for renal insufficiency 
(including dialysis) were much higher than for any other ICD10-subchapter, and accounted 
for 6.8% of total costs among top-1% beneficiaries. We use table 2, with a selection of 
ten ICD10-subchapters in top-1% beneficiaries, to illustrate the other parameters for top-
1% beneficiaries. Renal insufficiency, certain cancers, and several cardiovascular diseases 
were frequently found as the most cost-incurring condition among top-1% beneficiaries. 
Furthermore, for beneficiaries that were treated for cancer, the cancer itself was in most 
cases the most cost-incurring condition (e.g. 74.3% of beneficiaries with leukemia). In 
contrast, circulatory disorders were mainly found as secondary condition: for example, in 
less than 30% of patients with ischemic heart disease or heart failure this was their most 
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cost-incurring condition. Finally, we determined the contribution of ICD10-subchapters 
towards total costs per beneficiary. The most cost-incurring condition accounted for 40-70% 
of total costs per beneficiary, depending on the ICD10-subchapter. 
TABLE 2  Ten conditions with highest total costs among top-1% beneficiaries. 
Prevalencea % of total 
costsb
% as most 
cost-incurring 
conditionc
% most 
cost-incurring/
prevalenced
% of costs by 
most cost-incur-
ring conditione
N17-N19 Renal failure  12.2% 6.8% 6.4% 52.4% 66.0%
C81-C96 Leukemia  5.6% 3.0% 4.1% 74.3% 41.4%
C15-C26 Malignant 
neoplasms of digestive 
organs  
7.5% 2.4% 5.4% 71.2% 47.9%
I60-I69 Cerebrovascular 
diseases  
7.9% 2.1% 4.2% 53.1% 52.7%
I70-I79 Diseases of 
arteries, arterioles and 
capillaries  
9.6% 2.0% 4.1% 42.7% 47.3%
C30-C39 Lung cancer  5.9% 1.7% 3.5% 59.1% 52.5%
I51-I52 Complications/
ill-defined descriptions, 
other heart disorders
9.6% 1.6% 3.2% 33.1% 50.3%
I44-I49 Atrial fibrillation, 
rhythm and conduction 
disorders
11.8% 1.6% 2.9% 24.3% 58.5%
I20-I25 Ischemic heart 
diseases  
12.7% 1.6% 3.7% 29.0% 41.9%
I50 Heart failure 9.3% 1.5% 2.6% 28.4% 57.1%
a   Prevalence of each ICD10-subchapter among top-1% beneficiaries. E.g. 12.2% of top-1% benefi-
ciaries were treated for renal failure.
b   Sum of total treatment costs per ICD10-subchapter. E.g. treatment of renal failure accounted 
for 6.8% of total expenditures of top-1% beneficiaries. 
c   Percentage of top-1% with this ICD10-subchapter as most cost-incurring condition. E.g. 6.4% of 
top-1% beneficiaries had renal failure as most cost-incurring condition. 
d   Percentage most cost-incurring condition relative to prevalence: fourth column divided by 
second column. E.g. for 52.4% of top-1% beneficiaries who were treated for renal failure, this 
was also their most cost-incurring condition. 
e   Percentage of costs accounted for by the most cost-incurring condition. E.g. among top-1% 
beneficiaries with renal failure as most cost-incurring condition, this disease accounted for on 
average 66% of total costs per beneficiary. 
Utilization according to most cost-incurring ICD10-chapter
Table 3 and appendix 2 show cross-tables for spending, demographics and indicators for 
(expensive) healthcare use. In these analyses, beneficiaries were selected by most cost-
incurring ICD10-chapter, to avoid multimorbid beneficiaries being analyzed on multiple 
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rows. Among top-1% beneficiaries, three ICD10-chapters were frequently found as most 
cost-incurring ICD10-chapter: mental or behavioral disorders, neoplasms and diseases of 
the circulatory system. These groups had quite different characteristics and utilization. 
Beneficiaries with mental or behavioral disorders were relatively young, had a low number of 
morbidities and low mortality. Beneficiaries with neoplasms were the largest subgroup with 
high mortality. Beneficiaries with diseases of circulatory system were oldest (on average 
69 years old) and predominantly men. Expensive drugs were heavily concentrated among 
beneficiaries with neoplasms. ICU costs were distributed more proportionally; a quarter was 
incurred by beneficiaries with circulatory diseases. 
 Among top-2-5% beneficiaries, the same three most cost-incurring ICD10-chapters 
predominated, albeit they represented a smaller share of the group. Several other 
ICD10-chapters had relatively high costs, including diseases of the digestive system; 
injury, poisoning and certain other consequences of external causes (femur fracture 
most prominently); and diseases of the musculoskeletal system and connective tissue. 
Beneficiaries with neoplasms; diseases of the respiratory system; and symptoms, signs 
and abnormal clinical and laboratory findings most frequently died. Expensive drugs were 
primarily used by beneficiaries with diseases of the musculoskeletal system (rheumatoid 
arthritis), neoplasms and diseases of the digestive system. 
Health care use across age groups
Figure 1 and appendix 3 provide an overview of cost segments per age category among top-1% 
and top-2-5% beneficiaries. With the exception of infants, treatment at the ICU represented 
a maximum of 10% of costs per age group. Moreover, treatment at the ICU represented a 
major cost driver primarily among top-1% beneficiaries. The proportion of costs spent on 
expensive drugs was highest (13.4% of total costs) among top-1% beneficiaries between 21 
and 30 years old. Mental care accounted for a  large share of costs among children and young 
and middle aged adults. The percentage of cost incurred by outpatient and non-expensive 
pharmaceuticals was more pronounced among top-2-5% beneficiaries than among top-1% 
beneficiaries.  
 Table 4 and appendix 4 present the five  ICD10-chapters with highest total costs per age 
group for top-1% and top-2-5% beneficiaries. As mentioned before, we found that high-
cost beneficiaries are generally older than low-cost beneficiaries. However, table 4 shows 
that within the top-1% beneficiaries average costs decreased with higher age: average costs 
ranged from €47,000 on average for top-1% beneficiaries over 80 of age to >€80,000 on 
average for infants. In addition, 54% of top-1% and 57% of top-2-5% beneficiaries were 65 
years of age or younger.
 For each age group, there were different ICD10-chapters with highest costs. Among top-
1% beneficiaries, cardiovascular diseases and diseases of the genitourinary system gained 
importance with higher age, whereas mental and behavioral disorders predominated 
among younger and middle-aged beneficiaries. Among top-2-5% beneficiaries, a similar 
pattern of diseases across age groups was observed. However, pregnancy-related conditions 
played a more significant role among beneficiaries between 20 and 40 years of age, and 
musculoskeletal conditions played a more significant role in several age groups than they 
did among top-1% beneficiaries.  
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FIGURE 1  Cost drivers per age group in top 1% beneficiaries.
Discussion 
In this study, we determined medical needs, demographics and utilization patterns of high-
cost beneficiaries in the Netherlands. Expensive treatments, most cost-incurring condition, 
and age proved to be informative variables for studying this heterogeneous population. We 
found that expensive care use (expensive drugs, ICU treatment, dialysis, transplant care, 
DRG > €30,000) contributed to high costs in one third of top-1% beneficiaries and in less 
than 10% of top-2-5% beneficiaries. High-cost beneficiaries were overwhelmingly treated 
for diseases of circulatory system, neoplasms, and mental disorders. However, neoplasms 
and mental disorders were mainly found as most cost-incurring condition for a beneficiary, 
whereas circulatory disorders were mainly found as secondary condition. More than 50% of 
high-cost beneficiaries were 65 years of age or younger, and average costs decreased sharply 
with higher age within the top-1% population. Such insights are needed to develop tailored 
interventions and inform policy aimed at the high-need, high-cost populations.
Strengths and limitations
This was the first study assessing utilization patterns of high-cost beneficiaries in a European 
universal health system, and we used innovative variables to examine characteristics and 
utilization. We used data from one health insurer with a market share of approximately 27%, 
with data representative for the Dutch population. Despite the limited number of variables, 
our data allowed detailed identification of health care use and categorization of costs 
towards conditions. We chose to use expensive treatments, most cost-incurring condition 
and age as variables for further analyses as such analyses were lacking in the literature 
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and we regarded these most informative for policy and practice. One limitation is that our 
analysis was restricted to one year only. Consequently, we could not discern persistent high-
cost users from episodic high-cost users (those with a single high-cost event [5]). 
Reflections on our findings
Our findings generally align with prior research on high-cost beneficiaries. Similar to 
US studies [12,22], we identified three main subgroups of high-cost beneficiaries with 
cardiovascular diseases, mental disorders, and neoplasms, as well as several smaller 
subgroups. In addition, our findings confirm that high-cost beneficiaries are usually treated 
for several conditions and use care from multiple providers [10]. Like prior studies [12,22] we 
reported a high prevalence of diabetes, but this condition had a limited direct cost impact. 
This may be explained by the fact that Dutch diabetic care is primarily situated in primary 
care. Moreover, complications of diabetes were aggregated to the particular condition (e.g. 
retinopathy) using our link table. Furthermore, in line with Aldridge et al [5], we found that 
dying increases the risk for high costs (data not shown), but that less than ten percent of 
high-cost beneficiaries were in their last year of life. However, we also found that 64% of 
those dying did not incur high costs, compared to 80% of decedents in the US who did incur 
high costs [5]. This may be explained by decedents that could have used long term care services 
which were not included in our analyses. However, this may also result from the GP oriented 
organization of palliative care in the Netherlands, which is known for its low costs [23,24]. 
 Our study is unique in estimating the relative contribution of expensive treatments 
in high-cost beneficiaries. The findings indicate that high unit costs for selected services 
play a substantial role in high-costs beneficiaries. We identified expensive treatment users 
among expensive patients. Furthermore, our analyses show expensive treatment users may 
use a lot of care besides such expensive treatments, suggesting that better alignment of 
expensive treatments with other care may be worthwhile. In line with Joynt et al, we suggest 
that expensive procedures (including orthopedic surgery, pacemaker-implantation etc) and 
catastrophic events may be a more significant cost driver in high-cost beneficiaries than 
avoidable hospitalizations, and that a complementary approach (see below) in high-need 
high-cost programs is needed [22]. 
 To our knowledge, we are the first that have distinguished the most cost-incurring versus 
secondary conditions in high-cost beneficiaries. For example, diseases of circulatory system 
were mainly found as a secondary condition, though they also frequently occurred as most 
cost-incurring condition. In addition, mental disorders and neoplasms were predominantly 
the most cost-incurring condition. Our findings contribute to the rapidly evolving field 
of multimorbidity and patterns of healthcare use. We suggest that conditions that were 
frequently and primarily found as most cost-incurring condition should be priorities for 
policies that seek to contain costs and improve quality of care. However, the observational 
nature of our study does not allow for causal inference; i.e. the high number of morbidities in 
cancer patients may either indicate the many complications from cancer treatment, or point 
to prior chronic disease in patients with cancer.  
 Many high-cost beneficiaries were 65 years of age or younger; and the average costs 
decreased sharply with increasing age within the top-1% beneficiaries. In addition, we 
found typical care needs and utilization per age group. Both findings have rarely been 
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reported in literature [10] and underline the need for studies in the general population with 
comprehensive data. Furthermore, high-need, high-cost programs need to be aimed at 
beneficiaries of all ages; a mere focus on elderly would leave many high-cost beneficiaries 
unaddressed. 
Policy and research implications
Our findings suggest a need for approaches that address patients’ care needs across multiple 
conditions and to integrate care use across multiple providers. Important policy questions 
remain concerning the breadth of health care delivery innovations (i.e. care coordination 
programs, bundled payments; what should a bundle encompass?) [25]. We suggest that high-
need, high-cost programs may aim to align the usual care for most cost-incurring conditions 
with the care for associated or common secondary conditions in specific care pathways. 
Furthermore, based on our findings we recommend a complementary approach geared 
towards expensive procedures and drugs as well as the extensive additional care besides 
expensive treatments. This suggests bundled payments may be worthwhile, as well as 
multidisciplinary assessment of patients’ care needs for expensive treatments. In addition, 
prices for expensive drugs or procedures could be lowered, for example through reference 
pricing or competitive bidding [26,27]. 
 Our research provides a precise picture of high-cost beneficiaries, but further research is 
necessary to specify characteristics and utilization of high-cost beneficiaries at a local level. 
Patient segmentation analysis has been suggested as a method for identifying homogenous 
target population groups from diverse populations, which allows for tailored policies [28]. 
Our analyses may inform such segmentation analyses. Furthermore, we suggest research 
into longitudinal patterns of multimorbidity to identify relevant subgroups that benefit 
from intervention. More research is needed to identify beneficiaries at risk of incurring high 
costs [29].  
 In conclusion, our findings show that high-cost beneficiaries are usually treated for 
several conditions and use care from multiple providers. Expensive treatments, the most 
cost-incurring condition, and age proved to be informative variables for studying this 
heterogeneous population. Tailored interventions are needed to meet the needs of high-cost 
beneficiaries, and to avoid waste of scarce resources. 
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Abstract
Aims  Costs are concentrated among so-called ‘high-cost’ patients. Many high-cost patients 
suffer from congestive heart failure and may be an interesting population to seek for quality 
improvement and cost containment. We determined the characteristics of patients with 
heart failure and high costs (top 1%, top 2-5% highest costs in perspective of the general 
population) and explored the longitudinal healthcare utilization and persistency of high 
costs. 
Methods and results  Longitudinal observational study using claims data from 2006-2014 
in the Netherlands. We identified all patients that received a hospital treatment for chronic 
heart failure between 1 January 2008 and 31 December 2010. Our findings revealed that the 
difference in costs between top 1%, top 2-5% and bottom-95% patients with heart failure 
was mainly driven by hospital costs; and the top 1% group experienced a remarkable increase 
of mental health costs. More than 90% of the population incurred at least one top 5% year 
during follow-up, and 31.8% incurred at least one top 1% year. Top 1% and top 2-5% patients 
with heart failure differed from lower cost patients in their higher rate of chronic conditions, 
excessive polypharmacy, hospital admissions, and heart-related surgeries. Besides, top 1% 
patients were relatively young. Anemia, dementia, diseases of arteries veins and lymphatic 
vessels, influenza, and kidney failure were significantly associated with high costs. The end-
of-life period was also predictive of top 1% and top 5% costs.
Conclusion  Comprehensive and integrated efforts are needed to further improve quality of 
care and reduce unnecessary costs. 
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Introduction
It is known that healthcare costs are concentrated among so called ‘high-cost patients’ [1]. 
Although they receive substantial care from multiple sources, it is widely believed that many 
of these patients have critical unmet health care needs, and many receive unnecessary and 
ineffective care. In the US, about 40% of high-cost patients suffer from congestive heart 
failure (heart failure onwards) [2,3]. In earlier work, we found heart failure affected 12% of 
Dutch high-cost patients [1]. Repeated hospitalizations contribute to the high costs of 
patients with heart failure, and it is known that non-cardiovascular co-morbidities, a lack 
of multidisciplinary treatment, a lack of advance care planning, and a lack of guideline 
recommended care contribute to (preventable) hospitalizations [4,5]. Patients with heart 
failure may thus be exemplary for high-cost patients, and may be an interesting target 
population to seek for possible quality improvement and cost reduction.
 A variety of interventions and programs have been developed to improve the quality 
and efficiency of care for patients with heart failure [6]. Heart failure clinics with specialised 
nurses have shown to improve clinical outcomes and reduce all cause and heart failure 
related readmissions [7]. For high-cost patients, studies have shown that the effectiveness 
and efficiency dramatically increase when interventions are targeted at the patients that are 
most likely to benefit [8]. It is thus of utmost important to acquire an in-depth understanding 
of the characteristics and healthcare utilization of patients with heart failure, and those 
with high longitudinal utilization in particular. 
 Little is known about the variety in characteristics and longitudinal healthcare utilization 
of patients with heart failure. Studies focusing on the costs of heart failure are scarce and 
the few that are available do not focus on high-cost patients within this population [9,10]. 
Furthermore, previous studies have focused on the prediction and prevention of hospital 
readmissions, the predominant cost driver of heart failure, and such studies are often 
limited by a short time horizon [11,12]. 
 The overall objective of this study was to explore the characteristics and longitudinal 
healthcare utilization of patients with heart failure and high costs. We aimed to describe the 
characteristics of patients with heart failure and high costs, and to identify drivers of high 
costs. Furthermore, we aimed to study the longitudinal healthcare utilization of patients 
with heart failure, and to identify the persistency of high costs over time. 
Methods 
Design and context
The study was designed as a longitudinal observational study in routinely collected claims 
data. The study was situated in the curative health system in the Netherlands – a health 
insurance scheme based on the principles of managed competition that is governed by the 
Health Insurance Act. The system provides a wide range of services, including care provided 
by general practitioners, hospitals, and specialists; dental care through age 18; prescription 
drugs; physiotherapy through age 18; most mental care; medical aids and devices; maternity 
care; transportation and others. Voluntary complementary insurance benefits were excluded 
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from analysis, as were long-term care benefits that are covered under a separate scheme [13]. 
This study complies with the Declaration of Helsinki. No ethical approval is needed for this 
type of research in the Netherlands according to current legislation.  
High-cost patients
Top-1% and top-5% of annual care utilization in perspective of the total population are widely 
used indicators for intensive utilization of health resources. We used the total beneficiary 
population (including beneficiaries without heart failure) to establish this characteristic per 
patient per year. The data were not available for the years before 2009. Therefore, the cut-off 
values for the top 1% and top 2-5% classes were extrapolated from subsequent years and 
used to determine top-1% and top-2-5% utilization. 
Patient selection and data source 
Data were drawn from the claims database of Zilveren Kruis, a health insurer currently 
covering 4.5 million beneficiaries who are primarily living in the central, eastern and western 
parts of the Netherlands. Detailed information about (a predecessor of) this database has 
been published in an earlier study [14]. 
 We identified all patients that received an in- or outpatient hospital treatment for chronic 
heart failure between 1 January 2008 and 31 December 2010. We selected all patients with a 
claim containing specialism code 320 (cardiology) and diagnostic code 302 (chronic heart 
failure). We verified the correctness of this selection criterion with a cardiologist in our 
hospital. Analyses were limited to patients that were insured at the insurer during the entire 
study period or until death. Patients younger than 18, and patients who already received 
hospital treatment for heart failure before January 1 2008 were excluded. 
 Since our inclusion period covered a time horizon of three years, some patients received 
initial hospital  treatment for heart failure in 2008 while others started heart failure 
treatment in 2009 or 2010. Therefore, years were recoded relative to the initial hospital 
treatment for heart failure. This enabled analysis of data relative to the first presentation of 
heart failure in hospitals (see figure 1).  
FIGURE 1  Timeline used to recode time relative to initial heart failure treatment.
 
 
 
 
 
 
 
 
Baseline year:  
Two years prior initial 
CHF-diagnosis 
Index year: 
Year of initial CHF-
diagnosis 
Follow-up: 
Till maximum 7 years 
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Of each selected patient, all claims with a starting date between 1 January 2006 and 31 
December 2014 were extracted. Pharmaceutical claims contained Anatomical Therapeutic 
Chemical (ATC) class codes, which were aggregated to ATC level 2. In addition, several 
beneficiary characteristics were obtained from the insurer’s databases, including gender, 
date of birth, and date of death. Zip-codes (first four digits) were obtained to subsequently 
derive socio-economic status based on income estimates (appendix 1).
Variables 
Literature was searched to identify factors known to affect the progression, prognosis 
and healthcare utilization of patients with heart failure [10,15,16]. Appendix 1 shows which 
variables were identified, and how the variables were operationalized in the present study. 
Polypharmacy was defined as receiving five or more prescription medications (ATC level 
2) within a period of three months. We averaged this over a one year period to account for 
incidental medication [17]. Excessive polypharmacy was defined similarly for receiving at 
least ten prescription medicines. 
 We developed two measures to establish multimorbidity. Hospital DRGs in the 
Netherlands contain specialism and diagnosis codes, and we used these to categorize the 
claims according to ICD-10 (sub)chapters (e.g. ICD10-chapter IX: diseases of the circulatory 
system; and ICD10-subchapter I60-I69 cerebrovascular diseases). We summed all ICD-10 
subchapters to establish a hospital-DRG-based multimorbidity measure. Second, we used 
pharmaceutical claims to establish chronic conditions based on a validated set of ATC-codes 
[18]. We summed al chronic conditions to establish a drug-based multimorbidity measure. 
 We used hospital claims to create dichotomous variables for heart related admissions 
and surgical interventions. Time since first hospital treatment for heart failure, previous 
healthcare expenditures and end-of-life period have all been identified as important cost 
drivers  [19-21] and were included as well.
 We combined chronic conditions derived from pharmaceutical claims and ICD-10 
subchapters derived from hospital claims to establish dichotomous variables for specific 
conditions. Hospital claims and claims from specialized mental health institutions were 
combined to establish indicators for mental health care use.
Analyses
For each year, we determined the percentage of patients that incurred top-1% or top 
2-5% costs. Descriptive analyses were performed to describe the characteristics of our 
study population at the index year (t=0). The analyses were performed separately for the 
hierarchical spending groups (top 1%, top 2-5%, and bottom 95% patients).
Longitudinal healthcare utilization and persistency of high costs
Descriptive analyses were used to analyze the longitudinal healthcare utilization per 
healthcare domain for the entire cohort, and per hierarchical spending group. The level 
of healthcare utilization during the index year (t=0) determined whether a patient was 
categorized to the top 1% , top 2-5%, or the bottom 95% subgroup for this analysis. In the 
following analyses all repeated measurements (t≥0) were our unit of analysis. We determined 
the percentage of top-1% and top-5% high-cost years, and identified the percentage of high-
cost years that occurred consecutively. 
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Drivers of high costs
We used logistic generalized estimating equation (GEE) models to determine which 
factors were associated with high costs, while taking into account the clustering of 
repeated measurements within patients. We used GEE models  with an exchangeable 
working correlation structure to account for this clustering [22]. In these analyses, repeated 
measurements (per year) were our unit of analysis; all follow-up years (t≥0) were analyzed. 
Our aim was to identify all factors significantly associated with high costs. Two types of 
dichotomous outcomes were analysed in separate models: 1) the top 1% as opposed to the 
lowest 99% cost years, and 2) the top 5% high cost years as opposed to the lowest 95% 
cost years. As independent variables we used all predictors, including demographics, 
disease specific variables, excessive polypharmacy, previous top-1%/top-2-5% healthcare 
utilization, heart related admission, heart related surgery, times since initial heart failure 
treatment in years, quarter of dying. All continuous variables were tested for the assumption 
of linearity and categorized if linearity could not be assumed. Backward selection was 
performed manually on basis of the type 3 significance tests (p<0.05), which is based on 
likelihood ratio statistics (PROC GENMOD in SAS). Associations were expressed as odds 
ratio’s (OR) and 95% confidence intervals (95% CI). To determine the performance of the 
models, area under the curve (AUC) was assessed. 
 All analyzes were performed using SAS 9.4. 
Results 
Table 1 gives an overview of the repeated measurements (years) in our study. There were 25.372 
unique patients with heart failure in our study. The percentage of patients that incurred 
top-1% or top-2-5% costs steadily increased until the index year (t=0). In the index year, the 
percentage incurring high costs was highest. From t=2 and onwards the percentage that 
incurred high costs levelled: 7% incurred top-1% costs, and 20% incurred top-2-5% costs. 
TABLE 1  The percentage of top-1% and top-2-5% patients in each of the study years.
1   Since our inclusion period covered a time horizon of three years, some patients received initial 
hospital  treatment for heart failure in 2008 while others started heart failure treatment in 2009 
or 2010. Therefore, years were recoded relative to the initial hospital treatment for heart failure.
 Year1 -4 -3 -2 -1 0 1 2 3 4 5 6
Total number  
of patients
8976 17327 25372 25372 25372 23714 21792 20133 18368 10859 4747
Top-1% 3% 4% 5% 7% 16% 9% 7% 7% 7% 7% 7%
Top-2-5% 13% 14% 16% 19% 34% 23% 22% 21% 20% 21% 20%
Bottom-95% 84% 82% 80% 74% 49% 68% 71% 72% 73% 72% 73%
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Characteristics during the index-year
Table 2 shows the characteristics for the three spending groups during the index year 
(t=0). More than half of the cohort incurred top 1% or top 2-5% costs. Top 1% patients were 
younger and the top 2-5% patients were older than those in the bottom 95%. Despite the 
difference (5.2 years) in age between the top 1% and the top 2-5% group, survival rates were 
similar. The rate of excessive polypharmacy was three times higher in the top-1% and top-2-
5% groups than in the low-cost group. Most variability was observed in our multimorbidity 
measure based on hospital services: top 1%, top 2-5% and bottom 95% patients were 
treated for respectively 6.6, 4.9, and 2.9 ICD10-subchapters respectively. In addition, the 
three groups differed in their use of heart-related surgeries and admissions. The percentage 
admitted to the hospitals was four times higher in the top 1% group than in the bottom 
95% group. Heart related surgeries were performed in 54% of top 1% patients. Not shown 
in the table: remaining top 1% patients differed in many aspects, most notably in their rate 
and intensity of mental health and pharmaceuticals use, and rates of chronic conditions and 
multimorbidity. They incurred 15.5% lower average costs.  
TABLE 2   Characteristics of patients in hierarchical spending groups in the index year and survival 
after initial heart failure treatment.
Bottom 
95%
Top 
2-5%
Top 
1%
Demographics
Percentage of total cohort 49.2% 34.5% 16.3%
Mean age in years 73.5 75.8 70.6
Gender = male 50% 48% 60%
Socioeconomic status = low 48% 51% 49%
Generic indicators of care needs
Mean number of chronic conditions 3.1 4.2 4.4
Mean number of ICD-10 subchapters 2.9 4.9 6.6
Percentage polypharmacy (≥ 5 medications) 71% 90% 91%
Percentage excessive polypharmacy (≥ 10 medications) 11% 32% 36%
Percentage surgery (heart-related) 0.2% 10% 54%
Percentage admission (heart-related) 20% 65% 82%
Prevalence of conditions
Anemia 6% 15% 20%
Cardiac arrest and arrhythmias 12% 20% 29%
Chronic lung disease 28% 41% 38%
Dementia 1% 4% 5%
Depression, anxiety and sleep disorders 12% 22% 25%
Diabetes 19% 30% 32%
Diseases of arteries, veins and lymphatic vessels 6% 12% 20%
Gout 5% 9% 10%
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Hyperlipidimia 47% 51% 63%
Influenza, pneumonia or use of antibacterials 24% 46% 51%
Ischemic heart disease 9% 21% 36%
Kidney failure 2% 7% 13%
Neoplasms 14% 23% 25%
Pain 12% 24% 29%
Psychosis 2% 6% 7%
Thyroid disorders 7% 9% 8%
Valve disorders 4% 7% 12%
Adjustment and management of devices, cardiac rehabilitation 
and others 
1% 3% 12%
Follow-up services after surgery 6% 12% 41%
Survival in years after the day of initial heart failure treatment   1 94% 85% 84%
2 90% 76% 75%
3 84% 67% 69%
4 78% 59% 62%
5 72% 51% 54%
Longitudinal healthcare utilization 
Figure 2 shows the average total costs over time for the full cohort of patients, and separately 
for survivors (those alive at the latest year with cost data). The overall patterns of utilization 
were similar. Highest average costs were found during the index year. The average cost per 
patient increased between t=-2 to t=0, and this increase was mainly driven by increasing 
hospital costs. After the year of initial heart failure treatment, costs quickly declined 
and stabilized at a level that was significantly higher than in the years prior initial heart 
failure treatment. Hospital costs were the predominant cost drivers in all years, followed 
by pharmaceutical costs. Not shown in the figure is that at any individual year, decedents 
incurred 90% higher costs than remaining patients in that year. The overall average costs in 
figure 2 are similar because in each year ≈10% of patients die.   
 
 
FIGURE 2  Average costs for survivors and the total cohort.
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Appendix 2 shows the same healthcare utilization patterns, but for the three hierarchical 
spending groups separately. Groups were based on healthcare utilization during the index 
year. During the index year, average costs in the top 1% group (€ 48.120) were ten times as 
high compared to the bottom 95% group (€ 4.627). Top-1% incurred higher costs in each 
healthcare domain at any moment. This difference in total costs between the hierarchical 
spending groups was mainly driven by differences in hospital costs. The top 1% group 
experienced a remarkable increase of mental health care costs during the index year.  
Persistency of high costs 
Figure 3a and 3b show the persistency of high costs after first heart failure treatment (t≥0) 
for top 5% and top 1% utilization respectively. The height of the bars (y-axis) indicate the 
percentage of the cohort incurring a certain number of high-cost years (x-axis). Colour 
saturation shows the proportion of high-cost years which occurred consecutively. While 
more than 90% of the population incurred at least one top 5% year during follow-up, only 
31.8% incurred at least one top 1% year. Furthermore, 57.0% incurred multiple top 5% years 
whereas only 8.6% incurred multiple top 1% years. In addition, top 5% years were more 
frequently consecutive than top 1% years. 
 
FIGURE 3   Frequency and persistency of high-cost years during follow-up period (t≥0). For example, 
figure 3a shows that 22% of the cohort had two top 5% years: 12% experienced two 
consecutive top 5% years, and 10% experienced two non-consecutive top 5% years. 
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3B: top 1% high-cost years. 
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Drivers of high costs 
GEEs were performed for top 1% or top 5% high-cost years compared to bottom 99% and 
bottom 95% years, respectively. As explained above, all repeated measurements (t≥0) were 
our unit of analysis. Of the 125.166 follow-up years included in this study, 11.483 (9.2%) and 
30.056 (24.0%) were top 1% and top 2-5% high-cost years, respectively. 
 Table 3 shows the estimated odds ratios (OR) for our final models. Younger groups were 
more likely to incur top 1% costs. Excessive polypharmacy, high costs in the previous year, 
and end-of-life periods were all predictive of top 1% and top 5% costs. Heart related surgeries 
and heart related admissions showed highest OR’s. In year one and two after initial heart 
failure treatment the odds of high costs were decreased, and in the following years the odds 
of high costs increased. Influenza was a specific disease with a high OR for high costs as well 
as a high prevalence among high-cost patients (see table 2). 
TABLE 3  Odds Ratios for high cost years derived from GEE estimates: Diseases specific model. 
Top 1% year Top 5% year
Variables OR (95% CI) OR (95% CI)
Gender male ref=female 1.17 (1.11-1.24) NS
Age 60-69 0.86 (0.78-0.94) 1.00 (0.93-1.07)
Ref=18-59 70-79 0.71 (0.65-0.78) 1.05 (0.98-1.12)
80-89 0.41 (0.38-0.46) 0.93 (0.87-0.99)
≥90 0.23 (0.20-0.27) 0.73 (0.67-0.79)
Socioeconomic status Average NS 0.93 (0.89-0.98)
Ref = high Low NS 0.99 (0.95-1.03)
Excessive polypharmacy 1.56 (1.47-1.66) 1.95 (1.88-2.03)
Heart related surgery 22.00 (20.08-24.09) 65.08 (51.16-82.80)
Heart related admission 2.38 (2.22-2.55) 6.77 (6.45-7.11)
Time since heart failure treatment in years 
Ref= 0 (year of initial hospital treatment)
1
2
0.57 (0.52-0.61)
0.80 (0.75-0.87)
0.56 (0.52-0.59)
0.79 (0.75-0.83)
3 1.16 (1.07-1.25) 0.97 (0.92-1.01)
4 1.63 (1.50-1.77) 1.15 (1.09-1.21)
5 1.62 (1.47-1.78) 1.19 (1.12-1.27)
Quarter of dying
Ref=0 (survived entire year)
1
2
0.37 (0.28-0.48)
0.98 (0.83-1.16)
0.41 (0.36-0.47)
1.23 (1.10-1.38)
3 1.83 (1.59-2.10) 2.33 (2.08-2.60)
4 2.82 (2.52-3.15) 3.93 (3.55-4.35)
Top 1%  in the previous year 3.51 (3.21-3.84) 3.04 (2.87-3.22)
Top 2-5% in the previous year 1.76 (1.67-1.86) 1.74 (1.67-1.81)
Disease specifc variables
Anemia 1.66 (1.55-1.77) 1.94 (1.85-2.04)
Cardiac arrest and arrythmias 0.91 (0.85-0.98) NS
Chronic lung disease NS 1.38 (1.33-1.43)
Dementia 1.90 (1.66-2.18) 2.27 (2.03-2.52)
Depression, anxiety and sleep disorders 1.34 (1.25-1.43) 1.44 (1.37-1.51)
Diabetes 1.13 (1.07-1.20) 1.40 (1.35-1.45)
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Diseases of arteries,  
veins and lymphatic vessels
2.26 (1.09-2.46) 1.93 (1.80-2.06)
Gout 1.15 (1.06-1.24) 1.21 (1.15-1.28)
Influenza, pneumonia  
or use of antibacterials
1.81 (1.72-1.90) 2.04 (1.97-2.10)
Ischemic heart disease 0.74 (0.68-0.81) NS
Kidney failure 2.11 (1.90-2.34) 2.10 (1.93-2.28)
Neoplasms 1.70 (1.59-1.82) 2.00 (1.91-2.10)
Pain 1.60 (1.51-1.69) 1.87 (1.80-1.94)
Psychosis 1.32 (1.19-1.47) 1.41 (1.31-1.53)
Valve disorders 1.44 (1.31-1.60) NS
Adjustment and management of devices, cardiac 
rehabilitation, and others 
1.26 (1.10- 1.44) 1.33 (1.12-1.58)
Follow-up services after surgery NS 0.71 (0.67-0.76)
AUC 0.87 0.85
NS: Some variables were excluded in the backward selection process in the model for top-1% and 
not for the top-5%, and vice versa. 
Discussion
In this study, we explored the longitudinal healthcare utilization and the persistency of 
high costs in patients with heart failure. Furthermore, we determined the characteristics of 
patients with heart failure and high costs, and identified drivers of high costs. Our findings 
revealed that the difference in costs between the three groups was mainly driven by hospital 
costs. In addition, the top 1% group experienced a remarkable increase of mental health 
costs during the index year. More than 90% of the population incurred at least one top 
5% year during follow-up, and 31.8% incurred at least one top 1% year. Top 5% years were 
more frequently consecutive than top 1% years. Top 1% and top 2-5% patients with heart 
failure differed from lower cost patients in their higher rate of chronic conditions, excessive 
polypharmacy, hospital admissions, and heart-related surgeries. Besides, top 1% patients 
were relatively young and elder patients were less likely to incur a top 1% year. Several of 
the disease specific variables showed significant OR’s for high costs, including anemia, 
dementia, diseases of arteries veins and lymphatic vessels, influenza, and kidney failure. 
The end-of-life period was also predictive of top 1% and top 5% costs. These results provide 
necessary information for further increasing quality of care and reducing costs for patients 
with heart failure.
Strengths and limitations 
To our knowledge, this is the first longitudinal study focusing on high-cost patients 
within a population of patients with heart failure. By using administrative data from our 
country’s largest health insurer, we created a large set of variables that covered demographic 
characteristics, chronic conditions, hospital treatments and mental health utilization. This 
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allowed us to assess which characteristics were particularly associated with high costs. Due 
to having data of multiple consecutive years, we were also able to explore the longitudinal 
healthcare utilization and persistency of high costs. One limitation was our lack of clinical 
data, data of long-term care, and individual patient data of quality of care. Such data could 
facilitate a deeper understanding of healthcare utilization, care needs and opportunities to 
intervene in patients with heart failure. 
Reflection on our findings
Our findings generally align with prior research, which supports the generalizability of 
our findings. The prevalence of most comorbid conditions such as chronic lung diseases, 
diabetes, anemia and depression were similar to previous studies [15,16,23-25], as was rate of 
mortality [26]. We found that the odds of high costs decreased in the two years following 
initial heart failure treatment, and increased in the years thereafter. This corresponds with 
the progressive nature of heart failure and associated increase of healthcare needs [10, 21]. The 
relatively high costs at initial diagnosis are surprising, and may reflect extensive diagnostic 
trajectories or time for the treatment to take effect. 
 We were the first to explore the frequency and persistency of high costs in patients 
with heart failure. Our findings indicate that top-1% utilization predominantly occurs 
incidentally and among less than a third of patients with heart failure, whereas almost 
all patients with heart failure experience at least one top 5% year, and more than half 
experience two or more top 5% years. Our breakdown of characteristics and cost drivers 
revealed the most important cost drivers in patients with heart failure. Heart-related 
surgeries contributed to the incidental high costs in 54% of top 1% patients, and the costs of 
the remaining top 1% patients were driven by mental health and pharmaceuticals use, and 
rates of chronic conditions and multimorbidity. The high frequency and persistency of top 
5% utilization point to the well-known fact that heart failure is a devastating disease with 
severe symptoms, which is often accompanied by many comorbidities and low quality of 
life, which requires intensive medical treatment.
 Our work contributes to existing literature because of our extensive inclusion of potential 
drivers for high costs. Wammes et al. and Joynt et al. argued that expensive procedures 
may be a more significant cost driver in high-cost patients than avoidable hospitalizations 
[1,3]. Our results confirm that procedures are important cost drivers in patients with heart 
failure. Besides, our findings point to a select set of key cost drivers. Such drivers include 
chronic conditions and multimorbidity, excessive polypharmacy, and mental healthcare 
needs. Furthermore, we found that decedents incurred 90% higher costs in the year they 
died. Reducing end-of-life expenditures are important targets for intervention. However, 
the benefits of interventions aimed at longer term drivers of high costs may be of more 
importance if one seeks for additional value and efficiency for these patients.      
Policy and research implications
Many initiatives to stimulate value and efficiency of care among patients with heart 
failure primarily concern reducing heart failure related re-admissions. For example, disease 
management programs at heart failure clinics have shown to improve patient well-being, 
reduce both hospitalizations and mortality, and may even save costs. Key ingredients of such 
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programs are guideline adherence and the integration and coordination of multidisciplinary 
heart failure treatment across the continuum of care, which includes treatment by 
specialized heart failure cardiologists and specialized heart failure nurses, adequate post-
discharge planning, and advance care planning in advanced heart failure [27]. 
 Our findings revealed a range of drivers for high costs that may be beyond the scope of 
such initiatives. The scope of care improvement programs may be widened to include also 
the treatment of common co-morbidities. Moreover, it is widely known that mental care 
needs are underestimated in heart failure patients and may be underserved in current health 
systems, and timed treatment, or tailored treatment for heart failure induced depression, 
might have prevented the high mental care expenditures we observed. 
 Furthermore, identified indicators may reflect overuse of care. The optimal indication 
criteria for surgical interventions tend to evolve in time, and in the Netherlands there is 
a nascent trend towards operating less in (frail) elderly. Unnecessary transaortic valve 
replacements were reduced through a multidisciplinary approach [28]. Research of medical 
practice variation has identified unwarranted variation in a range of services [29]. Especially 
near the end of life, patient preferences vary substantially and shared-decision making is 
warranted [30].   
 This study used administrative data from the perspective of patients with heart failure 
and high costs, in order to inform policy and practice. Inclusion of clinical data, patient-
reported outcome measures and of quality of care might further improve the validity 
and actionability of our findings. For example through identification of organisational 
characteristics (at hospital or health system level) or processes that are associated with 
costs, outcomes of care,  and/or unwarranted variation of care. In addition, further research 
may be needed to discern preventable spending from high-value spending in patients with 
heart failure, and further research is needed to study the effects of organisational factors 
and medical practice variation towards high costs in patients with heart failure. 
 In conclusion, our study has addressed persistently high costs and drivers of high costs 
in patients with heart failure. Comprehensive and integrated efforts are needed to further 
improve quality of care and reduce unnecessary costs. 
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Appendix 1. Definition of variables 
Variable Data source/definition
Demographics
Sex Insurance file
Age Insurance file
Date of death Insurance file
Socioeconomic status Derived from postal ZIP-code (first four digits)
Generic characteristics
Surgery by cardiologist Specialism code 320, treatment code 11-36
Surgery by cardiothoracic surgeon Specialism code 328, diagnostic code 2210-2940
Cardiology related admission Specialism code 320, setting code 3
Number of ICD10-subchapters Identified from hospital claims
Polypharmacy ≥5 prescription drugs ATC level 2
Excessive polypharmacy ≥10 prescription drugs ATC level 2
High costs in previous year Top 1%, top 2-5%  in the previous year
Time since initial heart failure treatment Initial heart failure treatment in hospital, identified 
from hospital claims
Disease specific indicators Hospital DRG-based  
(ICD-10 subchapter)
Medication-based 
(ATC code)
Anemia D50-D59 B03Ax
Cardiac arrest and arrythmias I44-I49 -
Chronic lung disease J40-J47 R03Ax or R03Bx
Dementia F00-F09 N06Dx
Depression, anxiety  and sleep disorders F30-F48 N05Bx or N05Cx or N06Ax
Diabetes E10-E14 A10Ax or A10Bx or A10X
Diseases of arteries, veins and lymphatic vessels I70-I89 -
Gout - M04A x
Heart failure I50 -
Hyperlipidimia - C10x
Influenza, pneumonia or use of antibacterials J09-J18 J01Cx  or  J01Mx
Ischemic heart disease I20-I25 -
Kidney failure N17-N19 -
Neoplasms C00-D49 L01x
Pain - N02Ax or N02Bx
Psychosis F20-F29 N05Ax
Thyroid disorders E00-E07 H03x
Valve disorders I34-I39 -
Adjusting of pacemakers, cardiac rehabilitation and 
other treatments coverder by ICD10-subchapter 
Z40-Z54 and performed by a cardiologist
Z40-Z54 and specialism 
code 320
-
Heart transplants and other treatments covered 
by ICD10-subchapter Z80-Z99 and performed by a 
 cardiologist
Z80-Z99 and specialism 
code 320
-
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Appendix 2: Cost trajectories per healthcare sector per 
hierarchical spending group. Costs in € (y-axis) over time (x-axis) 
HOSPITAL CARE INCLUDED
AVERAGE TOTAL COSTS 
HIERARCHICAL 
SPENDING 
GROUP
Bottom 
95%
Top 
2-5%
Top 
1%
HOSPITAL CARE EXCLUDED
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The studies in this thesis explored two approaches for reducing unnecessary and possibly 
harmful care – so-called low-value services – while simultaneously improving outcomes 
of care, and reducing spending. As such, this thesis was aimed at improving the fiscal 
sustainability of healthcare. The first approach aimed to track down unnecessary care and 
to identify the determinants of unnecessary care provision in Dutch healthcare; in order to 
effectively reduce unnecessary spending. The second approach encompassed an exploration 
of the characteristics and utilization of high-cost patients; the sickest patients who are 
in heaviest need for care, but who are at highest risk to receive suboptimal treatment and 
unnecessary care. Our research questions were: 
1  What are opportunities for cost-reduction through reduction of low-value services in the 
Netherlands? 
2  What are the characteristics and healthcare utilization of high-cost patients and what 
strategies do likely improve high-cost patients’ care and reduce costs?
This chapter starts by providing answers to the research questions outlined above. Next, 
several methodological considerations and lessons for future research are discussed. 
Furthermore, the implications of our research for future policy and research are discussed. 
Finally, an overall conclusion will be given. 
 This thesis was situated in the Netherlands. Chapter two gives an overview of the current 
health system of the Netherlands. 
Main findings
Opportunities for cost-reduction through reduction of low-value services 
We broke down our first research question into four sub-questions, which will be discussed 
below. 
A In which healthcare domains does low-value care typically prevail? 
This thesis was (partly) inspired by a remarkable finding in the 2012 International Health 
Policy (IHP) survey: more than half (57%) of the surveyed Dutch general practitioners (GPs) 
perceived that Dutch patients receive (much) too much medical care. Chapter three was 
aimed at understanding this figure, and to track the amount of unnecessary care across 
healthcare domains and care types through an exploratory survey among Dutch GPs. The 
surveyed GPs pointed to a remarkably consistent pattern of unnecessary service use: too 
much care is delivered in private clinics, at GP cooperatives, in hospitals, and by general 
practitioners themselves. The consensus was that patients receive too much diagnostic care, 
medical treatments, as well as too much monitoring and follow-up.  
B What are the main determinants for low-value care provision?
In chapter three we also identified a range of determinants that are associated with too much 
care provision, both in general practices as well as in other healthcare domains, including 
hospitals. The chapter demonstrated that the GPs’ demand-satisfying attitude and the 
increased availability of diagnostic facilities most saliently contribute to the provision of 
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perceived excess care in general practices. Patients tend to experience healthcare as a right 
to receive, and many GPs are willing to comply with the wishes of the patients in order to 
maintain their relationship. In addition, GPs may be willing to provide unnecessary care, 
in order prevent much more unnecessary care elsewhere (in hospitals). Moreover, our 
analysis pointed to a range of financial incentives that were associated with unnecessary 
care provision, both in general practices as in hospitals. For example, funding gaps between 
primary care and hospitals impede cooperation and coordination, and this provokes 
unnecessary care.
 Together, our findings indicate that Dutch GPs have a clear view on which of the 
treatments their patients receive may be unnecessary. Besides, our findings show GPs are 
willing to reduce unnecessary spending, but that the system is misaligned, and that the GPs’ 
ability to further improve the financial sustainability of health care may be limited. The new 
covenant for primary care has addressed some of these concerns. For example, there will 
be more time for pro-active, person-centred and integrated care for frail elderly; relevant 
stakeholders intend to establish local cooperation agreements to stimulate integrated care; 
and there will be further investments in information technology [1].   
C How to identify low-value services from clinical practice guidelines?
We developed a standardized approach to identify low-value services from medical practice 
guidelines. Chapter four describes the development of the Dutch do-not-do list (Beter-Niet-
Doen lijst). On the basis of a shortlist of search terms, a total of 1366 lower value services 
was found in 193 Dutch hospital guidelines. Of the lower value services 30% covered 
diagnostics, 29% related to surgical and medical treatment without drugs and 39% related 
to drug treatment. The majority (77%) of all low-value services was on care that should not 
be offered at all, whereas the other 23% recommended on care that should not be offered 
routinely. 
 It has often been said that due to a lack of clinical evidence, it is simply not known which 
services are of high-value, and which services should be considered low-value. This is partly 
true, it is known that for 50% of the treatments the effectiveness is unknown [2]. However, 
our findings show that for many services there is broad consensus in medical practice 
guidelines that the use of these low-value services should be very much reduced, if not 
totally abolished. 
D  How do Dutch healthcare providers deal with the entry of low-value and cost-ineffective 
services and what policy might improve this?
In chapter five we studied how cost-increasing services have entered Dutch hospitals and 
what services were displaced to accommodate the entry of these services. We interviewed 
84 professionals with various roles and responsibilities (practitioners, department chairs, 
board of directors, insurers, and others). Our findings show that it is difficult to identify the 
services that are displaced to accommodate the cost-increasing health technologies; limited 
transparency in the flow of funds within a hospital contributed to this. Besides, we found 
that the entry of new innovations and cost-containment are two parallel processes that 
are not causally linked. The way of financing is pivotal in displacement in the Netherlands. 
The budget pressure of expensive drugs seems to be linked to horizontal reallocation across 
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departments, whereas the budget pressure of remaining services seems to be linked to 
vertical reallocation within departments or divisions. Hospitals have reacted to budget 
pressures primarily through a narrowing in the portfolio of their services, and a range of other 
efficiency measures. The board of directors is central in these processes, insurers are involved 
only to a limited extent at a high level of healthcare purchasing. Capacity (constraints) and 
financing are pivotal in understanding displacement effects. 
Characteristics and healthcare utilization of high-cost patients
This part of the thesis was inspired upon the well-known fact that healthcare costs are 
heavily skewed towards a small share of high-cost patients. It is thus necessary to acquire an 
in-depth understanding of the characteristics, healthcare utilization and other factors that 
drive the costs of high-cost beneficiaries. 
 Chapter six presented our systematic review of high-cost patients’ characteristics and 
healthcare utilization, and chapter seven presented our Dutch claim database analysis on the 
same issue. Both studies showed that high-cost patients are overwhelmingly characterized 
by multiple (chronic) conditions, and that many high-cost patients suffer from mental and 
behavioural disorders. Our review highlighted that many health system characteristics 
may contribute to high costs, and that ‘preventable’ spending was estimated at maximally 
ten percent of spending. Furthermore, a considerable share (approximately 40%) of high-
cost patients persistently incurs high costs over the years. In addition, high-cost patients 
are more likely to die, and decedents are more likely to incur high-costs. However, no 
more than 30% of high-cost patients are in their last year of life. Besides, we identified a 
range of diverging cost drivers across payers and countries, which suggests that tailored 
approaches are needed for improving care and reducing costs. Our Dutch study showed that 
expensive services (expensive drugs, ICU treatment, dialysis, transplant care, DRG > €30,000) 
contributed to high costs in about a third of Dutch top 1% patients, and in less than ten 
percent of top 2-5% patients. Besides, high-cost patients were overwhelmingly treated for 
diseases of circulatory system, neoplasms, and mental disorders. Finally, in both studies we 
found that elderly are generally overrepresented in high-cost patients; but that more than 
halve of high-cost patients are younger than 65 of age, and in the Netherlands the average 
costs sharply declined with age within the top 1%.   
 We chose patients with heart failure to further study (persistency of high) utilization in 
high-cost patients. Chapter eight showed that more than 90% of patients with heart failure 
incurred at least one top 5% year, and 32% incurred at least one top 1% year. Besides, top-
1% utilization predominantly occurs incidentally, whereas more than half experience two 
or more top 5% years and the majority of these top 5% years were incurred consecutively. 
Patients with heart failure and top 1% and top 2-5% utilization differed from others in their 
higher rate of chronic conditions and multimorbidity, excessive polypharmacy, hospital 
admissions, and heart-related surgeries. In addition, the top 1% group experienced a 
remarkable increase of mental health care costs during the initial year with heart failure.
 One important empirical question is whether low-value services (first approach) or 
‘preventable spending’ is concentrated among high-cost patients (second approach). In 
chapter six we found that this was the case: Figueroa et al. found that 4.8% of US Medicare 
spending was preventable, and that high-cost patients accounted for 73.8% of preventable 
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spending [3]. Similarly, McWilliams and Schwartz found that the 17% highest-risk patients 
received twice as many low-value services (31 low-value services, detected in claims) as lower-
risk patients. However, their argument was that patient-focused strategies are not directly 
targeted towards low-value services, and as such must be substantially more effective than 
system-focused efforts intended to reduce low-value services, in order to achieve an equal 
number in the total number reduced [4]. However, this reasoning is very much dependent on 
what is considered of low-value. 
Methodological considerations
This thesis is timely in an era of increasing healthcare costs, and explores two novel 
approaches for stimulating quality of healthcare while simultaneously reducing costs. 
An interdisciplinary approach was taken through a variety of research methods, including 
survey research, document analysis, a qualitative interview study, a systematic review, and 
claim database analyses. The specific limitations of each study have already been discussed 
in each of the chapters. Below, general methodological considerations are presented. 
 One main limitation of this thesis is that it lacks a direct estimation of the prevalence 
of low-value or unnecessary care in Dutch healthcare. This is partly due to a lack of data 
with sufficient clinical detail. Furthermore, as we have shown in chapter one, there is a lack 
of agreement on how to discern low-value from high-value care, which may be partly be a 
normative rather than scientific question. Moreover, there is a general lack of evidence of 
the value of most of medical services. Additionally, the value of care may very much depend 
upon the preferences of individual patients, and such preferences are not always noted in 
electronic health records, and never available in claim databases. Finally, there is a general 
lack of data on the outcomes of care, and such data may be needed to discern low-value from 
high-value practices. 
 To overcome these difficulties, we developed alternative approaches towards low-value 
and unnecessary care in the Netherlands. We surveyed Dutch GPs as we expected that they 
would be well-positioned to overview and assess the value of care throughout the system. 
It is not possible to directly verify these assessments due to the reasons above. However, 
we were actually surprised by the degree of consistency of the observed patterns; and 
such agreement/consensus strengthens our findings. In addition, we have developed a 
standardized approach to identify low-value services from medical practice guidelines; and 
as such, measurement of low-value care is only one step ahead. 
 Our second approach encompassed an exploration of the characteristics and utilization of 
high-cost patients. Our analysis was aimed at providing a patient-centric perspective towards 
costs, and to provide a comprehensive overview of high-cost patients’ characteristics and 
utilization, in order to inform policy and intervention. The meaningfulness of such analyses 
improves when the breadth of service coverage increases, to fully understand drivers of high 
utilization across healthcare domains. One limitation of our Dutch research on high-cost 
patients is that our analyses were limited to the Health Insurance Act, as insurers argued 
that long term care data were of insufficient quality for our research purposes. Our research 
was partly aimed at overcoming this problem, and we focused our review towards studies 
that covered a broad range of services across the continuum of care at health system 
level, and excluded all studies with a narrow scope of costs and all studies with a narrow 
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population base. We prefer increasingly broad approaches in high-cost patients analyses 
above narrow approaches at local level. However, the latter analyses (see box 1, a high-cost 
patients analysis in one general hospital in the Netherlands) are also valuable on their own, 
and may actually address shortcomings of broader approaches, through their use of other 
data sources, and an increasing focus on subpopulations that were identified in the broad 
studies. Besides, local approaches may be more able to directly identify opportunities to 
intervene.     
Broader context of our findings
The fiscal sustainability of healthcare depends on numerous factors. Chapter one and two 
provided an overview of (recent reforms in) the Dutch healthcare system. This thesis should 
be interpreted in the context of a range of other trends. 
Aging and multimorbidity 
The Dutch population is aging and as a result there are more elderly at a higher average age. 
It is known that increasing age is associated with a higher prevalence of common chronic 
conditions, and that the number of chronic diseases is nearly exponentially related to 
costs [5]. Our studies also show multimorbidity is the prime driver of high costs. Besides, 
our studies actually show that multimorbidity is ubiquitous in high-cost patients, and 
that multimorbidity is not merely limited to elderly. For example, one primary subgroup of 
high-cost patients are mental health high-cost patients, and these patients are known for 
their co-morbid somatic care needs and utilization. At present, medical practice guidelines 
in the Netherlands are too much focused on one single disease. In the English NHS, a 
multimorbidity guideline was developed with the aim of reducing treatment burden and 
unplanned care, and to improve quality of life by promoting shared decision making [6]. 
As such, the aim of this guideline is to stimulate person-centred care, or care that is based 
on what is important to each person in terms of treatments, health priorities, lifestyle and 
personal goals. Multimorbidity also comes with challenges for the organization of our health 
system; as multimorbid patients are very likely to get treatments from several practitioners 
across several healthcare domains, for increasingly complex medical needs. Consequently, 
high quality of care requires coordination and integration of care across health care domains; 
as well as coordination and integration within healthcare domains.  
Evolving role of GPs in the Netherlands
Decades ago, GPs used to accompany their patients in hospitals, and used to be involved in 
in-hospital decision making; whilst anecdotal evidence tells that GPs nowadays are involved 
only to a minor extent in the care for chronic multimorbid (and high-cost) patients. In other 
words: there seems to be a gap between the GP practice and hospitals; and coordination 
and integration across healthcare domains is lacking. We have also found this in other 
research. In the 2017 International Health Policy Survey among Dutch elderly we found that 
coordination of care may be improved. Of all respondents who said that they needed help 
in the coordination of care, only 69% received help from the GP or other professional in the 
GP practice [7].  In a policy document in 2012, the professional association of GPs proposed to 
strengthen their role as coordinators and ‘guides’ in the health system [8], but the effects of 
192 Chapter 9
this proposal are unknown. In sum, in chapter three we have shown that GP’s gatekeeping 
abilities may be limited, and above we have shown that their role in the treatment of complex 
patients might be strengthened. 
Continuing innovation, concentration and specialisation
There is ever more innovation in the healthcare sector, and scientific evidence of the value 
of new innovations typically lags behind. There are thus ever more treatment alternatives 
available for which comparative benefits and costs may be largely unknown. Chapter five 
showed that many technologies enter the health system without formal assessment 
of the costs and benefits. For such innovations, there is a lack of evidence of the value of 
the treatments, and a more strict control of the entry of these innovations is warranted. 
Besides, the chapter showed that hospitals choose their particular key topics, procedures, 
or patients groups that they are willing to invest in; and that they disinvest in other services. 
There is a broad consensus that the concentration and dispersion of new technologies 
and expertise may increase quality of care, and may help guarantee the future financial 
sustainability of such innovations. However, experience in the past has shown concentration 
primarily serves organisational and professional interests, rather than quality of care [9]. For 
patients, accessibility to innovations is at stake, and from a financial perspective, increased 
concentration may result in higher prices for specialized services. 
 Parallel to this trend of concentration of specialised services is the continuing proliferation 
of scientific evidence, and the inability of professionals to keep up with the evidence base in 
the full breadth of their specialty. There is a trend towards ‘super-specialization’, which may 
come at costs of generic knowledge and competences. This may hold especially for patients 
with multimorbidity (and high costs) in an aging population. The Dutch Federacy of Medical 
Specialists has proposed to bend this trend (they aim to educate more ‘generalists’) [10], but 
the effects of this proposal remain to be seen. 
Routine data collection and learning health systems
There is ever more data, and routinely collected data are used more and more to inform 
healthcare service provision and policy. In the United States, routinely collected data have 
been used to identify low-value services to stimulate the systematic reduction in use of 
services (deimplementation) [11]. Chapters seven and eighth are also examples of such work. 
In addition, in the Netherlands there have been analyses of medical practice variation, and 
clinical registries are used more and more to inform practice and policy. Taken together, 
however, progress clearly lags behind its potential use. In the Netherlands, there is a general 
lack in the interoperability of systems (each general practice, hospital, etc. has its own 
electronic health record system), and there are many legislative and operative hurdles for 
using the data. 
 In previous work, we have elaborated on two approaches of using routinely collected data 
to reduce unwarranted variation in the use of services [12]. Especially the ‘Shapiro-method’ 
may be applied to high-cost patients (see also below, and box 1). In this method, much 
emphasis is put on stimulating and convincing the professionals. Central to projects is a 
physician champion, a professional with high esteem who is being coached and supported 
by data-analysts and experts. Physicians are in the lead to adapt analyses, in order to discern 
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warranted from unwarranted variation, and to identify opportunities to intervene. In the 
context of high-cost patients, hospitals and specialists themselves may be able to segment 
and analyze their patient population, in order to reconfigure their service organisation to 
those in heaviest need. As such, this approach fits perfectly within the novel learning health 
systems paradigm, which means “A learning health system is designed to generate and 
apply the best evidence for the collaborative healthcare choices of each patient and provider; 
to drive the process of discovery as a natural outgrowth of patient care; and to ensure 
innovation, quality, safety, and value in healthcare” [13]. Routinely collected data are used 
to compensate for the drawbacks of the evidence based medicine paradigm which we have 
outlined above. The feasibility of such approaches, however, may be largely dependent upon 
local incentives, most notably a (financially) safe local environment. 
Experience with high-cost patients elsewhere
In Canada and the United States many interventions have been taken to increase the value 
of care for high-need high-cost patients [14-23], and such initiatives might inform future 
initiatives in the Netherlands. Together, evaluations point out that there is no single 
approach that outperforms others, and that activities require adaptation to local contexts 
and populations. Besides, interventions heavily rely on data and IT systems, and follow 
integrated, holistic and patient-centred approaches across the continuum of care. 
 In Canada, Community Health Links were introduced to bring together healthcare 
providers to better coordinate care [24]. Health links are voluntary, self-organizing systems 
inspired by US ACOs, and multispecialty physician networks [25,26]. It was named a ‘low rules’ 
intervention and at its implementation, the Ministry sought to find a balance between 
structure and flexibility, to allow for change through improvisation. All health links provide 
an added coordinating service that aims to increase access and bring together patients’ 
health and social care teams. It is said that participating patients all 1) have an individualized, 
coordinated care plan 2) have care providers who follow the plan 3) get support to take the 
right medications 4) are able to call a providers who knows them and is familiar with the 
personal situation. 
 In the US, ACOs appeared to reduce utilization and spending among high-cost patients 
[25]. In addition, Sherry et al examined five community-oriented programs that successfully 
improved care for high-need, high-cost patients. The five programs shared common 
attributes, including flexible financing, shared leadership, shared data, and a strong shared 
vision of commitment toward delivery of person-centered care. Other studies listed other 
sets of common attributes for successful programs, including closely targeting patients for 
intervention, comprehensive assessments of risks and needs, specially trained managers 
who facilitate coordination and communication and effective interdisciplinary teamwork 
[14,23]. One notable example is the Ambulatory Intensive Caring Unit; wherein high-cost 
patients receive all their care from a separate high-risk clinic or a high-risk team within a 
clinic. Patients no longer receive care from a primary care provider who sees both complex 
and non-complex patients, such that the entire attention of the team is focused on only a 
small number of high utilizing patients [27, 28]. Such an approach is now about to be taken in 
one hospital in the Netherlands (see box 1).
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Box 1. Bernhoven and high-cost patients 
Bernhoven reviewed the characteristics and healthcare utilization of their highest-
cost patients. In their year of analysis, the top-1% of their population accounted for 
20% of total costs. After identification of high-cost patients a sample of 55 patients 
was selected for systematic analysis. Experienced medical specialists reviewed 
patient health records, as comprehensive/integral as possible. A multidisciplinary 
team discussed the findings and discussed possible implications for practice. 
Many patients were characterized by complex and advanced stages of disease, and 
analysis pointed to a small set of shared problems across the cases, that all have to 
do with a lack of coordination of care and lack of an integral view upon the patient’s 
care needs. For some patients, the decision to proceed to a palliative trajectory posed 
problems; the geriatrician or palliative team were not involved, or too late. One 
problem was that ‘agreed on policy’ was not acted upon in practice. For example, 
patients were hospitalized against the advice of the palliative team and the patient’s 
wish, or pre-terminal patients were admitted to the intensive care unit. Patients were 
often admitted to non-dominant specialisms (for example cardiologists in patients 
with heart failure, and other minor comorbidities), and the dominant specialists 
were sometimes unaware of the admission. Furthermore, patients received contra-
indicated treatments (predominantly contra-indicated medications). In addition, 
the general practitioner was only to a limited extent involved in the treatment of 
the patient. He/she receives many letters from the hospital, but patients were not 
visiting to the GP anymore when they go to the hospital often. 
Based on this information, Bernhoven is about to open a separate high-risk clinic for 
high-need high-cost patients (all patients following specific criteria ). A generalist 
(either a internist-geriatrician, or geriatrician) and specialized nurse will run the 
clinic. Patients will no longer be followed routinely by remaining specialists, but the 
generalist is very much in control and is the one to request additional consultation 
if needed. The generalist will actively cooperate with the general practice, and 
palliative team. 
Implications for policy and practice 
Based on the broader context and our research findings, we drafted the following 
recommendations for policy and practice. Some recommendations are new for the 
Netherlands, and some build on ongoing initiatives that can be accelerated or extended. 
All recommendations should be interpreted as broad directions for policy that need further 
validation. 
Societal level:
-  To support integrated care for complex patients, data systems need to be improved, 
so that practitioners can get a complete insight into the healthcare use and medical 
records of patients. In the short term this requires interoperability of regional health 
records; in the longer term a national health record or personal health environment could 
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provide for this. The facilities must also be able to communicate a patient’s care plan, 
and the patient’s perspective on his or her life. Such data systems may also facilitate the 
identification of low-value services.
-  It is important that much more attention is paid to regional coordination and cooperation 
between the different levels (vertical networks), such as university medical centres, top 
clinical hospitals, general hospitals, general practices, allied healthcare, and the social 
domain. This also requires guidance from health insurers who can play a mediating role 
here.
-  At the national level, more attention is warranted to the theme of multimorbidity. To 
support general practitioners (who are too busy, and may have insufficient knowledge 
and facilities) and geriatricians (specialists of the elderly and geriatric syndromes, not 
multimorbidity in particular), more generalists need to be trained, such as ‘hospital 
doctors’ or ‘multimorbidity doctors’ [29]. In addition, more attention should be paid to 
multimorbidity in new (or updates of) medical practice guidelines. In addition, a separate 
multimorbidity guideline could be developed for hospital specialists, in accordance with 
the guideline in the English NHS. Based on this guideline, doctors are able to not comply 
with disease-specific guideline recommendations, if necessary.
-  The ‘open’ benefit package for non-pharmaceutical innovations could be more ‘closed’, to 
prevent widespread use of questionable services that lack a solid evidence base, such as 
Da Vinci surgery. Stakeholders could cooperate more, to ‘guide’ the introduction of new 
innovations. For example, minimum quality requirements could be established. Coverage 
with evidence development could also be used for non-pharmaceuticals. Although health 
insurers increasingly pay attention to the entry of innovations, a more active purchasing 
policy seems justified.
Local/regional level:
-  Our do-not-do list has been integrated in the website that presents all medical practice 
guidelines to medical specialists. In addition, in the development of new medical practice 
guidelines attention is being paid to define new do-not-do recommendations, in order 
to stimulate disinvestment of such activities. To further stimulate deimplementation, 
the value of treatments could be discussed much more, and much more critically at local 
levels. Insurers might opt to stop funding low-value services.   
-  Patient selection for major procedures or expensive medicines can be improved, not 
only in the elderly. There are several options for this, including geriatric screening, or 
multidisciplinary decision-making which helps to prevent seeking ‘the edges of the 
indication criteria’ or that the treatment choice does not match the preferences of the 
patient.
-  Individual providers, such as general practitioners, hospitals (or their departments), may 
analyze and segment their top 1% or top 5% patient population themselves, to inform 
policy and practice. An analysis based on administrative claims may be sufficient for this. 
However, such analyses can also be performed bottom-up, by implementing the 5x5x5 
method. A provider identifies five random patients with particularly high healthcare costs 
(costs are included as widely as possible) and analyzes as comprehensive as possible (in 
an integrated way, from multiple angles, all treating professionals, the patient, informal 
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carer) and as accurately as possible what the care process of these patients looked like, 
what went well and what could have gone better. On the basis of the first five cases, 
shared problems are identified and improvement measures can be taken. Later on, the 
project can be repeated but for 25 patients and later for 125 patients. Box one shows how 
Bernhoven has applied this method and what steps they took on basis of their findings. 
This is a perfect solution in a search for horizontal integration, alignment of care within 
one organisation or organisational level. Patients with multimorbidity are diverse 
populations, which requires flexibility in the organisation of their services to organize the 
care according to their particular needs.
-  More attention should be paid to high quality transitional care for hospitalized patients. 
This is currently lacking, partly because the responsibility for this is not clearly stated. 
Activities such as the ‘Transmurale zorgbrug’ could be scaled up, and may also be 
extended beyond frail elderly. GPs primarily play a role stepped-down for these patients, 
for organizing and providing good post-discharge care. In addition, GPs may find their 
way back into the hospital, to accompany their patients as authoritative advisor in 
complicated treatment decisions, in order to stimulate treatment decisions that best fit 
with the patient’s preferences and social context.
-  GPs and medical specialists might receive additional training for the treatment of 
complex patients. Training might be developed according to the ‘Ariadne’ principles , 
‘collaborative goal setting’, and shared decision making [30-33]. In the care of vulnerable 
patients, multiple professionals are involved and irrevocably, problems arise with 
respect to the mutual division of responsibilities. It is important that such issues are 
acknowledged and that professionals agree on a set of processes about how to deal with 
the patients. This includes informing each other much more, and more (multidisciplinary) 
discussion about the appropriateness of alternative treatment options.
Implications for future research
This thesis has provided a solid base for deimplementation projects, and the evaluation of 
these projects might powerfully inform larger projects at the national level. Further research 
is needed to identify low-value services in practice, preferably on the basis of routinely 
collected data. In addition, as the identification of low-value care is only one of several 
necessary steps, more research is needed on how to effectively reduce low-value services. 
Future approaches might consider to combine current approaches with financial incentives. 
 Above we suggested that patient selection for major procedures or expensive medicines 
might be improved through geriatric screening, or multidisciplinary decision-making. 
One notable example of this is the AGE-CRC-study, that aims to develop a pre-operative 
prediction-model in order to prevent under- and overtreatment in colon cancer [34]. Similarly, 
a multidisciplinary approach proved to reduce inappropriate transaortic valve replacements 
[35]. Alternatives such as patient selection by a professional that is not the surgeon may 
conflict with the professional autonomy of doctors. Further research is needed to determine 
feasibility of such measures, and if such measures can contribute to keeping healthcare 
affordable and reduce unnecessary treatments.
 We have shown that multimorbidity is a prime driver of high costs, that multimorbid 
patients are likely to incur high hospitals costs, and that these patients may benefit from 
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person-centred and integrated healthcare. Future studies might investigate whether 
integrated care models within the hospital, or with the hospital as a locus (box 1 shows one 
example of an integrated care initiative with the hospital as a locus), may contribute to 
keeping healthcare affordable. Above we argued that there is a need for more vertical as well 
as horizontal integration. Further research is needed to investigate how such networks are 
best developed and what (contextual) factors stimulate or discourage the process of efficient 
network development. 
 We have also shown that care improvement programs need adaptation to local contexts 
and populations, and that such programs follow integrated approaches across the continuum 
of care. Data and IT systems can be used to identify target populations, to align providers 
and provide them with reference data, and to inform the continuous development of the 
program. Zulman et al recently published about partnered research in healthcare delivery 
redesign for high-cost patients. In this approach researchers firstly analyze healthcare use 
and characteristics of high-cost patients, and perform stakeholder need assessments to 
inform the redesign of healthcare delivery [36]. Canadian work showed that complex adaptive 
systems (CAS) theory may have strong potential to understand and support policy design 
and implementation. The theory views healthcare as numerous subsystems characterized 
by diverse agents that interact, self-organize, and continuously adapt; and is used to 
describe systems that cannot be understood in their entirety as a result of many interacting 
variables and forces. As such, it is useful for understanding the implementation of integrated 
networks. According to complex adaptive systems theory, initiatives should enhance scope 
for new interconnections, sensemaking, self-organization, emergence, and co-evolution 
[24]. More generally, in learning health systems, patient segmentation analysis about the 
characteristics in healthcare utilization of high-cost patients may be pivotal [37], and there 
is a need for interdisciplinary work using a variety of both quantitative and qualitative 
research. Such qualitative work is needed to provide quantitative analysis with the right 
context and processes, to align stakeholders, and to further inform future quantitative work. 
Conclusion
In this thesis we explored two approaches for reducing unnecessary and low-value care while 
simultaneously improving outcomes of care, and reducing spending. An interdisciplinary 
approach was taken through a variety of research methods, including survey research, 
document analysis, a qualitative interview study, a systematic review, and claim database 
analyses. Our results show that that there is ample room for quality improvement and cost 
reduction. For low-value services, continuing reassessment and discussions are needed to 
identify those services that may be of little value, and to inform concomitant policy and 
intervention, in order to reduce unnecessary spending. A myriad of policy alternatives are 
available for redesigning our health system according to the needs of the patients in heaviest 
need for high-quality healthcare, and to reduce unnecessary spending. Both approaches are 
best informed through multidisciplinary research, that include both quantitative as well as 
qualitative work and engagement of professionals to inform local redesign.  
198 Chapter 9
References
1 Landelijke Huisartsenvereniging (LHV), InEen (vereniging van organisaties voor 
eerstelijns zorg), Patiëntenfederatie Nederland, Zorgverzekeraars Nederland 
(ZN), De minister voor Medische Zorg en Sport (VWS). Onderhandelaarsakkoord 
huisartsenzorg 2019 t/m 2022. 2018.
2 Garrow JS. What to do about CAM: How much of orthodox medicine is evidence 
based? BMJ. 2007;335(7627):951.
3 Figueroa JF, Joynt Maddox KE, Beaulieu N, Wild RC, Jha AK. Concentration of 
Potentially Preventable Spending Among High-Cost Medicare Subpopulations: An 
Observational Study. Annals of internal medicine. 2017.
4 McWilliams JM, Schwartz AL. Focusing on High-Cost Patients – The Key to Addressing 
High Costs? The New England journal of medicine. 2017;376(9):807-9.
5 Lehnert T, Heider D, Leicht H, Heinrich S, Corrieri S, Luppa M, et al. Review: health care 
utilization and costs of elderly persons with multiple chronic conditions. Medical 
care research and review : MCRR. 2011;68(4):387-420.
6 NICE. Multimorbidity: clinical assessment and management. 2016.
7 Wammes JJG, van der Wees P, Westert GP. International Health Policy Survey 2017. 
Onderzoek onder 65-plussers in 11 landen. Nijmegen: Scientific Institute for Quality in 
Healthcare (IQ healthcare), Radboudumc; 2017.
8 NHG, LHV. Toekomstvisie huisartsenzorg 2022. 2012.
9 Zuiderent-Jerak T, Kool T, Rademakers J. De relatie tussen volume en kwaliteit van 
zorg: tijd voor een brede benadering. Utrecht/Nijmegen/Rotterdam.: Consortium 
onderzoek kwaliteit van zorg; 2012.
10 Federatie medisch specialisten. Visiedocument Medisch Specialist 2025 Utrecht; 2017.
11 Schwartz AL, Chernew ME, Landon BE, McWilliams JM. Changes in Low-Value Services 
in Year 1 of the Medicare Pioneer Accountable Care Organization Program. JAMA 
Intern Med. 2015;175(11):1815-25.
12 Wammes JJG, Atsma F, de Man Y, Groenewoud S, Westert GP. De zorg is niet overal 
hetzelfde; het reduceren van ongewenste verschillen in kwaliteit en kosten in 
Nederland?.  Betaalbare zorg. Nijmegen: Celsus academie voor betaalbare zorg; 2018.
13 Institute of Medicine (US). Roundtable on Evidence-Based Medicine, the Learning 
Healthcare System: Workshop Summary. Washington (DC): National Academy Press 
(US); 2007.
14 Anderson GF, Ballreich J, Bleich S, Boyd C, DuGoff E, Leff B, et al. Attributes common 
to programs that successfully treat high-need, high-cost individuals. American 
Journal of Managed Care. 2015;21(11):e597-e600.
15 Blumenthal D, Abrams MK. Tailoring Complex Care Management for High-Need, 
High-Cost Patients. Jama. 2016.
16 Blumenthal D, Chernof B, Fulmer T, Lumpkin J, Selberg J. Caring for High-Need, 
High-Cost Patients – An Urgent Priority. The New England journal of medicine. 
2016;375(10):909-11.
17 Brown RS, Peikes D, Peterson G, Schore J, Razafindrakoto CM. Six features of Medicare 
coordinated care demonstration programs that cut hospital admissions of high-risk 
patients. Health affairs. 2012;31(6):1156-66.
General discussion 199
18 Gawande A. The hot spotters: can we lower medical costs by giving the neediest 
patients better care? The New Yorker. 2011.
19 Hong CS, Siegel AL, Ferris TG. Caring for high-need, high-cost patients: what makes 
for a successful care management program? Issue brief. 2014;19:1-19.
20 Sherry M, Wolff JL, Ballreich J, DuGoff E, Davis K, Anderson G. Bridging the Silos 
of Service Delivery for High-Need, High-Cost Individuals. Population health 
management. 2016.
21 Vrijhoef B, Thorlby R. Developing care for a changing population: supporting patients 
with costly, complex needs. Nuffield Trust; 2016.
22 Bleich SN, Sherrod C, Chiang A, Boyd C, Wolff J, DuGoff E, et al. Systematic Review of 
Programs Treating High-Need and High-Cost People With Multiple Chronic Diseases 
or Disabilities in the United States, 2008-2014. Prev Chronic Dis. 2015;12:E197.
23 Blumenthal D, Anderson G, Burke SP, Fulmer T, Jha AK, Long P. Tailoring Complex-Care 
Management, Coordination, and Integration for High-Need, High-Cost Patients, 
2016.; 2016.
24 Grudniewicz A, Tenbensel T, Evans JM, Steele Gray C, Baker GR, Wodchis 
WP. ‘Complexity-compatible’ policy for integrated care? Lessons from the 
implementation of Ontario’s Health Links. Soc Sci Med. 2018;198:95-102.
25 Hsu J, Price M, Vogeli C, Brand R, Chernew ME, Chaguturu SK, et al. Bending The 
Spending Curve By Altering Care Delivery Patterns: The Role Of Care Management 
Within A Pioneer ACO. Health affairs. 2017;36(5):876-84.
26 Stukel TA, Glazier RH, Schultz SE, Guan J, Zagorski BM, Gozdyra P, et al. Multispecialty 
physician networks in Ontario. Open Med. 2013;7(2):e40-55.
27 Milstein A, Gilbertson E. American medical home runs. Health affairs. 2009;28(5):1317-26.
28 Bodenheimer T. Strategies to Reduce Costs and Improve Care for High-Utilizing 
Medicaid Patients: Reflections on Pioneering Programs. Centre for Health Care 
Strategies; 2013.
29 Plochg T, Keijsers JF, Levi MM. [The ‘multimorbidity generalist’ is the future]. Ned 
Tijdschr Geneeskd. 2012;156(42):A5515.
30 Vermunt N, Harmsen M, Westert GP, Olde Rikkert MGM, Faber MJ. Collaborative goal 
setting with elderly patients with chronic disease or multimorbidity: a systematic 
review. BMC Geriatr. 2017;17(1):167.
31 Bower P. Better management of multimorbidity: a critical look at the ‘Ariadne 
principles’. BMC Med. 2014;12:222.
32 Muth C, van den Akker M, Blom JW, Mallen CD, Rochon J, Schellevis FG, et al. The 
Ariadne principles: how to handle multimorbidity in primary care consultations. BMC 
Med. 2014;12:223.
33 Prados-Torres A, Del Cura-Gonzalez I, Prados-Torres JD, Leiva-Fernandez F, Lopez-
Rodriguez JA, Calderon-Larranaga A, et al. [Multimorbidity in general practice and the 
Ariadne principles. A person-centred approach]. Aten Primaria. 2017;49(5):300-7.
34 IKNL, Prospectief Landelijk CRC cohort (colon cancer). AGE-CRC-studie: betere 
kwaliteit van leven voor ouderen met darmkanker 2017 [Available from: https://www.
iknl.nl/over-iknl/nieuws/nieuws-detail/2017/11/13/age-crc-studie-betere-kwaliteit-
van-leven-voor-ouderen-met-darmkanker.
200 Chapter 9
35 Schoon Y, de Boer M, Olde Rikkert M. Niet elke oudere heeft baat bij nieuwe hartklep. 
2015.
36 Zulman DM, Ezeji-Okoye SC, Shaw JG, Hummel DL, Holloway KS, Smither SF, et al. 
Partnered research in healthcare delivery redesign for high-need, high-cost patients: 
development and feasibility of an Intensive Management Patient-Aligned Care Team 
(ImPACT). J Gen Intern Med. 2014;29 Suppl 4:861-9.
37 Vuik SI, Mayer EK, Darzi A. Patient Segmentation Analysis Offers Significant Benefits 
For Integrated Care And Support. Health affairs. 2016;35(5):769-75.
 201
Summary
The studies in this thesis explored two approaches for reducing unnecessary and possibly 
harmful care – so-called low-value services – while simultaneously improving outcomes 
of care, and reducing spending. As such, this thesis was aimed at improving the fiscal 
sustainability of healthcare. Our research questions were: 
1  What are opportunities for cost-reduction through reduction of low-value services in the 
Netherlands? 
2  What are the characteristics and healthcare utilization of high-cost patients and what 
strategies do likely improve high-cost patients’ care and reduce costs?
In line with the research questions, this thesis is divided into two parts. The first part about 
low-value services and unnecessary care is covered in chapters 3-5. The second part about 
high-cost patients is covered in chapters 6-8. Chapters 1 and 2 provide necessary introductory 
information, but will not be discussed below. Below we summarize the research results of 
this thesis and its implications for policy and practice, and research. 
Chapter 3 presents an exploratory survey among Dutch GPs. We found that, according to 
Dutch GPs, patients receive too much care in general hospitals, in primary care, in GP 
cooperatives as well as in private clinics. The Dutch GPs’ demand-satisfying attitude and 
the increased availability of diagnostic facilities most saliently contribute to the provision 
of excess care at the entry point of care in the Netherlands. Also misaligned incentives 
induce that Dutch GPs may not sufficiently pick up the gatekeeping role. Our results show 
practitioners often find it difficult to deny enduring patients access to further care, even if 
they think treatment is unnecessary from a medical point of view. This creates an image of 
GPs acting in a demand-satisfying way in their referrals and treatment decisions. Besides, 
our results indicate that GPs themselves are prepared to avoid unnecessary hospital care - 
versus reducing unnecessary care in primary care - yet that the preconditions at the level 
of the health system do not meet. For example, GPs found that funding gaps between 
primary care and hospitals impede cooperation and coordination, and that this provokes 
unnecessary care. This chapter concludes that discussion and exploration by GPs and policy 
makers about the complicated and sometimes unintended effects of strengthening primary 
care and its interactions with unnecessary care may be fruitful.   
Chapter 4 describes the development of a list of lower value services identified from 193 
Dutch clinical practice guidelines, published between 2010 and 2015. In total, 1366 lower value 
services were extracted from 193 Dutch guidelines. Of the lower value services 30% covered 
diagnostics, 29% related to non-drug treatment and 39% to drug treatment. The majority 
(77%) of all low-value services was on care that should not be offered at all, whereas the 
other 23% recommended on care that should not be offered routinely. ICD10-chapters that 
included most lower value services were neoplasms and diseases of the nervous system. This 
chapter concluded that the development of a comprehensive list of lower value services and 
prioritization is only the first of several necessary steps in reducing low-value services.
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Chapter 5 shows the results of our interview study of displacement effects in Dutch 
hospitals. We studied how cost-increasing services have entered Dutch hospitals and what 
services were displaced to accommodate the entry of these services. Our findings show that 
it is difficult to identify the services that are displaced to accommodate the cost-increasing 
health technologies; limited transparency in the flow of funds within a hospital contributed 
to this. Besides, we found that the entry of new innovations and cost-containment are two 
parallel processes that are generally not causally linked. The way of financing is pivotal in 
displacement in the Netherlands. The budget pressure of expensive drugs (that amounts 
to a separate budget, not part of department budgets) is linked to horizontal reallocation 
across departments, whereas the budget pressure of remaining services is linked to vertical 
reallocation within departments or divisions. This chapter concludes that hospitals ration 
mainly in response to cumulative cost pressures, production ceilings and capacity problems, 
and that active surveillance of waiting lists is warranted to prevent waiting list driven 
morbidity.
Chapter 6 presents the results of our systematic review of high-cost patients’ characteristics 
and healthcare utilization. We used Andersen’s behavioral model to organize the findings. 
Our results indicate that across health systems and nations, a high prevalence of multiple 
(chronic) conditions consistently explain high-cost patients’ utilization. Besides, we found 
a high prevalence of mental illness across all the studies, most notably in US Medicaid and 
total population studies. We found that various health system characteristics may contribute 
to high costs, and that preventable spending was estimated at maximally ten percent of 
spending. Furthermore, we found that high costs are associated with increasing age and that 
clinical diagnoses and utilization patterns varied across age groups. However, still more than 
half of high-cost patients are younger than 65 years. High costs were associated with higher 
incomes in the US, but with lower incomes elsewhere. Finally, we confirmed that high-cost 
patients are more likely to die, and decedents are more likely to incur high-costs. However, 
no more than 30% of high-cost patients were in their last year of life. This chapter concluded 
that high-cost patients make up the sickest and most complex populations and that their 
high utilization is primarily explained by high levels of chronic and mental illness. 
Chapter 7 presents our Dutch claim database study of high-cost patients’ characteristics 
and healthcare utilization. We found that expensive treatments, most cost-incurring 
condition, and age proved to be informative variables for studying this heterogeneous 
population. Expensive care use (expensive drugs, ICU treatment, dialysis, transplant care, 
DRG > €30,000) contributed to high costs in one third of top-1% beneficiaries and in less 
than 10% of top-2-5% beneficiaries. High-cost beneficiaries were overwhelmingly treated 
for diseases of circulatory system, neoplasms, and mental disorders. More than 50% of high-
cost beneficiaries were 65 years of age or younger, and average costs decreased sharply with 
higher age within the top-1% population. This chapter concludes that high-cost patients are 
usually treated for several conditions and use care from multiple providers, and that tailored 
interventions are needed to meet the needs of high-cost beneficiaries, and to avoid waste of 
scarce resources. 
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Chapter 8 presents our claim database study of patients with heart failure and high costs. We 
found that more than 90% of patients with heart failure incurred at least one top 5% year, 
and 32% incurred at least one top 1% year. Besides, top-1% utilization predominantly occurs 
incidentally, whereas more than half experience two or more top 5% years and the majority 
of these top 5% years were incurred consecutively. Patients with heart failure and top 1% 
and top 2-5% utilization differed from others in their higher rate of chronic conditions and 
multimorbidity, excessive polypharmacy, hospital admissions, and heart-related surgeries. 
In addition, the top 1% group experienced a remarkable increase of mental health care costs 
during the initial year with heart failure. This chapter concludes that comprehensive and 
integrated efforts are needed to further improve quality of care and reduce unnecessary 
costs.
Following the results in this thesis, we drafted a range of recommendations for policy and 
practice. Below we present a selection. First of all, to support integrated care for complex 
patients, data systems need to be improved, so that practitioners can get a complete 
insight into the healthcare use and medical records of patients. Such data systems 
may also facilitate the identification of low-value services. At the national level, more 
attention is warranted to the theme of multimorbidity. We argue that there is a need for 
more generalists, and more attention to multimorbidity in medical practice guidelines. 
Furthermore, we suggest the ‘open’ benefit package for non-pharmaceutical innovations 
could be more ‘closed’, for example through coverage with evidence development for non-
pharmaceuticals. Furthermore, we argue for more (multidisciplinary) discussion about the 
value of treatments, to stimulate the deimplementation of low-value services. In addition, 
we suggest that GPs may find their way back into the hospital, to accompany their patients 
as authoritative advisor in complicated treatment decisions, in order to stimulate treatment 
decisions that best fit with the patient’s preferences and social context.
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Patiënten met hoge zorgkosten en mogelijkheden om 
onnodige uitgaven te verminderen
Dit proefschrift had als doel te onderzoeken hoe onnodige en mogelijk schadelijke zorg vast 
te stellen, om het gebruik hiervan te verminderen en de uitgaven te verminderen. Als zodanig 
was dit proefschrift gericht op het verbeteren van de betaalbaarheid van de gezondheidszorg. 
De onderzoeksvragen waren:
1  Wat zijn mogelijkheden voor kostenbeheersing door vermindering van onnodige zorg in 
Nederland?
2  Wat zijn de karakteristieken en het zorggebruik van de patiënten met hoogste zorgkosten 
en welke strategieën verbeteren de zorg voor deze patiënten en verlagen de kosten?
Dit proefschrift is verdeeld in twee delen. Het eerste deel heeft betrekking op onnodige zorg 
en wordt behandeld in hoofdstukken 3 tot en met 5. Het tweede deel gaat over patiënten met 
hoge zorgkosten en wordt behandeld in hoofdstukken 6 tot en met 8. Hoofdstukken 1 en 2 
bieden noodzakelijke inleidende informatie, maar zullen hieronder niet worden besproken. 
Hieronder vatten we de resultaten van dit proefschrift samen en bespreken we de implicaties 
voor onderzoek, beleid en praktijk.
Hoofdstuk 3 presenteert een survey-onderzoek onder Nederlandse huisartsen. Nederlandse 
huisartsen vonden dat patiënten te veel zorg ontvangen in ziekenhuizen, in de eerstelijn, 
in huisartsenposten en in privéklinieken. De vraaggerichte houding van Nederlandse 
huisartsen en de toegenomen beschikbaarheid van diagnostische faciliteiten dragen 
bij aan de verlening van onnodige zorg in de eerstelijn in Nederland. Huisartsen vinden 
het vaak moeilijk om vasthoudende patiënten de toegang tot verdere zorg te ontzeggen, 
zelfs als zij van mening zijn dat dit vanuit medisch oogpunt niet nodig is. Dit creëert een 
beeld van huisartsen die op een vraaggerichte manier handelen bij hun verwijzingen en 
behandelbeslissingen. Onze resultaten duiden er ook op dat huisartsen bereid zijn onnodige 
ziekenhuiszorg te voorkomen, maar dat zij hierin ook gehinderd worden door ontbrekende 
randvoorwaarden op het niveau van het gezondheidssysteem. Huisartsen gaven aan dat 
financieringsschotten een belemmering vormen voor samenwerking en coördinatie tussen 
de eerstelijnszorg en ziekenhuizen, met onnodige zorg als gevolg. Er is behoefte aan meer 
onderzoek naar, en discussie over de gecompliceerde en soms onbedoelde effecten van 
versterking van de eerstelijn en de interacties die dit heeft met onnodige zorg.
Hoofdstuk 4 beschrijft de ontwikkeling van de Beter-niet-doen-lijst, een lijst van 
zorghandelingen met weinig toegevoegde waarde geïdentificeerd uit 193 Nederlandse 
klinische richtlijnen, die waren gepubliceerd tussen 2010 en 2015. In totaal werden 1366 
handelingen met weinig toegevoegde waarde geïdentificeerd. Van deze handelingen betrof 
30% diagnostiek, 29% had betrekking op niet-medicamenteuze behandeling en 39% op 
medicamenteuze behandeling. De meerderheid (77%) van alle handelingen met weinig 
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toegevoegde waarde had betrekking op zorg die helemaal niet aangeboden zou moeten 
worden, terwijl de andere 23% zorg betrof die niet-routinematig moet worden aangeboden. 
ICD10-hoofdstukken met de meeste handelingen met weinig toegevoegde waarde waren 
nieuwvormingen en ziekten van het zenuwstelsel. De ontwikkeling van een lijst van 
handelingen met weinig toegevoegde waarde en prioritering hiervan is slechts een eerste 
van verschillende noodzakelijke stappen om deze handelingen te verminderen.
Hoofdstuk 5 toont de resultaten van ons interviewonderzoek naar verdringingseffecten 
in Nederlandse ziekenhuizen. We hebben onderzocht hoe kostenverhogende innovaties 
hun intrede deden in Nederlandse ziekenhuizen en welke zorg is ‘verdrongen’ om de 
intrede van de innovatie mogelijk te maken. Onze bevindingen tonen aan dat het moeilijk 
is specifieke zorghandelingen aan te wijzen die zijn verdrongen om ruimte te bieden 
aan kostenverhogende innovaties; beperkte transparantie in de geldstromen binnen 
ziekenhuizen heeft hieraan bijgedragen. Bovendien ontdekten we dat de intrede van nieuwe 
innovaties en kostenbeheersing twee parallelle processen zijn die over het algemeen 
niet met elkaar zijn verbonden. Wij vonden dat de manier van financiering cruciaal is bij 
verdringing in Nederland. De kostendruk van dure geneesmiddelen (dat een afzonderlijk 
budget vormt, geen deel van afdelingsbudgetten) is gerelateerd aan horizontale herallocatie 
tussen afdelingen, terwijl de budgetdruk van de resterende zorg is gerelateerd aan verticale 
herallocatie binnen afdelingen of divisies. Ziekenhuizen rantsoeneren voornamelijk ten 
gevolge van cumulatieve budgetdruk, productieplafonds en capaciteitsproblemen. Actieve 
monitoring van wachtlijsten is gerechtvaardigd om nadelige effecten ten gevolge van 
wachtlijsten zoveel mogelijk te voorkomen.
Hoofdstuk 6 presenteert de resultaten van ons systematisch literatuuronderzoek naar 
de karakteristieken en zorggebruik van patiënten met hoge zorgkosten. Wij maakten 
hierin een vergelijking tussen verschillende landen en zorgsystemen. We gebruikten het 
behavioral model van Ronald Andersen om de bevindingen te ordenen. Onze resultaten 
laten zien dat in alle onderzochte zorgstelsels en landen een hoge prevalentie van 
meerdere (chronische) aandoeningen consistent het gebruik van hoge kosten verklaarde. 
Bovendien vonden we een hoge prevalentie van psychische aandoeningen. We ontdekten 
dat verschillende kenmerken van het gezondheidssysteem kunnen bijdragen aan hoge 
kosten. Maximaal tien procent van de uitgaven waren ‘vermijdbaar’. Bovendien hebben we 
geconstateerd dat hoge zorgkosten geassocieerd zijn met toenemende leeftijd en dat de 
kenmerkende klinische diagnoses en patronen in zorggebruik variëren per leeftijdsgroep. 
Echter, nog steeds is meer dan de helft van patiënten met hoge zorgkosten jonger dan 65 
jaar. Hoge kosten waren geassocieerd met hogere inkomens in de VS, maar juist met lagere 
inkomens in overige landen. Tenslotte vonden we dat patiënten met hoge zorgkosten 
meer kans lopen om te overlijden, en dat overledenen vaker hoge kosten hebben. Echter, 
niet meer dan 30% van de patiënten met hoge zorgkosten was in hun laatste levensjaar. 
Patiënten met hoge zorgkosten zijn de ziekste en meest complexe populaties. Hun hoge 
zorggebruik wordt voornamelijk verklaard door een hoog niveau van chronische en 
psychische aandoeningen.
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Hoofdstuk 7 presenteert ons Nederlandse longitudinale databaseonderzoek naar de 
karakteristieken en zorggebruik van patiënten met hoge zorgkosten. We vonden dat 
dure behandelingen, de meest kostbare aandoening en leeftijd informatieve variabelen 
zijn voor het bestuderen van deze heterogene populatie. Dure zorgvoorzieningen (dure 
geneesmiddelen, ICU-behandeling, dialyse, transplantatiezorg, DBC > € 30.000) droegen 
bij aan hoge kosten bij een derde van de top 1% patiënten en bij minder dan 10% van de 
top 2-5% patiënten. Patiënten met hoge zorgkosten werden voornamelijk behandeld voor 
cardiovasculaire aandoeningen, nieuwvormingen en psychische- en gedragsstoornissen. 
Meer dan 50% van de patiënten met hoge zorgkosten was 65 jaar of jonger en de gemiddelde 
kosten daalden scherp met een hogere leeftijd binnen de top 1% groep. Patiënten met hoge 
zorgkosten worden vaak behandeld voor meerdere aandoeningen en gebruiken zorg bij 
meerdere aanbieders. Gerichte interventies zijn nodig voor het verbeteren van de zorg aan 
patiënten met hoge zorgkosten en om verspilling van schaarse middelen te voorkomen.
Hoofdstuk 8 presenteert onze databasestudie naar patiënten met hartfalen en hoge 
zorgkosten. We ontdekten dat meer dan 90% van de patiënten met hartfalen minstens één 
top 5% jaar had en dat 32% minstens één top 1% jaar had. Bovendien vonden wij dat top 
1% gebruik overwegend incidenteel plaatsvindt, terwijl meer dan de helft van de patiënten 
met hartfalen meerdere top 5% jaren ervaart. Het merendeel van deze top 5% jaren vindt 
achtereenvolgens plaats. Patiënten met hartfalen en hoge zorgkosten verschilden van 
andere patiënten met hartfalen op tal van kenmerken, waaronder het aantal chronische 
aandoeningen, multimorbiditeit en het percentage met overmatige polyfarmacie, 
ziekenhuisopnames en hartgerelateerde operaties. Bovendien kende de top 1% groep een 
opmerkelijke stijging van de kosten voor geestelijke gezondheidszorg. Er zijn geïntegreerde 
inspanningen nodig om de kwaliteit van zorg verder te verbeteren en onnodige kosten te 
verminderen.
Op basis van de bevindingen van dit proefschrift hebben wij een reeks aanbevelingen 
opgesteld voor beleid en praktijk. Hieronder presenteren we de belangrijkste aanbevelingen. 
Verbeterde informatievoorziening binnen en tussen zorgaanbieders is nodig om goede 
geïntegreerde zorg voor complexe patiënten te ondersteunen, zodat behandelaars een 
volledig inzicht kunnen krijgen in de medische dossiers en het zorggebruik van hun 
patiënten. Dergelijke informatievoorzieningen kunnen ook de identificatie van zorg met 
weinig toegevoegde waarde vergemakkelijken. Op nationaal niveau is meer aandacht nodig 
voor het thema multimorbiditeit. Er behoefte aan meer generalisten en meer aandacht 
voor multimorbiditeit in medische richtlijnen. Verder stellen we voor dat het ‘open’ pakket 
voor niet-farmaceutische medische zorg meer ‘gesloten’ zou kunnen worden, bijvoorbeeld 
door sluisconstructies te ontwikkelen voor kostbare niet-farmaceutische producten en 
interventies. Verder pleiten we voor meer (multidisciplinaire) discussies over de waarde van 
behandelingen. Tot slot stellen we voor dat huisartsen meer intensief contact hebben met 
het ziekenhuis om hun patiënten te begeleiden als gezaghebbend adviseur bij ingewikkelde 
behandelbeslissingen. 
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